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Protein aggregation occurs when proteins adopt non-native conformations, 
exposing hydrophobic surfaces due to misfolding. The exposed regions of two or more 
proteins associate to form amorphous deposits or highly ordered, stable fibrillar 
structures called amyloid aggregates. Within the cell, a robust network of proteins 
safeguard against protein misfolding and aggregation. This network is referred to as the 
proteostasis network and includes molecular chaperone proteins, co-chaperone 
proteins, and the ubiquitin proteasome system. Molecular chaperone proteins function in 
various cellular processes including intracellular transport, oligomeric assembly, and 
efficient protein folding. Moreover, molecular chaperones are required for folding 
denatured, misfolded, and de novo proteins into their native conformation. It is thought 
that neurodegenerative diseases may be the result of a derailed proteostasis network in 
response to aging, mutations, and environmental stress, among other factors that 
contribute to protein aggregation. 
The neurodegenerative diseases Alzheimer’s disease, Huntington’s disease, and 
Parkinson’s disease are characterized by protein misfolding and accumulation into 
aggregates composed of amyloid fibrils. In each of these protein misfolding diseases, 
the roles of chaperone proteins are complex and not well understood. Given that these 
diseases share a common theme of protein misfolding and aggregation, researchers 
have questioned whether molecular chaperone proteins are involved in disease 
pathology, which has led to investigations into the possible use of chaperone-based 
strategies as treatment options. It is thought that protein aggregation in 
neurodegenerative diseases results from disturbances in pathways that regulate protein 
quality control. This thesis investigates the role of ATP-dependent chaperone proteins in 
 
 
disaggregating and resolubilizing protein aggregates, including model aggregates, 
amyloids of Sup35 in yeast and hyperphosphorylated tau in human cells. Here, we 
investigated the biochemical properties of the Hsp100/Clp chaperone protein family, 
which couples ATP binding and hydrolysis to unfold and reactivate aggregated and 
misfolded polypeptides.  We studied the role of molecular chaperone proteins in the 
progression of protein aggregation in a model of Alzheimer’s disease and developed 
novel chaperone tools for targeting amyloid proteins for protein clearance.  Furthermore, 
we investigated the mechanism of substrate recognition and amyloid disassembly by 
Hsp104 in a yeast [PSI+] prion model of amyloid assembly. Moreover, we identified a 
novel function of the chaperone protein ClpX in protein disaggregation in vitro and in 
vivo. We observed that ClpX can bind and reactivate native and engineered protein 
aggregates in the absence of ATP. Lastly, in an Alzheimer’s disease model of 
hyperphosphorylated tau, we monitored changes in chaperone protein levels in 
response to inhibition of protein phosphatases. Research from this dissertation will 
contribute to further understanding Alzheimer’s disease pathogenesis, and, more 
broadly, the breakdown of protein homeostasis in neurodegenerative disease, and roles 
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1. Introduction to Protein Conformational Disorders and Neurodegeneration  
 Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), 
and transmissible spongiform encephalopathies such as Creutzfeldt-Jakob disease are a 
group of progressive, fatal neurodegenerative diseases that share the common 
pathological feature of protein aggregation and amyloid deposits [1]. Amyloid deposits 
are composed of protein aggregates that result from proteins that adopt an aberrant, 
non-native conformation through a misfolding event [2]. Neurodegenerative diseases 
that share the common feature of protein misfolding are also referred to as protein 
conformational disorders [3].  
 Neurodegenerative diseases have a devastating impact on family members, 
caregivers, and society. Most diseases involve processes that impact the quality of life of 
an individual, from classic involuntary muscle movements witnessed in both PD and HD, 
to cognitive decline that occurs in individuals with AD. Neurodegenerative diseases also 
have a major impact on the economy and caregivers. In the case of AD, in 2015, 
American caregivers are estimated to have contributed over 18.2 billion hours of unpaid 
assistance to people with Alzheimer’s dementia and other dementias, which amounts to 
approximately $230.1 billion in unpaid care [4]. Incidence rates of these age-related 
neurodegenerative diseases are expected to rise as the population ages. As of 2017, the 
Alzheimer’s Association reports that an estimated 5.5 million people in the United States 
have Alzheimer’s disease and by 2050, this number may increase to 16 million [4]. 
Understanding the biochemical, molecular, and cellular pathways and mechanisms 
involved in Alzheimer’s disease pathology and progression is important for developing 
more efficient disease-modifying therapeutic strategies. This chapter will discuss in vitro 
technologies commonly used to isolate, visualize, and characterize amyloidogenic 
protein aggregates and in vivo methods of identifying protein aggregates in the brains of 
3 
 
patients with Alzheimer’s disease.  We will also provide examples of agents that have 
been shown to promote aggregation, and discuss different approaches that may inhibit 
or stall amyloid formation.  
2. Proteostasis, Protein Misfolding and Aggregation  
2.1 Protein Quality Control 
 Protein function is dependent on proper folding of a protein into a native, 
thermodynamically stable and biologically active conformation, with a three-dimensional 
structure. To ensure that proteins fold correctly there is a protein quality control network 
in cells, which consists of a group of molecular chaperone proteins and proteases. 
Stress and subsequent damage to functional, folded proteins may be caused by 
environmental changes (for example, shifts in temperature or hydration), free radicals, 
heavy metals, or tissue injury. These stresses can also modify the expression levels of 
components of the protein quality control machinery within the cell to manage the 
disruption to protein homeostasis [5,6] [7]. Thermotolerance studies in cells have led to 
the identification of many proteins that are highly expressed during exposure to heat 
stress. Therefore, these proteins were given the name “heat shock proteins”. In 
eukaryotes, the heat shock response, which includes the increased expression of heat 
shock proteins in response to physiological stressors, is stimulated by activation of heat 
shock transcription factor (HSF-1) and transcription of chaperone genes, such as genes 
encoding chaperone proteins Hsp70 and Hsp40 [8-10]  
Heat shock proteins are highly conserved and ubiquitous proteins that represent 
a component of the cellular protein quality control network. Heat shock proteins, or 
molecular chaperone proteins, are essential for managing protein folding and 
maintaining protein homeostasis in both normal conditions and conditions of 
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physiological cell stress [11]. Misfolded proteins pose a threat to cell viability by 
interfering with protein-protein interactions, protein-membrane interactions, promoting 
aberrant protein interactions and inducing aggregation. Protein misfolding also increases 
the demands on the protein quality control network, which is thought to lead to further 
misfolding and aggregation events [12,13]. During aging, the cell’s ability to mount a 
heat shock response in response to stress conditions decreases [14] . Expression of 
ATP-dependent chaperone proteins, such as Hsp90 and Hsp70, declines with age and 
this decrease in expression levels is even greater in Alzheimer’s disease and 
Huntington’s disease [15]. 
Another component of the quality control network within the cell is the 26S 
proteasome, a large protein degradation machine that promotes the clearance of 
misfolded proteins and proteins with an ubiquitin tag. In some cases, misfolded and 
dysfunctional proteins are tagged with multiple ubiquitin domains by ubiquitin ligases and 
directed to the 26S proteasome for degradation. Protein degradation may also play a 
role in age-associated neurodegenerative diseases, including AD and PD, where protein 
aggregates have been shown to contain high levels of ubiquitin, which may contribute to 
neurodegeneration and neuronal cell death [16] . Research suggests that proteasome 
activity declines and may be impaired in the aging brain [17,18]. Together, the molecular 
chaperones and the 26S proteasome maintain steady-state levels of healthy proteins 
within the cell, creating a balance of active and degraded proteins, which becomes more 
fragile as the proteostasis network weakens or is overburdened.  
2.2 Protein aggregation and amyloids 
 When proteostasis is disrupted due to protein folding inefficiency or instability, 
proteins become insoluble and aggregate. Several neurodegenerative diseases contain 
a highly specialized and thermodynamically stable aggregate, called an amyloid. 
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Amyloid deposits are composed of bundled fibrillar aggregates rich in stacked beta-
sheets that are oriented perpendicular to the long axis of the amyloid fiber [19,20]. A 
network of hydrogen bonding interactions within and between beta sheets stabilize the 
highly ordered beta-rich structure of amyloids [21]. Amyloid fibrils have common beta-
rich structures, fibril morphologies, and chemical properties. Generally, the mature 
amyloid fibril is approximately 100 Angstroms in diameter, twisted, and unbranched [22]. 
Amyloids are insoluble and resistant to detergents and many other chemicals known to 
disrupt protein folding and proteolysis [23,24].  A unifying feature of amyloids is their 
distinctive cross-beta pattern observed in X-ray diffraction studies. The amyloid fibril 
structure is characterized by stacked beta-sheets that have an approximate intersheet 
distance of 11 Angtstroms and interstrand distances of 4.8 Angstroms [22] . 
It is thought that amyloids arise from a nucleation-dependent polymerization 
event called fibrillization (Figure 1). By contrast, intermediates in the amyloid assembly 
pathway, such as pre-amyloid oligomers, are soluble in solution and have diverse sets of 
conformational states [25]. How proteins progress through conformational stages of the 
amyloid assembly pathway(s) from oligomers to protofibrils and finally, to amyloid fibrils, 
is not well understood, but novel methods using molecular probes and optical 
spectroscopy may provide important information about these intermediate oligomeric 
species [26]. Although the precise molecular events of amyloid assembly are not known, 
in vitro experiments suggest that small oligomers assemble and polymerize to form an 
intermediate protofilament, which further aggregates to become a mature fibril [25]. The 
fibrillar aggregates accumulate into a deposit called an amyloid plaque, which is thought 
to be irreversible. In vivo preformed amyloids can act as “seeds” to promote mature 
amyloid formation in mouse models of amyloid assembly [27]. Although it is unknown 
how amyloids propagate, a prion-like mechanism has been suggested, where a 
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misfolded protein (i.e., an amyloid) induces conformational changes in folded protein by 
templated conformational conversion [28] . In this model, the amyloid acts as a seed or 
template to spread the beta-rich structure to other proteins, promoting fibrillization and 
thus seeding aggregation. 
 The pathogenesis of several neurodegenerative diseases is linked to the 
formation of amyloids that accumulate within specific tissue regions. In AD, amyloid beta 
plaques are formed from the misprocessing and overproduction of the amyloid precursor 
protein (APP), and plaques are typically found extracellular to neurons in the frontal 
cortex and hippocampus of patients (Figure 1B). A second hallmark of AD pathology is 
known as the tau tangle. Tau tangles, or neurofibrillary tangles (NFTs) are intracellular 
aggregates formed by the polymerization of paired helical filaments (Figure 1B) [29-31] 
[32]. In PD, misfolded, aggregated alpha-synuclein (α-synuclein) has been shown to be 
the major constituent of  both Lewy bodies and Lewy neurite pathology in the brains of 
patients with PD patients [33]. HD is predominantly genetic, and involves duplications in 
the Huntingtin gene (Htt). Individuals with htt mutations develop aggregates of Htt in 
amyloid-containing inclusion bodies, which are typically found in the striatum, cortex, and 
the spinal cord [34].  Although these neurodegenerative diseases share the common 
feature of amyloids deposits, they also exhibit differences. The neuronal cell populations 
that are lost in each of the diseases varies, the disease symptoms are heterogeneous, 
and the pathological proteins that misfold into amyloid in each disease share few 
similarities in sequence and structure. In addition, amyloid load is poorly correlated to 
cognitive decline in neurodegenerative diseases and accumulating research points to  
prefibrillar oligomers as the toxic species responsible for neurodegeneration and 
behavioral symptoms [35]. 
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 Besides age-related neurodegenerative diseases, transmissible spongiform 
encephalopathies, also referred to as prion disorders, provide further examples of 
pathological alterations in protein conformation that are associated with  
neurodegeneration and lead to death in humans [1]. In these disorders, a soluble prion 
protein (PrP) adopts a new conformation, or protein fold. This new conformer of the prion 
protein is an amyloid and it has self-templating and infectious properties. In the prion 
conformation, the protein can then bind to another native protein and cause it to adopt 
the aberrant, alternative conformation. In this way, the abnormal conformer can self-
template and propagate the disease-associated protein conformation [36]. Diseases that 
fall within the TSE category include scrapie in sheep, bovine spongiform encephalopathy 
(“mad cow” disease), chronic wasting disease in deer and elk, and Creutzfeldt-Jakob 
disease in humans [37] [38]. 
3. Detecting Amyloids and Monitoring Fibrillization  
3.1 Monitoring the Kinetics of Amyloid Formation in vitro and Quantifying Aggregation 
 It is hypothesized that the mechanism of amyloid assembly is a nucleation-
dependent fibrillization characterized by a rate-limiting, slow lag phase required to form a 
critical nucleus followed by the polymerization of fibrils at an exponential rate [39,40]. For 
a nucleus to form (termed “nucleation”), a set of high-energy oligomeric intermediates 
must be stabilized by a molecular event, such as a protein conformational change. The 
factors that drive nucleation and the structures of the high-energy conformational states 
that compose the nucleus are not well understood [41]. Although amyloids are stable 
structures in general, the fibrils can break into smaller fragments that may seed 
additional amyloids. Multiple detection and quantification methods for amyloids rely on 
the optical qualities of amyloids and the kinetics of amyloidogenesis. Congo Red and 
Thioflavin T (ThT) are small molecules that bind selectively to amyloids, inducing 
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changes in optical features such as fluorescence quantum efficiency [26]. Light 
scattering or fluorescence assays are used to monitor the kinetics of amyloid fibril 
assembly over time [38]. Traditional methods for screening amyloid aggregates include 
biophysical, optical, and microscopic techniques that visualize small molecule binding to 
amyloids, such as Congo red (CR) and ThioflavinT (ThT) dye binding [42]. The most 
commonly used techniques for reporting and quantifying amyloids, in addition to novel 
methods for identifying different conformational states of amyloids, are explained below.  
3.2 Detection of Amyloids by Molecular Probes and Fluorescence Spectroscopy  
 Fluorescence spectroscopy is used to identify and characterize protein 
conformations of amyloids in vitro under both steady state and kinetic conditions, 
allowing researchers to investigate amyloid assembly and visualize amyloid fibrils. The 
most commonly used fluorescent dyes that bind selectively to amyloid are Congo Red 
[43] and ThioflavinT [44]. ThT is a benzothiazole-based fluorescent dye that specifically 
binds to the surface of cross-β sheets of amyloid fibrils[45]. Vassar and Culling 
demonstrated that ThT showed highly specific binding to amyloid deposits in tissue 
sections and this binding was associated with an enhanced fluorescence signal from 
ThT [23]. When ThT binds amyloid fibril in vitro or in situ, it shows enhanced 
fluorescence that can be monitored by fluorescent spectroscopy [46]. In vitro binding of 
amyloid fibrils to ThT was first described by Naiki and coworkers[44]. When ThT was 
added to samples containing up to 2.0 µg/mL of amyloid fibrils, researchers observed an 
intense fluorescence at an excitation maximum of 450 nm and an emission maximum of 
482 nm [44]. The molecular probe ThT has also been used to monitor amyloid fibril 
assembly in real-time [47,48].  
There are limitations and caveats to quantifying amyloid fibrils based on ThT 
fluorescence assays. The selectivity of ThT binding to amyloid fibrils is unclear. ThT 
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fluorescence emission can be affected by different amyloid fibril morphologies and pH; at 
a basic pH, the ThT molecule becomes hydroxylated [22]. ThT can also bind to other 
fibrils besides amyloids, such as keratin and elastin [49] . Moreover, research shows that 
ThT can bind to nucleic acids of DNA and this binding is associated with enhanced ThT 
fluorescence;[50]  however, reducing the pH lowers the affinity of ThT for nucleic acids 
[51]. The presence of polyphenols such as curcumin, quercetin, and resveratrol in 
samples containing fibrillar amyloid-beta interferes with ThT fluorescence readings in 
both in situ ThT assays and single time-point ThT assays [52]. Considering that factors 
such as ionic strength, pH, fibril morphology, and concentration of both ThT and protein 
fibril can modify the fluorescence emission of ThT, it may be more useful to combine 
other methods of measuring amyloid fibril kinetics with ThT fluorescence assays [53].   
 Congo Red is a crimson-hued, lipophilic diazo dye that selectively binds with high 
specificity to amyloid fibrils in vitro, in situ, and ex vivo [46]. . The Congo Red 
birefringence assay can be used to identify amyloid fibrils. Using a polarized light 
microscope, the presence of amyloid can be investigated by determining if the sample 
stained with Congo Red shows apple-green birefringence under crossed polarizers; if no 
birefringence is observed, then it can be concluded that no amyloid is present [46].  The 
characteristic apple-green birefringence can be difficult to detect and other problems 
with this technique include high levels of background staining and challenges to 
reproducibility [53,46]. Research supports that Congo red does not bind to different 
amyloid fibrillar deposits by the same mechanism and may have relatively low sensitivity 
[54-56]  
A spectroscopic assay that examined Congo Red dye binding to fibrillar beta-
pleated sheet insulin, a representative amyloid, showed that the absorbance spectrum of 
Congo Red changes upon binding to amyloid [43]. Klunk and coworkers further 
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developed and extended the Congo Red-insulin fibril spectroscopic assay to quantify 
amyloid fibrils by examining amyloid-beta aggregation with Congo Red. Briefly, the 
absorbance of amyloid samples stained Congo Red and amyloid samples alone must be 
measured at the wavelengths 403 nm and 541 nm before performing necessary 
calculations to quantify the aggregated amyloid beta concentration in the samples [57]. 
When Congo Red binds to amyloid fibrils, it exhibits a red shift in absorbance maxima 
from 490 nm to 540 nm [58]. Congo red dye binding to amyloid fibrils causes Congo red 
to change in color from orange-red to rose and because of this, a spectral shift in the 
absorbance spectrum of Congo Red can be measured using a UV-Vis 
spectrophotometer [59]. 
Congo Red and Thioflavin T dyes do not bind to pre-amyloid conformations in the 
amyloid assembly pathway. The development and use of fluorescent dyes 1-
anilinonapthalene-8-sulfonate (ANS), 4-4-bis-1-phenylamine-8-napthalene sulfonate 
(Bis_ANS), and 4-(dicyanovinyl)-julolidine (DCVJ) allows for identification and monitoring 
of early amyloid protein conformations [60]. Bis-ANS has been shown to bind to 
prefibrillar protein conformations associated with the early stages of the amyloid 
assembly pathway. When Bis-ANS binds to the hydrophobic residues on the surface of 
proteins and is excited at 360 nm, it emits a 530 nm wavelength [48].  DCVJ was shown 
to bind selectively to prefibrillar oligomers, making it a useful tool for studying the early 
stages of amyloid assembly [60].  
Moreover, A drawback of Congo Red and Thioflavin T dyes is that they cannot 
be used in vivo. The development of BoDipy-Oligomer (BD-Oligo) by the research group 
of Teoh et al. may have bridged this gap in the field. BD-Oligo is a fluorescent probe 
selective for oligomeric intermediates in amyloid formation [61]. BoDipy-Oligomer can 
cross the blood brain barrier and can label disease-associated oligomers in real-time 
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without using radiation, making it an attractive candidate for clinical screens of 
presymptomatic patients of AD [61] [62]. A novel stain that has recently begun to be 
employed for the detection of Aβ plaques is Amylo-Glo. While this has recently been 
shown to bind to Aβ plaques in 11 month APP/PS1 transgenic mice, the specificity of the 
marker for Aβ as opposed to other aggregated proteins has not been predetermined 
[63]. Unlike Congo Red and Thioflavin T, Amylo-glo has a blue UV excitable stain, 
making it ideal for co-labeling and staining studies, it is also much brighter than these 
traditional dyes and appears more sensitive [64].  
3.3 Seeding and Amplification Assays 
3.3.1. Protein Misfolding Cyclic Amplification  
 Protein Misfolding Cyclic Amplification (PMCA) is a technique that was 
developed in 2001 for the detection and amplification of prion proteins [65]. The first 
phase of PMCA involves utilizing a trace amount of infectious prion purified from either 
brain homogenates or cell lysates to induce the conversion of the normal protein into the 
misfolded infectious aggregate. In the second phase, the sample is sonicated, which 
fragments the aggregate and therefore frees up the template to polymerize again. 
Therefore, by PMCA the fibril concentration increases exponentially [66]. A concern of 
the PMCA reaction and technique is its ability to detect low levels of prion protein in a 
sample, as well as the efficiency of the reaction. PMCA may vary depending on 
experimental conditions, such as the reaction components and sonication. A 
modification of the experimental design to include Teflon beads (PMCAb) increased the 
efficiency of the PMCA reaction and the sensitivity of prion detection [67].  
 Quantitative ‘qPMCA’ was developed to quantify the prion concentration in a 
sample since the amount of cycles of PMCA needed to detect the prion is directly related 
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to the amount present in the original sample [68,69]. Briefly, the procedure involves the 
purification of prion from the original lysate, followed by PMCA reactions containing 
multiple dilutions of prion. Then the number of rounds of PMCA required to produce a 
detectable signal are determined by Western blot analysis. From this, a curve is 
generated of prion concentration versus PMCA detection round. Extrapolating from this 
curve would provide the original prion levels in the sample [68,69]. Although developed 
for prions associated with TSEs, PCMA has recently been applied to the detection of Aβ 
oligomers in cerebrospinal fluid of patients with AD [70]. 
3.4 Inducing Amyloid Formation and Seeding  
3.4.1 Quaking Induced Conversion Assay and the Amyloid Seeding Assay (ASA)   
 The amyloid seeding assay (ASA) is a method in which rapid amyloid formation 
or seeding occurs when amyloid fibrils are added to a fresh pool of soluble proteins. The 
ASA is useful tool to screen for agents that may be aggregation inhibitors, and for 
detecting prions in biological samples. The formation of these aggregates can be 
observed by monitoring Thioflavin T (ThT) binding to amyloid fibers over time [71].  
Similar to PMCA, the Quaking Induced Conversion Assay (QuIC) was developed 
to address technical difficulties associated with PMCA. In QuIC automated orbital 
shaking is utilized instead of sonication, which is used in PMCA. Both the ASA and QuIC 
assays are limited in their ability to accurately quantify protein aggregates and are 
considered less reliable than the new real-time quaking induced conversion assay (RT-
QuICK) [72]. RT-QuICK utilizes some components of the QuIC assay, such as 
intermittent shaking but also incorporates ThT to monitor the formation of fibrils, as seen 
in ASA’s [73].Furthermore, prion and fibril concentration is accurately determined by 
using RT-QuICK if it is coupled with end-point dilution analysis. In this method, 
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homogenates are serially diluted. Then the samples are analyzed by RT-Quick for each 
dilution, and then ThT fluorescence levels are measured to establish a baseline. The 
advantage of utilizing RT-QuICK is that it is a rapid, sensitive, cost-effective assay as 
compared to alternative techniques [72]. 
3.4.2 Monitoring Amyloids in vivo 
  The ability to develop in vivo detection and monitoring methods for amyloid 
assembly remains difficult for most of the amyloidogenic diseases, especially in HD and 
PD. In HD, researchers have had success utilizing positron emission topography (PET) 
to monitor disease progression in individuals diagnosed with the disease relative to 
healthy individuals. However, in both PD and HD there is still no tracer that can both 
bind to aggregates and be simultaneously monitored by PET scans. In contrast, there 
have been more successful developments of radioligands selective for beta-amyloid and 
paired helical filament tau protein that enable in vivo monitoring and visualization of AD-
related amyloid plaque and neurofibrillary tau protein aggregate accumulation.  
The PET imaging agents that are selective for fibrillar amyloid-beta plaques 
include 11-C-labeled Pittsburgh compound B and florbetapir-F18 [74]. The first PET 
imaging probe developed that could bind to amyloid beta aggregates was Pittsburgh 
Compound B (PiB-C11) [75]. PiB-C11 effectively binds to amyloid plaques in brain 
regions of people with Alzheimer’s disease that correlate with the same brain regions 
showing amyloid accumulation from post-mortem histopathological analysis of brain 
tissue [76]. However, PiB-C11 has a short half-life of approximately 20 minutes, which 
limits its efficiency [77]. The first FDA-approved PET tracer for clinical imaging of 
amyloid-beta deposits is florbetapir-F18 (AmyvidTM) [76]. The PET ligand florbetapir-F18 
(18F-AV-45) binds to amyloid beta plaques with similar specificity and regional uptake as 
PiB-C11 and has a half-life of approximately 110 minutes [77]. Recent studies have 
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shown that florbetapir-F18 is both sensitive and specific to the detection of Aβ and can 
be used to clinically distinguish individuals [78]. Moreover, in vitro analysis of the of 
florbetapir-F18 binding in human postmortem brain tissue sections confirmed that the 
labeling intensity of florbetapir-F18 correlates with amyloid plaque density and the PET 
tracer did not bind to neurofibrillary tangles [74]. 
Research findings from postmortem brain analyses show that neurofibrillary 
tangles correlate with cognitive decline and neuronal death whereas amyloid plaques do 
not strongly correlate with dementia severity [79,80]. Therefore, there development of 
PET tracers that bind to paired helical filaments, which are composed of pathologically 
hyperphosphorylated tau, could be used to diagnose and monitor treatment outcomes in 
vivo [81]. The PET ligand 18F-AV-1451 binds selectively and with high affinity to 
hyperphosphorylated tau in paired helical filaments [82,83]. A study that investigated 18F-
AV-1451 binding in healthy elderly people found that uptake and retention of AV-1451 
correlated with age and amyloid plaque accumulation [84]. AV-451 uptake in the medial 
temporal lobe was also found to be significantly associated with cognitive decline and 
impaired episodic memory [84]. The development of amyloid beta and tau PET-imaging 
probes provide a new tool for measuring pathological amyloid beta and neurofibrillary 
tangle deposits in vivo, which could be useful in the clinic for diagnosis of Alzheimer’s 
disease. 
4.0 Cytotoxicity assays 
 Amyloid assembly intermediates are widely considered to be more toxic species 
in the amyloidogenesis pathway, rather than the mature amyloid fiber present in 
plaques, yet there is still ambiguity about whether protofibrils, oligomer species, or a 
combination of both causes toxicity. Research shows that oligomers from the self-
assembly of amyloid beta peptide are 10-fold more toxic to neuronal cell cultures than 
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fibrillar amyloid-beta (1-42) peptide. Amyloid-beta peptide (1-42) is toxic to cells at 
micromolar concentrations whereas oligomeric species are toxic at nanomolar 
concentrations [85]. Reliable cytotoxicity assays provide important information about 
cellular health and viability following exposure to a toxic substance and are useful for 
investigating the correlation between protein aggregation and cytotoxicity, which may 
provide information important for understanding the pathogenesis of protein 
conformational diseases.  
In vitro cytotoxicity assays are used to determine the viability of a cell following 
exposure to a toxic substance, such as a misfolded protein conformer or mature 
amyloid. The in vitro assays rely on the markers of cell death, whether that is the 
compromised integrity of the cell membrane, the release of enzymes into the 
extracellular space that are normally compartmentalized, etc., as direct and indirect 
measurements of cell viability. However, assays to monitor long-term cytotoxicity are 
lacking. Colorimetric in vitro assays are widely used pharmacology and ecotoxicology 
studies to determine cell death following exposure to a toxicant or a suspected toxic 
species [86]. Often several cytotoxicity assays are employed to accurately determine cell 
fitness and survival. Cytotoxicity assays have also shown the correlation that as the 
order of oligomer species increases, the degree of toxicity of the oligomer also increases 
providing valuable information about the identity of most toxic soluble oligomer species, 
which has implications for drug target research [87].  
Below are examples of commonly used and robust assays for measuring the 
number of living cells (cell viability) and determining the number of dead cells 
(cytotoxicity). The LDH assay and MTT assay are spectrophotometry-based assays for 
measuring cytotoxicity in vitro. Despite the ease of use of these inexpensive assays and 
their ability to be used in high-throughput screening, there are several limitations 
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associated with their use. Notably, spectrophometric assays that indirectly measure 
plasma membrane breakdown do not distinguish among different cell death modalities 
[88]. Vital dye assays represent another method for measuring cell viability in response 
to cytotoxic agents in vitro. However, vital dyes are also limited by their inability to 
distinguish different modes of cell death [89].  
4.1 LDH Leakage Assay for Compromised Membrane Integrity 
 Lactate dehydrogenase (LDH) is a cytosolic enzyme that can be used as a 
biomarker of cell death and cell lysis  [90]. The lactate dehydrogenase assay is an 
example of an intracellular protein release assay. After cell death, the cell membrane 
loses its structural integrity, which results in the release of normally intracellular enzymes 
into the cell culture medium  [91]. Colorimetric and fluorometric detection of LDH using 
commercially available kits allows researchers to monitor cytotoxicity in vitro  [88] . LDH 
is catalyzes the oxidization of lactate to pyruvate and generates NADH; NADH strongly 
absorbs 340 nm light. Monitoring absorbance values using a 96-well plate provides an 
estimation of cytotoxicity [90]. The LDH assay is widely used to investigate cytotoxic 
affects and was recently applied to detect cytotoxicity of amyloids in rat embryonic 
neuronal cell culture [92,93]. However, disadvantages of the LDH assay include low 
sensitivity and a high degree of variability [86]. Moreover, LDH enzymatic activity can be 
affected by cell culture medium, such as pH and components within the medium, leading 
to an underestimation of cell death [88] . 
4.2 MTT Assay 
 The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction 
inhibition assay, commonly referred to as the MTT assay, is a robust colorimetric assay 
for assessing cell viability in a variety of cultured cell types [90]. The MTT assay of cell 
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viability was first described by Mosmann [94]. MTT is a water-soluble tetrazolium salt 
that converts toformazan, which is purple and water insoluble, by reduction of the 
tetrazolium ring mediated by mitochondrial dehydrogenase enzymatic activity [95]. Only 
viable, metabolically active cells will convert MTT to formazan. Thus, formazen will 
accumulate as  as a precipitate in viable, healthy cells. Spectrophotometric quantification 
of relative levels of formazan  allows researchers to measure MTT conversion and 
overall cell viability [90]. The MTT assay is versatile and linear over a broad range of 
densities. However, the MTT assay may be more useful in cells with high metabolic 
activity [86]. 
4.3 Vital Dyes 
 Besides the LDH and MTT assay, vital dyes are frequently used by researchers 
to distinguish between living and dead cells in vitro. Vital dyes are fluorescent or colored 
molecules that can be used in membrane permeability assays to measure cell death [89] 
. Exclusion dyes, such as Trypan blue, cannot cross plasma membranes of healthy cells, 
and can be used to measure cell viability. Other commonly used exclusion dyes include 
propidium iodide and 4’,6-diamidino-2-phenylindole, which label dead cells that no 
longer have intact plasma membranes [96]. Researchers determine the percentage of 
viable cells in response to a cytotoxic agent by staining the cells with an exclusion dye 
and counting the number of viable cells using a light microscope and a cell counting 
instrument, such as a hemocytometer. The percentage of viable cells is the ratio of 
viable cells to the total number of cells [89] .  
Dyes can also be used to label living cells, such as calcein acetoxymethyl ester 
(calcein-AM). The vital dye calcein-AM has been used effectively in cytotoxicity assays 
[97,98]). Calcein-AM is lipid soluble and easily crosses cell membranes. Inside the cell, 
is hydrolyzed by cytosolic esterases to yield calcein, a fluorescent and membrane 
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impermeable product [89] . Cells with intact plasma membranes will retain fluorescent 
calcein. Dying or dead cells with damaged plasma membranes release calcein, which 
has a strong green fluorescence signal at 530 nm [99]. Therefore, cytotoxicity can be 
determined by measuring the release of calcein from lysed cells using a fluorimeter. A 
drawback of calcein-AM is that esterase enzymatic activity may be affected by events 
not related to cell death, which may lead the researcher to underestimate levels of 
cytotoxicity [89]. 
5. Pharmacological Agents and Drug Therapies for Protein Misfolding Diseases  
 Aggregation can be promoted by intrinsic and extrinsic factors, including the 
amino acid sequence of a polypeptide, pH, temperature, chaperone protein levels, and 
protein concentration [38]. Aggregation can be inhibited in vitro by different classes of 
compounds, notably anthracycline, anionic sulphonates, Congo red, and rifampicin, 
which prevent the formation of oligomers, as well as by other proteins. Prefibrillar 
oligomers are the most toxic protein conformation, not the mature amyloid fibril [100], 
therefore many pharmacological studies have explored different avenues for abrogating 
protein aggregation and its associated toxicity. Strategies explored so far include 
increasing the activity of the protein quality control network, stabilizing the soluble 
disease-associated protein, destabilizing the insoluble misfolded protein, preventing 
aggregation at the early stages of amyloid formation, and changing the protein folding 
landscape to favor native protein folding. 
5.1 Metals 
 It has been shown that metals may have a role in inducing protein aggregation. 
Specifically, divalent Cd2+, but not Mn2+ impairs proteosomal activity in mouse neuronal 
cells expressing prion protein. This impaired proteasome system lead to an 
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accumulation of high molecular weight ubiquitinated proteins in the cell, and ultimately 
cell toxicity and death [101]. These observations were also replicated in yeast [102]. 
Arsenite, As (III) was also found to interfere with chaperone activity and with the folding 
of peptides in yeast. As (III) exposure was shown to induce the formation of over 140 
protein aggregates, which can further induce misfolding and aggregation of other 
proteins [102]. A number of other metals have also been identified as promoting protein 
aggregation, and inhibiting of protein refolding both in vivo and in vitro, including Hg2+ 
and Pb2+ [103,104].  
5.2 Therapeutic Intervention Methods Targeting Aggregates 
 A number of therapeutic strategies have been implemented as a means to target 
amyloid and aggregate formation due to the inherent toxicity of both the fibrils and 
aggregates [105,106]. Some techniques include inhibiting the formation of the β-sheet 
secondary structure by using short peptides, or small inhibitory molecules. Others 
include bolstering the natural defense towards aggregates, such as heat shock proteins, 
or agents that induce chaperone activity, to enhance clearance mechanisms.  
5.2.1 β-sheet Breakers  
 β-sheet breakers are short peptides that recognize and inhibit the amyloid 
conformation. Specifically, this is commonly done using short peptides, that recognize 
the hydrophobic or “central core” of the beta amyloid (Aβ) peptide [100]. This class of 
peptides can bind to oligomers and fibrils to destabilize the β-sheet structure that is a 
common trait of amyloids. The unique property of these peptides is their specificity for 
abnormally folded proteins; they destabilize only non-native protein conformers without 
affecting the soluble protein conformer [100]. Thus, this class of drugs can deter amyloid 
fibrillogenesis and downstream aggregation [107].Two β-sheet breaker peptides, KLVFF 
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and LPFFD , have been shown to prevent the oligomerization of oligomers into amyloid 
fibrils, thus preventing the formation of amyloid plaques [108,109]. Research shows that 
the LPFFD peptide can better halt amyloid fibrillogenesis than KLVFF due to its lower 
hydrophobicity [110].   
5.2.2 Antibodies  
 Several monoclonal antibodies have been developed that specifically target 
amyloid-beta monomers and oligomers, as well as some polyglutamine aggregates 
[105]. Two antibodies have been specifically examined for their role in mitigating Aβ 
pathology: bapineuzumab and solanezumab. Bapineuzumab targets the N-terminus of 
amyloid-beta whereas solanezumab binds to the central region. Both monoclonal 
antibodies have been tested in clinical trials in patients diagnosed with mild to moderate 
AD. However, despite success in the laboratory, monoclonal antibodies have not yet 
shown significant clinical changes or altered disease endpoints in patients [111].  
 A conformation specific peptide, which mimics a pathological conformation of 
amyloids, was developed using polymerized British amyloidosis (pABri) peptide.  
Although the peptide does not have sequence homology to amyloid-beta or any other 
human protein, pABri is synthesized in the beta-sheet form and elicits an immune 
response against the pABri peptide, as well as other amyloids. This technique been 
used successfully in APP transgenic mice to direct the immune system against amyloid 
formation, which led to a reduction in amyloid plaque burden and improved cognition 
[112].  
5.2.3 Natural Products as Putative Therapeutic Agents  
 Pharmacological studies have identified many diverse compounds associated 
with increasing molecular chaperone expression, restoring proper protein folding, 
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decreasing the levels of pathologic misfolded proteins and inhibiting amyloid formation. 
For example, polyphenols have strong anti-amyloidogenic activity and act by promoting 
clearance of amyloid from the system. Most polyphenols have been shown to disrupt 
aggregation of α-synuclein [106]. A polyphenol that is commonly found in green tea, (−)-
epigallocatechin-gallate has been shown to inhibit Huntington aggregation [113].  Other 
polyphenols such as curcumin have also been shown to aid in reducing protein 
aggregation through the induction of heat shock proteins [114]. Other examples include 
natural products that may interrupt or modulate the processing of amyloid in the brain, 
specifically pomegranate extract has been shown to disrupt Aβ in transgenic mice 
favoring the Aβ40 species over Aβ42 [115].  
  Drugs that inhibit amyloid fibrillization are also under investigation as potential 
therapies for protein conformational disorders. For example, cyclohexanehexol 
stereoisomers exhibit anti Aβ aggregation activity and are naturally occurring 
compounds with high absorption levels and no reported adverse side effects [100]. 
Additional research is focused on applications of chemical chaperones, ligands that bind 
to native proteins and osmolytes to stabilize the native protein state and destabilize the 
non-native, aberrantly folded state [38].  
5.2.4 Molecular Chaperones   
 Molecular chaperone proteins, also referred to as heat shock proteins, are 
activated during cellular stress, and recognize and bind to surfaces of non-native or 
misfolded proteins to prevent or alleviate protein aggregation [116]. Biochemical assays 
have shown that several classes of molecular chaperones can modulate amyloid levels 
and inhibit amyloid fibrillization. Hsp70 and the co-chaperone Hsp40 were reported to 
block the self-assembly of polyglutamine [117]. Therefore, heat shock proteins represent 
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a potential therapeutic avenue for future development of drugs to alleviate amyloid 
burden.  
Another class of possible therapeutic agents that may be effective against 
neurodegeneration includes small molecules that target the heat shock response or 
selectively alter the activity of chaperone proteins. Hsp90 has emerged as a possible 
target for neurodegeneration and cancer therapy because of its role as a robust protein 
chaperone that assists in stabilizing and activating several disease-related proteins. 
Geldanamycin is a potent inhibitor of the chaperone protein [118]. . Inhibiting Hsp90 
activates the heat shock response of the cell by de-repressing expression of the global 
chaperone transcription factor HSF-1 [119]  Preclinical studies for geldanamycin showed 
that the small molecule causes hepatotoxicity [120]. The quinone 19-position of 
geldanamycin is reactive with biological nucleophiles, such as glutathione [121]. 
Geldanamycin analogues with substitutions at the C19 position block nucleophilic 
substitution, thereby reducing unwanted reactions with biological molecules. 
Isomerization change from trans to cis-amide conformation of these geldanamycin 
analogues allowed for strong protein binding. Importantly, the analogues had reduced 
toxicity in epithelial and endothelial cells. The study provided strong evidence that these 
C19 substituents of geldanamycin did inhibit Hsp90 in dopaminergic neural cells and 
human cancer cells without incurring toxicity in cell lines, suggesting that these 
substituents may be promising agents for modulating protein folding in protein 
conformational disorders [121]. Inhibition of Hsp90 also activates Hsp70. Both 
chaperones recognize different sets of client proteins, and a reduction in Hsp90 function 
could promote Hsp70 function, leading to enhanced protein stabilization, degradation, or 
refolding [121]. Geldanamycin has also been shown to decrease cellular levels of 
hyperphosphorylated tau, which is stabilized by Hsp90 [122].  
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 Chaperones, including the Hsp70/Hsp40 system of co-chaperones increase the 
degradation of protein aggregates and clearance of misfolded polyQ proteins by 
targeting the abnormal proteins to the proteasome, as observed by decreased half-life of 
the misfolded polyQ protein [123]. Therefore, overexpression of Hsp70/40 proteins is a 
therapeutic option to enhance clearance of aggregates; overexpression of Hsp70/40 can 
prevent amyloid formation, as well as rescue cells with amyloid accumulation [100]. It is 
known that molecular chaperones can bind unfolded polypeptides and prevent protein 
aggregation in vitro by solublizing and reactivating protein aggregates. The Hsp100 
family of chaperones are composed of ATP-dependent disaggregases which unfold and 
reactivate proteins.  Studies by Schirmer et al. showed that Hsp100 chaperones can 
work in synergy with Hsp70 to reactivate protein aggregate [124]. Yeast protein Hsp104 
works with Hsp70/40 system to disassemble and rescue aggregated proteins has also 
been shown to disassemble amyloid fibers in vitro [125] . Overexpression of Hsp70 in a 
Drosophila model of Huntington’s Disease mitigated neurodegeneration and increased 
the lifespan of the fly [126].  
5.2.5 Chemical chaperones 
 Chemical chaperones are a unique class of drugs that can alter the balance of 
folded and misfolded proteins within the cell. Chemical chaperones are low molecular 
mass and can stabilize proteins against misfolding and aggregation, caused by thermal 
and chemical denaturing events. Some promising groups of compounds that target prion 
diseases include the anthracyclines, porphyrins, and diazo dyes.   Chemical chaperones 
can alter protein conformation by blocking the conversion of soluble, biologically active 
prion protein to the insoluble, transmissible prion conformer [127,128]. The clinically 
approved anti-malarial compound quinacrine, binds specifically to the C-terminal helix of 
the normal isoform of the prion protein and stabilizes the normal protein conformation 
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[129]. By stabilizing the normal, cellular non-prion protein, whose function is not known, 
conversion to the misfolded, transmissible prion isoform is blocked. However, quinacrine 
cannot pass through the blood-brain barrier so it has limited therapeutic applications in 
animal models [49]. Therapeutic research for prion diseases now includes an array of 
compounds such as the polycationic compounds (i.e., dendritic polyamines), 
polysulphate polyanions/glycosaminoglycans, tetracyclic compounds, and tetrapyrrolic 
compounds that have anti-prion activities [130]. 
6. Conclusion 
 Much progress has been made in characterizing and understanding the structure 
and assembly of amyloid. The most toxic species in amyloid disorders are widely 
considered to be the oligomers preceding the formation of mature amyloid fibrils and 
plaque deposits. In addition, the conformational conversion process itself may cause 
downstream events that contribute to neurodegeneration. There are many pressing 
questions left to address in the field of amyloid proteins and neurodegenerative disease. 
It has been challenging to determine the structural identity and associated toxicity of 
various oligomers. However, the heterogeneous nature of oligomers and amyloids could 
explain the diverse phenotypes and clinical symptoms associated with different 
neurodegenerative diseases. Additionally, it is unknown when the soluble oligomers 
cause toxicity during the course of a disease and what molecular events trigger an initial 
misfolding event, which leads to amyloid generation. Is the initiating molecular event 
gradual, stochastic, spontaneous, or cumulative? Moreover, what is the time course of 
protein aggregation, and how does the cellular protein quality control system contribute 
to the development of plaques and the onset disease? Early intervention will most likely 
provide the best therapeutic advantage to mitigating these diseases. Research that 
examines the molecular mechanisms of amyloid assembly and accumulation and 
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investigates the conformations of cytotoxic pre-amyloid oligomers will provide valuable 
information that could be applied to the development of disease-modifying therapies.  
 
References 
1. Selkoe DJ (2003) Folding proteins in fatal ways. Nature 426 (6968):900-904. 
doi:10.1038/nature02264 
2. Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative 
disease. Science 296 (5575):1991-1995. doi:10.1126/science.1067122 
3. Cerasoli E, Ryadnov MG, Austen BM (2015) The elusive nature and diagnostics of 
misfolded Abeta oligomers. Frontiers in chemistry 3:17. doi:10.3389/fchem.2015.00017 
4. Alzheimer's A (2017) 2017 Alzheimer's disease facts and figures. Alzheimers Dement 
13:325-373 
5. Morimoto RI, Kline MP, Bimston DN, Cotto JJ (1997) The heat-shock response: 
regulation and function of heat-shock proteins and molecular chaperones. Essays 
Biochem 32:17-29 
6. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease 
intervention. Science 319 (5865):916-919. doi:10.1126/science.1141448 
7. Chaudhuri TK, Paul S (2006) Protein-misfolding diseases and chaperone-based 
therapeutic approaches. The FEBS journal 273 (7):1331-1349. doi:10.1111/j.1742-
4658.2006.05181.x 
8. Sarge KD, Murphy SP, Morimoto RI (1993) Activation of heat shock gene transcription 
by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and 
nuclear localization and can occur in the absence of stress. Mol Cell Biol 13 (3):1392-
1407 
9. Sorger PK (1991) Heat shock factor and the heat shock response. Cell 65 (3):363-366 
26 
 
10. Richard I Morimoto DJ, P Kroeger, S Mathur, S Murphy, A Nakai, K Sarge, K 
Abravaya, L Sistonen (1994) Regulation of Heat Shock Gene Transcription by a Family 
of Heat Shock Transcription Factors. The Biology of Heat Shock Proteins and Molecular 
Chaperones:417-455 
11. Lindquist S, Craig EA (1988) The heat-shock proteins. Annu Rev Genet 22:631-677. 
doi:10.1146/annurev.ge.22.120188.003215 
12. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI (2006) Progressive 
disruption of cellular protein folding in models of polyglutamine diseases. Science 311 
(5766):1471-1474. doi:10.1126/science.1124514 
13. Gidalevitz T, Krupinski T, Garcia S, Morimoto RI (2009) Destabilizing protein 
polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 
toxicity. PLoS Genet 5 (3):e1000399. doi:10.1371/journal.pgen.1000399 
14. Ben-Zvi A, Miller EA, Morimoto RI (2009) Collapse of proteostasis represents an 
early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci U S A 106 
(35):14914-14919. doi:10.1073/pnas.0902882106 
15. Brehme M, Voisine C, Rolland T, Wachi S, Soper JH, Zhu Y, Orton K, Villella A, 
Garza D, Vidal M, Ge H, Morimoto RI (2014) A chaperome subnetwork safeguards 
proteostasis in aging and neurodegenerative disease. Cell Rep 9 (3):1135-1150. 
doi:10.1016/j.celrep.2014.09.042 
16. Tanaka K, Matsuda N (2014) Proteostasis and neurodegeneration: the roles of 
proteasomal degradation and autophagy. Biochimica et biophysica acta 1843 (1):197-
204. doi:10.1016/j.bbamcr.2013.03.012 
17. Gray DA, Tsirigotis M, Woulfe J (2003) Ubiquitin, proteasomes, and the aging brain. 




18. Carrard G, Bulteau AL, Petropoulos I, Friguet B (2002) Impairment of proteasome 
structure and function in aging. The international journal of biochemistry & cell biology 34 
(11):1461-1474 
19. Tycko R (2004) Progress towards a molecular-level structural understanding of 
amyloid fibrils. Curr Opin Struct Biol 14 (1):96-103. doi:10.1016/j.sbi.2003.12.002 
20. Golde TE, Miller VM (2009) Proteinopathy-induced neuronal senescence: a 
hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. 
Alzheimers Res Ther 1 (2):5. doi:10.1186/alzrt5 
21. Petkova AT, Yau WM, Tycko R (2006) Experimental constraints on quaternary 
structure in Alzheimer's beta-amyloid fibrils. Biochemistry 45 (2):498-512. 
doi:10.1021/bi051952q 
22. Groenning M (2010) Binding mode of Thioflavin T and other molecular probes in the 
context of amyloid fibrils-current status. J Chem Biol 3 (1):1-18. doi:10.1007/s12154-
009-0027-5 
23. Nelson R, Eisenberg D (2006) Recent atomic models of amyloid fibril structure. 
Current opinion in structural biology 16 (2):260-265. doi:10.1016/j.sbi.2006.03.007 
24. Greenwald J, Riek R (2010) Biology of amyloid: structure, function, and regulation. 
Structure 18 (10):1244-1260. doi:10.1016/j.str.2010.08.009 
25. Zerovnik E (2002) Amyloid-fibril formation. Proposed mechanisms and relevance to 
conformational disease. European journal of biochemistry / FEBS 269 (14):3362-3371 
26. Lindgren M, Hammarstrom P (2010) Amyloid oligomers: spectroscopic 
characterization of amyloidogenic protein states. FEBS J 277 (6):1380-1388. 
doi:10.1111/j.1742-4658.2010.07571.x 
27. Holmes BB, Diamond MI (2012) Cellular mechanisms of protein aggregate 




28. Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ (2015) Spreading of 
pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 
16 (2):109-120. doi:10.1038/nrn3887 
29. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) 
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer 
cytoskeletal pathology. Proc Natl Acad Sci U S A 83 (13):4913-4917 
30. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is 
a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl 
Acad Sci U S A 83 (11):4044-4048 
31. Ihara Y, Nukina N, Miura R, Ogawara M (1986) Phosphorylated tau protein is 
integrated into paired helical filaments in Alzheimer's disease. J Biochem 99 (6):1807-
1810 
32. Perl DP (2010) Neuropathology of Alzheimer's disease. The Mount Sinai journal of 
medicine, New York 77 (1):32-42. doi:10.1002/msj.20157 
33. Breydo L, Wu JW, Uversky VN (2012) Alpha-synuclein misfolding and Parkinson's 
disease. Biochimica et biophysica acta 1822 (2):261-285. 
doi:10.1016/j.bbadis.2011.10.002 
34. Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington's disease. 
Experimental neurology 238 (1):1-11. doi:10.1016/j.expneurol.2011.12.013 
35. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe 
KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive 
function. Nature neuroscience 8 (1):79-84. doi:10.1038/nn1372 
36. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 
216 (4542):136-144 
37. Moore RA, Taubner LM, Priola SA (2009) Prion protein misfolding and disease. 
Current opinion in structural biology 19 (1):14-22. doi:10.1016/j.sbi.2008.12.007 
29 
 
38. Fink AL (1998) Protein aggregation: folding aggregates, inclusion bodies and 
amyloid. Folding & design 3 (1):R9-23. doi:10.1016/S1359-0278(98)00002-9 
39. Murphy RM (2007) Kinetics of amyloid formation and membrane interaction with 
amyloidogenic proteins. Biochimica et biophysica acta 1768 (8):1923-1934. 
doi:10.1016/j.bbamem.2006.12.014 
40. Koo EH, Lansbury PT, Jr., Kelly JW (1999) Amyloid diseases: abnormal protein 
aggregation in neurodegeneration. Proceedings of the National Academy of Sciences of 
the United States of America 96 (18):9989-9990 
41. Ruschak AM, Miranker AD (2009) The role of prefibrillar structures in the assembly 
of a peptide amyloid. J Mol Biol 393 (1):214-226. doi:10.1016/j.jmb.2009.06.026 
42. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM (1998) Amyloid fibril 
formation by an SH3 domain. Proceedings of the National Academy of Sciences of the 
United States of America 95 (8):4224-4228 
43. Klunk WE, Pettegrew JW, Abraham DJ (1989) Quantitative evaluation of congo red 
binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem 
Cytochem 37 (8):1273-1281. doi:10.1177/37.8.2666510 
44. Naiki H, Higuchi K, Hosokawa M, Takeda T (1989) Fluorometric determination of 
amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 177 (2):244-
249 
45. Reinke AA, Gestwicki JE (2011) Insight into amyloid structure using chemical 
probes. Chemical biology & drug design 77 (6):399-411. doi:10.1111/j.1747-
0285.2011.01110.x 




47. Bolder SG, Sagis LM, Venema P, van der Linden E (2007) Thioflavin T and 
birefringence assays to determine the conversion of proteins into fibrils. Langmuir 23 
(8):4144-4147. doi:10.1021/la063048k 
48. Hawe A, Sutter M, Jiskoot W (2008) Extrinsic fluorescent dyes as tools for protein 
characterization. Pharm Res 25 (7):1487-1499. doi:10.1007/s11095-007-9516-9 
49. Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, Roy R, 
Singh S (2005) Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 151 
(3):229-238. doi:10.1016/j.jsb.2005.06.006 
50. Canete M, Villanueva A, Juarranz A, Stockert JC (1987) A study of interaction of 
thioflavine T with DNA: evidence for intercalation. Cell Mol Biol 33 (2):191-199 
51. Kelenyi G (1967) On the histochemistry of azo group-free thiazole dyes. J Histochem 
Cytochem 15 (3):172-180. doi:10.1177/15.3.172 
52. Hudson SA, Ecroyd H, Kee TW, Carver JA (2009) The thioflavin T fluorescence 
assay for amyloid fibril detection can be biased by the presence of exogenous 
compounds. FEBS J 276 (20):5960-5972. doi:10.1111/j.1742-4658.2009.07307.x 
53. Biancalana M, Koide S (2010) Molecular mechanism of Thioflavin-T binding to 
amyloid fibrils. Biochimica et biophysica acta 1804 (7):1405-1412. 
doi:10.1016/j.bbapap.2010.04.001 
54. Ratnaswamy G, Koepf E, Bekele H, Yin H, Kelly JW (1999) The amyloidogenicity of 
gelsolin is controlled by proteolysis and pH. Chem Biol 6 (5):293-304. 
doi:10.1016/S1074-5521(99)80075-1 
55. Jarrett JT, Lansbury PT, Jr. (1992) Amyloid fibril formation requires a chemically 
discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial 
protein OsmB. Biochemistry 31 (49):12345-12352 
31 
 
56. Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R (2002) Amyloid-like 
features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41 
(23):7391-7399 
57. Klunk WE, Jacob RF, Mason RP (1999) Quantifying amyloid beta-peptide (Abeta) 
aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal 
Biochem 266 (1):66-76. doi:10.1006/abio.1998.2933 
58. Miura T, Thomas GJ, Jr. (1995) Raman spectroscopy of proteins and their 
assemblies. Subcell Biochem 24:55-99 
59. Klunk WE, Jacob RF, Mason RP (1999) Quantifying amyloid by congo red spectral 
shift assay. Methods Enzymol 309:285-305 
60. Lindgren M, Sorgjerd K, Hammarstrom P (2005) Detection and characterization of 
aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence 
spectroscopy. Biophys J 88 (6):4200-4212. doi:10.1529/biophysj.104.049700 
61. Teoh CL, Su D, Sahu S, Yun SW, Drummond E, Prelli F, Lim S, Cho S, Ham S, 
Wisniewski T, Chang YT (2015) Chemical Fluorescent Probe for Detection of Abeta 
Oligomers. Journal of the American Chemical Society. doi:10.1021/jacs.5b06190 
62. Ono M, Watanabe H, Kimura H, Saji H (2012) BODIPY-based molecular probe for 
imaging of cerebral beta-amyloid plaques. ACS chemical neuroscience 3 (4):319-324. 
doi:10.1021/cn3000058 
63. Schmued L, Raymick J, Tolleson W, Sarkar S, Zhang YH, Bell-Cohn A (2012) 
Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer 
especially suited for multiple labeling and large scale quantification studies. J Neurosci 
Methods 209 (1):120-126. doi:10.1016/j.jneumeth.2012.05.019 
64. Sarkar S, Raymick J, Schmued LC (2014) The use of recently developed 
histochemical markers for localizing neurotoxicant induced regional brain pathologies. 
Toxins (Basel) 6 (4):1453-1470. doi:10.3390/toxins6041453 
32 
 
65. Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion 
protein by cyclic amplification of protein misfolding. Nature 411 (6839):810-813. 
doi:10.1038/35081095 
66. Barria MA, Gonzalez-Romero D, Soto C (2012) Cyclic amplification of prion protein 
misfolding. Methods in molecular biology 849:199-212. doi:10.1007/978-1-61779-551-
0_14 
67. Gonzalez-Montalban N, Makarava N, Ostapchenko VG, Savtchenk R, Alexeeva I, 
Rohwer RG, Baskakov IV (2011) Highly efficient protein misfolding cyclic amplification. 
PLoS pathogens 7 (2):e1001277. doi:10.1371/journal.ppat.1001277 
68. Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, Johnson LM, 
Onwubiko HA, Priola SA, Caughey B (2008) Simplified ultrasensitive prion detection by 
recombinant PrP conversion with shaking. Nature methods 5 (3):211-212. 
doi:10.1038/nmeth0308-211 
69. Chen B, Morales R, Barria MA, Soto C (2010) Estimating prion concentration in 
fluids and tissues by quantitative PMCA. Nature methods 7 (7):519-520. 
doi:10.1038/nmeth.1465 
70. Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C (2014) Detection of 
misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer's disease. 
Cell reports 7 (1):261-268. doi:10.1016/j.celrep.2014.02.031 
71. Colby DW, Zhang Q, Wang S, Groth D, Legname G, Riesner D, Prusiner SB (2007) 
Prion detection by an amyloid seeding assay. Proceedings of the National Academy of 
Sciences of the United States of America 104 (52):20914-20919. 
doi:10.1073/pnas.0710152105 
72. Wilham JM, Orru CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, 
Taubner LM, Timmes A, Caughey B (2010) Rapid end-point quantitation of prion 
33 
 
seeding activity with sensitivity comparable to bioassays. PLoS pathogens 6 
(12):e1001217. doi:10.1371/journal.ppat.1001217 
73. Atarashi R, Sano K, Satoh K, Nishida N (2011) Real-time quaking-induced 
conversion: a highly sensitive assay for prion detection. Prion 5 (3):150-153. 
doi:10.4161/pri.5.3.16893 
74. Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, 
Krautkramer MJ, Kung HF, Skovronsky DM, Hefti F, Clark CM (2012) Correlation of 
amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque 
deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 26 (1):8-16. 
doi:10.1097/WAD.0b013e31821300bc 
75. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, 
DeKosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using 
PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25 (11):1528-
1547. doi:10.1038/sj.jcbfm.9600146 
76. Koo J, Byun Y (2013) Current status of PET-imaging probes of beta-amyloid 
plaques. Arch Pharm Res 36 (10):1178-1184. doi:10.1007/s12272-013-0193-4 
77. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE (2012) Amyloid 
imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B 
positron emission tomography. J Neurol Neurosurg Psychiatry 83 (9):923-926. 
doi:10.1136/jnnp-2012-302548 
78. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, 
Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, 
Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM, 
Group A-AS (2012) Cerebral PET with florbetapir compared with neuropathology at 
autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. The 
Lancet Neurology 11 (8):669-678. doi:10.1016/S1474-4422(12)70142-4 
34 
 
79. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP (1995) 
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's 
disease. Arch Neurol 52 (1):81-88 
80. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary 
tangles but not senile plaques parallel duration and severity of Alzheimer's disease. 
Neurology 42 (3 Pt 1):631-639 
81. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y (2014) Tau PET 
imaging in Alzheimer's disease. Curr Neurol Neurosci Rep 14 (11):500. 
doi:10.1007/s11910-014-0500-6 
82. Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, 
Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, 
Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gomez-Isla T (2015) 
Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on 
postmortem brain tissue. Ann Neurol 78 (5):787-800. doi:10.1002/ana.24517 
83. Xia Y, Nivet E, Sancho-Martinez I, Gallegos T, Suzuki K, Okamura D, Wu MZ, 
Dubova I, Esteban CR, Montserrat N, Campistol JM, Izpisua Belmonte JC (2013) 
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like 
cells. Nat Cell Biol 15 (12):1507-1515. doi:10.1038/ncb2872 
84. Scholl M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker 
SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ (2016) PET Imaging 
of Tau Deposition in the Aging Human Brain. Neuron 89 (5):971-982. 
doi:10.1016/j.neuron.2016.01.028 
85. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ (2002) 
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal 




86. Bopp SK, Lettieri T (2008) Comparison of four different colorimetric and fluorometric 
cytotoxicity assays in a zebrafish liver cell line. BMC pharmacology 8:8. 
doi:10.1186/1471-2210-8-8 
87. Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of 
amyloid beta-protein oligomers. Proceedings of the National Academy of Sciences of the 
United States of America 106 (35):14745-14750. doi:10.1073/pnas.0905127106 
88. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, 
Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar 
S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, 
Zhivotovsky B, Melino G, Nomenclature Committee on Cell D (2009) Classification of 
cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell 
Death Differ 16 (1):3-11. doi:10.1038/cdd.2008.150 
89. Mery B, Guy JB, Vallard A, Espenel S, Ardail D, Rodriguez-Lafrasse C, Rancoule C, 
Magne N (2017) In Vitro Cell Death Determination for Drug Discovery: A Landscape 
Review of Real Issues. J Cell Death 10:1179670717691251. 
doi:10.1177/1179670717691251 
90. Fotakis G, Timbrell JA (2006) In vitro cytotoxicity assays: comparison of LDH, neutral 
red, MTT and protein assay in hepatoma cell lines following exposure to cadmium 
chloride. Toxicology letters 160 (2):171-177. doi:10.1016/j.toxlet.2005.07.001 
91. Decker T, Lohmann-Matthes ML (1988) A quick and simple method for the 
quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity 
and tumor necrosis factor (TNF) activity. J Immunol Methods 115 (1):61-69 
92. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, 
Lieberburg I, Becker GW, Brems DN, et al. (1994) Secondary structure of amyloid beta 




93. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG 
(2003) Common structure of soluble amyloid oligomers implies common mechanism of 
pathogenesis. Science 300 (5618):486-489. doi:10.1126/science.1079469 
94. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1-2):55-63 
95. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a 
tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity 
testing. Cancer Res 47 (4):936-942 
96. Crissman HA, Orlicky DJ, Kissane RJ (1979) Fluorescent DNA probes for flow 
cytometry. Considerations and prospects. J Histochem Cytochem 27 (12):1652-1654. 
doi:10.1177/27.12.391999 
97. Roden MM, Lee KH, Panelli MC, Marincola FM (1999) A novel cytolysis assay using 
fluorescent labeling and quantitative fluorescent scanning technology. J Immunol 
Methods 226 (1-2):29-41 
98. Papadopoulos NG, Dedoussis GV, Spanakos G, Gritzapis AD, Baxevanis CN, 
Papamichail M (1994) An improved fluorescence assay for the determination of 
lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods 177 (1-
2):101-111 
99. Weston SA, Parish CR (1990) New fluorescent dyes for lymphocyte migration 
studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods 
133 (1):87-97 
100. Wisniewski T, Sadowski M (2008) Preventing beta-amyloid fibrillization and 
deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC 
neuroscience 9 Suppl 2:S5. doi:10.1186/1471-2202-9-S2-S5 
101. Kanthasamy AG, Choi C, Jin H, Harischandra DS, Anantharam V, Kanthasamy A 
(2012) Effect of divalent metals on the neuronal proteasomal system, prion protein 
37 
 
ubiquitination and aggregation. Toxicology letters 214 (3):288-295. 
doi:10.1016/j.toxlet.2012.09.008 
102. Jacobson T, Navarrete C, Sharma SK, Sideri TC, Ibstedt S, Priya S, Grant CM, 
Christen P, Goloubinoff P, Tamas MJ (2012) Arsenite interferes with protein folding and 
triggers formation of protein aggregates in yeast. Journal of cell science 125 (Pt 
21):5073-5083. doi:10.1242/jcs.107029 
103. Tamas MJ, Sharma SK, Ibstedt S, Jacobson T, Christen P (2014) Heavy metals 
and metalloids as a cause for protein misfolding and aggregation. Biomolecules 4 
(1):252-267. doi:10.3390/biom4010252 
104. Basha MR, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK, Lashuel HA, Ge YW, Lahiri 
DK, Zawia NH (2005) Lead (Pb) exposure and its effect on APP proteolysis and Abeta 
aggregation. FASEB J 19 (14):2083-2084. doi:10.1096/fj.05-4375fje 
105. Cheng B, Gong H, Xiao H, Petersen RB, Zheng L, Huang K (2013) Inhibiting toxic 
aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding 
diseases. Biochimica et biophysica acta 1830 (10):4860-4871. 
doi:10.1016/j.bbagen.2013.06.029 
106. Hard T, Lendel C (2012) Inhibition of amyloid formation. Journal of molecular 
biology 421 (4-5):441-465. doi:10.1016/j.jmb.2011.12.062 
107. Francioso A, Punzi P, Boffi A, Lori C, Martire S, Giordano C, D'Erme M, Mosca L 
(2015) beta-sheet interfering molecules acting against beta-amyloid aggregation and 
fibrillogenesis. Bioorganic & medicinal chemistry 23 (8):1671-1683. 
doi:10.1016/j.bmc.2015.02.041 
108. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B (1998) 
Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: 
implications for Alzheimer's therapy. Nature medicine 4 (7):822-826 
38 
 
109. Soto C, Kindy MS, Baumann M, Frangione B (1996) Inhibition of Alzheimer's 
amyloidosis by peptides that prevent beta-sheet conformation. Biochemical and 
biophysical research communications 226 (3):672-680. doi:10.1006/bbrc.1996.1413 
110. Viet MH, Ngo ST, Lam NS, Li MS (2011) Inhibition of aggregation of amyloid 
peptides by beta-sheet breaker peptides and their binding affinity. The journal of physical 
chemistry B 115 (22):7433-7446. doi:10.1021/jp1116728 
111. Panza F, Solfrizzi V, Imbimbo BP, Logroscino G (2014) Amyloid-directed 
monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? 
Expert opinion on biological therapy 14 (10):1465-1476. 
doi:10.1517/14712598.2014.935332 
112. Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak 
R, Mehta P, Wisniewski T (2010) Immunomodulation targeting abnormal protein 
conformation reduces pathology in a mouse model of Alzheimer's disease. PloS one 5 
(10):e13391. doi:10.1371/journal.pone.0013391 
113. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, 
Legleiter J, Marsh JL, Thompson LM, Lindquist S, Muchowski PJ, Wanker EE (2006) 
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding 
and reduces toxicity in Huntington's disease models. Human molecular genetics 15 
(18):2743-2751. doi:10.1093/hmg/ddl210 
114. Maiti P, Manna J, Veleri S, Frautschy S (2014) Molecular chaperone dysfunction in 
neurodegenerative diseases and effects of curcumin. BioMed research international 
2014:495091. doi:10.1155/2014/495091 
115. Ahmed AH, Subaiea GM, Eid A, Li L, Seeram NP, Zawia NH (2014) Pomegranate 
extract modulates processing of amyloid-beta precursor protein in an aged Alzheimer's 
disease animal model. Curr Alzheimer Res 11 (9):834-843 
39 
 
116. Dobson CM (2004) Principles of protein folding, misfolding and aggregation. 
Seminars in cell & developmental biology 15 (1):3-16. 
doi:10.1016/j.semcdb.2003.12.008 
117. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU (2000) 
Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into 
amyloid-like fibrils. Proceedings of the National Academy of Sciences of the United 
States of America 97 (14):7841-7846. doi:10.1073/pnas.140202897 
118. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of 
heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone 
ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl 
Acad Sci U S A 91 (18):8324-8328 
119. Westerheide SD, Morimoto RI (2005) Heat shock response modulators as 
therapeutic tools for diseases of protein conformation. The Journal of biological 
chemistry 280 (39):33097-33100. doi:10.1074/jbc.R500010200 
120. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic 
evaluation of geldanamycin as an antitumor agent. Cancer chemotherapy and 
pharmacology 36 (4):305-315. doi:10.1007/BF00689048 
121. Kitson RR, Chang CH, Xiong R, Williams HE, Davis AL, Lewis W, Dehn DL, Siegel 
D, Roe SM, Prodromou C, Ross D, Moody CJ (2013) Synthesis of 19-substituted 
geldanamycins with altered conformations and their binding to heat shock protein 
Hsp90. Nature chemistry 5 (4):307-314. doi:10.1038/nchem.1596 
122. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, 
Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS, Jr., Hutton 
M, Burrows F, Petrucelli L (2007) The high-affinity HSP90-CHIP complex recognizes and 
selectively degrades phosphorylated tau client proteins. The Journal of clinical 
investigation 117 (3):648-658. doi:10.1172/JCI29715 
40 
 
123. Bailey CK, Andriola IF, Kampinga HH, Merry DE (2002) Molecular chaperones 
enhance the degradation of expanded polyglutamine repeat androgen receptor in a 
cellular model of spinal and bulbar muscular atrophy. Human molecular genetics 11 
(5):515-523 
124. Schirmer EC, Glover JR, Singer MA, Lindquist S (1996) HSP100/Clp proteins: a 
common mechanism explains diverse functions. Trends in biochemical sciences 21 
(8):289-296 
125. Shorter J, Lindquist S (2008) Hsp104, Hsp70 and Hsp40 interplay regulates 
formation, growth and elimination of Sup35 prions. The EMBO journal 27 (20):2712-
2724. doi:10.1038/emboj.2008.194 
126. Muchowski PJ (2002) Protein misfolding, amyloid formation, and 
neurodegeneration: a critical role for molecular chaperones? Neuron 35 (1):9-12 
127. Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine 
derivatives as pharmacotherapeutics for prion disease. Proceedings of the National 
Academy of Sciences of the United States of America 98 (17):9836-9841. 
doi:10.1073/pnas.161274798 
128. May BC, Fafarman AT, Hong SB, Rogers M, Deady LW, Prusiner SB, Cohen FE 
(2003) Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. 
Proceedings of the National Academy of Sciences of the United States of America 100 
(6):3416-3421. doi:10.1073/pnas.2627988100 
129. Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, Zahn R 
(2003) Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. 
Journal of medicinal chemistry 46 (17):3563-3564. doi:10.1021/jm034093h 
130. Trevitt CR, Collinge J (2006) A systematic review of prion therapeutics in 
























Figure 1. A.) Amyloid assembly cascade. Natively folded proteins that are 
amyloidogenic may misfold into a non-native conformation, which can then self-
associate and undergo nucleation to form fibrils. Additional elongation and 
condensation events enable further accumulation into amyloid containing 
aggregates. In vitro seeding and amplification assays such as PMCA, ASA, and 
RT-QuiCK can detect and quantitate pre-amyloid intermediates. Amyloid specific 
dyes ThioflavinT and Congo Red bind to amyloid-containing aggregates and can 
be used to monitor amyloid assembly kinetics in vitro.   
B.) Protein aggregates of Alzheimer's Disease. Alzheimer's disease (AD) is 
characterized by the histopathological hallmarks of extracellular amyloid plaques 
and intracellular neurofibrillary tangles (NFT's). Amyloid plaques are largely 
composed of amyloid-beta peptide, which is a product of cleavage of amyloid 
precursor protein (APP). Phosphorylated tau (p-Tau) is a microtubule-associated 
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Molecular chaperone proteins are required for maintaining protein 
homeostasis by facilitating proper folding of nascent polypeptides, misfolded proteins 
and unfolded proteins. Hsp104 belongs to the AAA+ (ATPases associated with 
diverse cellular activities) superfamily of ATPases that share similar domain 
organization. In Saccharomyces cerevisiae, heat shock protein 104 (Hsp104) 
regulates prion inheritance and coordinates with Hsp70 and Hsp40 to disassemble 
aggregated proteins, including amyloids. In the yeast prion model system of [PSI+], 
overexpression of Hsp104 cures yeast cells of the [PSI+] prion. Previous research 
showed that [PSI+] prion curing mediated by Hsp104 overexpression requires the N-
domain of Hsp104 (1). To further investigate the biochemical mechanism of amyloid 
recognition and prion curing by Hsp104 overexpression, we constructed an hsp104 
gene library containing mutations in the N-terminal domain and screened clonal 
isolates in Saccharomyces cerevisiae using the [PSI+] colorimetric assay. Using a 
novel, quantitative fluorescence-based assay we identified several specific sites in the 
N-domain of Hsp104 that are essential for [PSI+] curing by Hsp104 overexpression. 
This study provides novel insight into chaperone-mediated recognition and 
disassembly of amyloids, which are expressed in yeast as prions and are pervasive in 
human neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s 






 Prions are amyloidogenic protein conformations that propagate from cell to 
cell in either a functional or pathogenic capacity (2, 3, 4). Prions are non-genetic 
elements that self-template and are inherited in a non-Mendelian manner; reversion of 
the prion fold to the native fold, also referred to as prion curing, is reversible (5). 
Budding yeast have been shown to contain as many as eight propagating prions (4). 
One of the most extensively studied prions in yeast is Sup35, which confers the 
phenotype [PSI+].  
 Sup35 is a translation termination protein that exists in at least two 
conformations: the native conformation and the prion conformation (6). The [psi-] 
phenotype in S. cerevisiae is characterized by the presence of soluble, natively folded 
Sup35 protein (Sup35p), which recognizes stop codons and subsequently releases 
polypeptides from the ribosome (7). In yeast, Sup35 can adopt the prion conformation 
and subsequently aggregate into insoluble amyloid fibrils, thus decreasing the pool of 
soluble Sup35 protein (8). The [PSI+] phenotype is characterized by low levels of 
soluble Sup35p and high levels of insoluble Sup35, which results in translation 
termination errors from read-through of nonsense codons (9). Therefore, the 
presence or absence of [PSI+] in yeast can be determined by monitoring translation 
efficiency of a nonsense codon present in the adenine biosynthesis gene ade2. This 
mutation, ade2-1 ochre, leads to accumulation of aminoimidazole ribotide (AIR), a 
red-colored intermediate produced during in the formation of purine bases, in cells 
with functional Sup35 (10, 11). The [PSI+] red/white colorimetric assay is reliably used 
to monitor translation fidelity as a marker of prion phenotype in yeast. The 
accumulation of amyloid aggregates (prions) alleviates the accumulation of the red-
pigmented metabolite in strains carrying mutations in the adenine biosynthesis 
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pathway (11). The prion conformation of Sup35 protein, referred to as the [PSI+] 
phenotype, thus suppresses nonsense mutations and colonies appear white on solid 
media (12). This traditional [PSI+] assay is both qualitative and binary; the phenotype 
[psi-] can be identified by red colonies and the phenotype [PSI+] is associated with 
white colonies.  Strong [PSI+] and weak [PSI+] phenotypes in yeast have been 
observed in research studies that impaired Hsp70 binding to prion in yeast (13). A 
strong [PSI+] phenotype refers to strong lack of red pigmentation and mitotic stability 
(13). Mutations in the middle domain of Hsp104 also affect prion propagation in yeast 
and yield differential [PSI+] phenotypes that range in color from pink to red yeast 
colonies (14). 
Hsp104 is an ATP-dependent molecular chaperone protein that functions to 
remodel the Sup35 amyloid and segregate it into daughter cells during division. 
Hsp104 is a ring-shaped hexameric protein that belongs to the AAA+ (ATPases 
associated with diverse cellular activities) ATPase protein superfamily (15, 16). 
Common to all AAA+ proteins are highly conserved nucleotide binding domains that 
contain Walker motifs (17). Several proteins in the AAA+ superfamily use mechanical 
force to remodel substrate proteins by hydrolyzing ATP (18). Hsp104 contains two 
nucleotide-binding domains per subunit that function cooperatively (19, 20). The 
flexible pore loops of Hsp100 proteins are critical for substrate translocation and 
protein remodeling. Mutations targeting the pore loops of Hsp100 proteins, such as 
HslU and ClpX, impair substrate engagement and translocation of polypeptides 
through the axial channel (21, 22). The mechanism for Hsp104-mediated 
disaggregation is thought to rely on the threading of polypeptides through an axial 
channel. Cryoelectron microscopy maps of Hsp104 hexamers bound to different 
nucleotides suggests that the two nucleotide binding domains of Hsp104 form stacked 
47 
 
rings and a central cavity (23). Research suggests that substrates are disaggregated 
by Hsp104 by threading and translocation of substrate through the axial channel into 
the central cavity of Hsp104 due to substrate binding of the NBD1 and NBD2 rings 
coupled to sequential ATP hydrolysis (23). Conserved tyrosine residues (pore-loop) 
located in the central channel of Hsp104 bind to and grip polypeptides (24 – 28). The 
mechanism of disaggregation by substrate threading and translocation is conserved 
in ClpB, the bacterial homolog of Hsp104 (26, 28, 29, 30). ATP hydrolysis cycles 
cause changes in the conformation of Hsp104, thus providing the mechanical force 
required to unfold and translocate polypeptides through the axial pore of Hsp104 (23, 
26). 
Hsp104 remodels heterogenous aggregates, including amorphous as well as 
highly ordered amyloid aggregates (31 – 33). Hsp104 reactivates misfolded proteins 
and is necessary for prion inheritance in Saccharomyces cerevisiae (34, 35). It is 
thought that Hsp104 fragments prions and generates seeds for prion assembly, which 
catalyzes the propagation of prions in yeast (36). All yeast prions with the exception of 
[PSI+] require Hsp104 for prion propagation (37 – 42). Deletion of the hsp104 gene 
results in the loss of the prions [PSI+], [URE3], [PIN+]/[RNQ+], [SWI+], and [MOT3] (35, 
41). Hsp104 fragments prion fibrils and generates amyloid seeds, which function as 
propagation units that accelerate the self-assembly of prions; deletion of hsp104 is 
thought to inhibit the fragmentation of prions, resulting in large aggregates that cannot 
be efficiently transmitted from mother to daughter yeast cells (41). Moreover, 
overexpression of the Hsp40 yeast protein Ydj1p cures the [URE3] prion, possibly by 
an Hsp70/Hsp40 mechanism (42). The overexpression of Hsp104 cures yeast of the 
[PSI+] and [MCA] prions (41, 43).  
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The N-terminal domain of Hsp104 (amino acid residues 1 – 147) is 
dispensable for thermotolerance, protein disaggregation of select substrates, and 
[PSI+] prion propagation, but is required for [PSI+] loss (prion curing) when Hsp104 is 
overexpressed in vivo (1). Hsp104 cooperates with the Hsp70/40 chaperone system 
to disaggregate proteins in vivo (44, 45). Hsp70 acts upstream of Hsp104 and 
regulates Hsp104 binding to protein aggregates (46). Hsp70 is required for species-
specific targeting of client proteins to ClpB and Hsp104, suggesting a conserved 
mechanism of substrate binding and disaggregation by the Hsp70-Hsp100 chaperone 
system at the surface of protein aggregates (32). Hsp70 binds to the middle domain 
of Hsp104, which may facilitate threading of protein substrates through the Hsp104 
axial channel (47, 48).  
Analysis of the crystallized structure of the N-terminal domain of Hsp104 in S. 
cerevisiae suggests that misfolded proteins may bind to the N-domain (49). The 
unstructured linker of ClpB is thought to regulate the position of the N-domain and 
affect substrate binding to aggregates (50). Currently, it is unknown where amyloids 
(prions) bind to Hsp104. Given that the N-domain is implicated in recognizing amyloid, 
further investigation into the N-domain of Hsp104 is warranted to better characterize 
substrate binding to Hsp104. Therefore, we randomly mutagenized the N-domain of 
Hsp104 and screened clonal isolates in S. cerevisiae using the [PSI+] colorimetric 
assay to monitor changes in prion phenotype and possible impairments of Hsp104 
binding to prion substrate. We found several mutations in the Hsp104 N-domain that 
are impaired for prion curing, thermotolerance, and disaggregation, suggesting an 






Curing of [PSI+] by Hsp104 overexpression detected by fluorescence 
Although the [PSI+] colorimetric conversion assay has been widely used to 
qualitatively assess amyloid abundance and prion inheritance, it does not allow for 
quantitative detection of intermediate phenotypes. Therefore, we developed a novel 
fluorometric assay to quantitatively characterize different [PSI+] phenotypes in yeast, 
which are associated with differential translation termination efficiency and [PSI+] 
prion propagation. Yeast carrying the ade2-1 nonsense mutation in the adenine 
biosynthesis pathways accumulate red pigment due to the polymerization of 
aminoimidazole ribotide (10). The polymerization and oxidation of 4-aminoimidazole 
ribotide in the yeast vacuole results in the accumulation of an endogenously 
fluorescent red pigment (51). The red pigment stably persists in the vacuole and 
fluorescence has been previously observed by excitation at 450 – 490 nm and 
visualization of emitted light at 520-nm (51). The [PSI+] prion phenotype in yeast can 
be detected in ade2-1 mutants by screening yeast cells for white colony color; red 
colonies of yeast carrying the ade2-1 mutation are [psi-] and contain mostly soluble, 
functional Sup35 protein (11).  
To determine if red pigment accumulation is quantifiable in cell lysates by 
fluorescence, we cultured [psi-] and [PSI+] yeast on agar plates for five days until red 
colonies were visible for the [psi-] strain (Figure 1A). We harvested cells from solid 
media, lysed the cells with glass beads and measured protein concentrations of the 
soluble lysate. We monitored fluorescence emission spectra of soluble cell extracts, 
normalized to total protein, following excitation at 488 nm. Fluorescence has also 
previously been used to separate mixed populations of red and white yeast cells by 
fluorescence-activated cell sorting (FACS) with an excitation at 488 nm (52). We 
50 
 
observed that [psi-] cell lysates produce a large, broad emission peak at 565 nm; 
however, a much lower emission peak was detected for [PSI+] cell lysates (Figure 
1B).  
To determine if the amplitude of the emission peak is dependent on the protein 
concentration in [psi-] cell lysate, we compared emission spectra over a range of 
concentrations (0.05 to 0.8 mg ml-1) (Figure 1C). We observed that as protein 
concentration increased, the amplitude of the emission peak at 565 nm also 
increased, indicating that the emission detected is concentration-dependent, tracking 
with soluble protein. This also provided evidence that our novel fluorometric assay 
was linearized and within the working range of detecting differences in fluorescence 
signal based on the presence or absence of the [PSI+] prion in adenine biosynthesis 
yeast mutants.  
The adenine biosynthesis pathway metabolite AIR accumulates over time in 
colonies of [psi-] during incubation at 30 °C. It is detectable as pink colony color at day 
3 and continues to develop into a darker red as the colonies age. To confirm that 
fluorescence associated with AIR-containing [psi-] colonies also accumulates with 
time, we streaked [psi-] yeast cells onto rich yeast extract/peptone/dextrose (YPD) 
solid media and incubated the plates for 3, 5 and 7 days at 30°C.  At each time point, 
we harvested the cells, collected soluble cell lysates and measured the peak emission 
amplitude. We observed that the differences in fluorescence emission intensity of [psi-
] and [PSI+] S. cerevisiae lysates was highly significant on day 5 (p-value = 0.0007) 
and day 7 (p-value = 0.006) of growth (Figure 1D). [PSI+] cells do not develop dark 
red colony color or soluble fluorescence over time. To visualize the fluorescence 
associated with red pigment accumulation in [psi-] cells, we performed confocal 
fluorescence microscopy using similar excitation/emission conditions. We compared 
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the basal fluorescence of [psi-] and [PSI+] yeast cells by confocal microscopy. As 
expected, we observed a strong fluorescence signal in [psi-] cells at the excitation 488 
nm (Figure 1E). However, under the same visualization conditions, we did not 
observe endogenous fluorescence in [PSI+] cells (Figure 1E).  
To determine if red pigment accumulation associated with Hsp104 overexpression 
in [PSI+] yeast is endogenously fluorescent similar to the wild-type [psi-] phenotype in 
yeast, we transformed the vector pYS104 (53) into [PSI+] cells containing 
chromosomal hsp104. We observed that curing of [PSI+] prion by Hsp104 
overexpression results in a conversion of white colony phenotype to red colony 
phenotype (Figure 2A). Moreover, the red pigment in [PSI+] yeast overexpressing 
Hsp104 has a similar endogenous fluorescence signal as [psi-] cells containing the 
empty pYES2 vector (Figures 2A and 2B). Thus, the fluorometric assay that we 
developed to quantify [PSI+] phenotype can be used to classify parental [PSI+] and 
[psi-] yeast strains as well as yeast strains carrying plasmids that modify [PSI+] 
phenotype.  
The Walker B motif in AAA+ proteins is responsible for ATP hydrolysis (54). To 
determine if a mutation known to impair ATP hydrolysis in Hsp104 also affects [PSI+] 
phenotype, we constructed the Walker B NBD1 mutation E285Q in hsp104. The S. 
cerevisiae containing the Hsp104(E285Q) mutation in the NBD1 domain had a pink 
colony color on SD-URA solid media, which is associated with a weakly [PSI+] 
phenotype (Figure 2A). We compared the development of fluorescence signal over 
time in yeast strains containing the ade2-1 mutation transformed with pYS104, 
pYES2, and the Hsp104(E285Q) Walker B mutation. Yeast cells were harvested on 
days 3, 5, and 7 of growth and analyzed protein lysates using our novel fluorometric 
assay. Significant differences in emission fluorescence intensities among the different 
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S. cerevisiae strains occurred on day 5 of growth (p-value = 0.0008) and day 7 of 
growth (p-value = 0.004). We found that the greatest differences in fluorescence 
signal among [PSI+] yeast containing empty pYES2 vector, pYS104, and 
Hsp104(E285Q) occurred at the emission wavelength 565 nm (Figure 2C). The 
fluorescence intensity of yeast lysates at 565 nm is significantly different between 
[PSI+] yeast and [psi-] yeast containing empty vector (p-value = 0.0084). Moreover, we 
found a significant difference in fluorescence intensity at the emission wavelength 565 
nm of [PSI+] yeast overexpressing Hsp104 and [PSI+] containing the Walker B 
mutation Hsp104(E285Q), p-value = 0.0359 (Figure 2C).  Confocal microscopy of 
yeast expressing pYES2, pYS104, and Hsp104(E285Q) showed that the weakly 
[PSI+] phenotype associated with Hsp104(E285Q) had endogenous fluorescence, 
which appeared much weaker in intensity than the fluorescence associated with S. 
cerevisiae overexpressing Hsp104 (Figure 2D). 
 
Identification of Hsp104 N-domain residues important for [PSI+] curing in 
Saccharomyces cerevisiae 
To identify which amino acids in the Hsp104 N-domain are important for 
amyloid recognition and curing of the [PSI+] prion phenotype, we performed random 
mutagenesis and phenotypic screening to monitor S. cerevisiae cells for colony color 
conversion in cells expressing Hsp104 mutant proteins in the plasmid pYS104 (Figure 
3A). Using error-prone PCR amplification, we generated random mutations in hsp104 
in the region spanning the N-domain (amino acid residues 1 – 307). Next, the 
mutagenized fragments were used as primers to amplify a plasmid containing full-
length hsp104, and DpnI-digested PCR products were subsequently transformed into 
E. coli. Mutagenized pYS104 plasmids were isolated from clonal isolates that grew on 
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ampicillin selection plates. In total, 127 plasmids extracted from E. coli were 
transformed into [PSI+] S. cerevisiae and screened for conferring a color change from 
white to red. Clonal isolates that had an intermediate or weak [PSI+] phenotype (pink), 
or loss of Hsp104 function (white) were sequenced and mapped to the Hsp104 N-
domain structure (Figure 3B). Mutations identified in the screen included seven 
frameshift mutations, five single and two double substitution mutations. High-level 
expression of plasmid-encoded Hsp104 wild type and mutant proteins was confirmed 
by Western blot using antibodies directed against Hsp104 (Figure 3C). 
We found five mutations in the N-domain of Hsp104 that are associated with 
intermediate [PSI+], or weakly [PSI+], phenotype in yeast: A133D, L54P, H34D/E138V, 
L36V, and P81L (Figure 4A). Moreover, we observed that cells cured of [PSI+] 
reverted to a strongly [PSI+] phenotype in cells carrying the mutation V69F in hsp104 
(Figure 4A). The double mutation A99T/V74A in hsp104 resulted in the phenotypic 
appearance of dark red colonies, which had more red pigmentation than yeast cells 
overexpressing hsp104, on SD-URA solid media. We further investigated double 
mutations of interest by generating single substitution mutations in the yeast 
expression plasmid pYS104 using site-directed mutagenesis. We observed that 
Hsp104 A99T is responsible for the red pigmentation of yeast colonies on SD-URA. 
Interestingly, the variant Hsp104 V74A was associated with a weakly [PSI+] 
phenotype. Furthermore, the yeast variant Hsp104 H34D was weakly [PSI+] and the 







Functional analyses of Hsp104 N-domain mutants in vivo 
 The phenotypic [PSI+] colorimetric differences that we observed among the 
hsp104 N-domain variants could have been caused by variable expression of Hsp104 
among yeast strains. To determine if variable Hsp104 expression was responsible for 
the phenotypic differences among our strains, we performed immunoblots using an 
antibody against Hsp104. S. cerevisiae strains containing H34D, L36V, L54P, V69F, 
V74A, P81L, A99T, A133D, and E138V all expressed Hsp104 protein. Mapping the N-
domain mutations to the crystal structure of the Hsp104 N-domain of S. cerevisiae 
(55) containing mutations shows that the following mutations are near the surface: 
L54P, V74A, P81L, A133D, and E138V (Figure 4B). Thus, it is possible that these 
residues may contact amyloid substrate and participate in substrate binding. 
Yeast strains carrying mutations in hsp104 show maximal differences in 
fluorescence intensity at 565 nm when excited at 488 nm. One-way ANOVA of the 
fluorescence intensities was used to determine that the means of the fluorescence 
intensity for each strain at the emission wavelength 565 nm is significantly different (p 
< 0.0001) (Figure 4C). Confocal microscopy was used to visualize the endogenous 
fluorescence of S. cerevisiae carrying the Hsp104(V69F) mutation, which is 
associated with loss of prion curing (Figure 4D). We observed reduced endogenous 
fluorescence in this yeast strain (Figure 4D), as expected from the conversion of 
colony color from red to white on SD-URA solid media. 
 
Characterization of Hsp104 N-domain variants by thermotolerance assays 
Hsp104 is required for thermotolerance in yeast. To determine if the mutations 
that we identified in the N-domain are impaired for thermotolerance, we carried out 
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thermotolerance assays with different strains of yeast containing mutations in hsp104. 
Yeast strains were grown to mid-logarithmic phase of growth and Hsp104 expression 
was induced by mild heat shock at 37°C for 30 minutes. Yeast cells were exposed to 
extreme heat shock at 52°C at 0, 5, and 10 minutes and serially diluted fivefold on 
SD-URA solid media. Heat shock at 52°C for 15 minutes and 30 minutes resulted in 
no colony growth on SD-URA plates (data not shown). We assessed the cell viability 
of the yeast strains carrying mutations in the Hsp104 N-domain after five days of 
growth at 30°C and found that cells expressing Hsp104(H34D), Hsp104(V69F), 
Hsp104(A133D), and Hsp104(E138V) had reduced viability and thus impaired 
thermotolerance (Figure 5B) compared to yeast strains that were not subjected to 
heat shock at 52°C (Figure 5A). It should also be noted that all cells have 
endogenous expression of Hsp104 from the chromosome and loss of function 
phenotypes likely emerge from dominant-negative mutations. 
To determine if the Hsp104 variants H34D, L36V, L54P, V69F, V74A, P81L, 
A99T, A133D, and E138V have impaired disaggregation and/or reactivation of 
aggregated proteins, we grew yeast strains containing Hsp104 mutations to early mid-
logarithmic growth, incubated the liquid cultures in 37°C for 30 minutes, heat shocked 
the cells at 52°C for 15 minutes, recovered the yeast cells at 30°C for 20 minutes and 
extracted soluble and insoluble protein fractions using mechanical lysis with glass 
beads. We monitored protein aggregate load in insoluble yeast protein fractions by 
SDS-PAGE and Coomassie stain (Figure S1). We observed that yeast containing the 
mutation Hsp104(L54P) had a 1.8-fold increase in thermal aggregate accumulation 
compared to yeast cells overexpressing wild-type Hsp104 (Figure 6). The mutation 
Hsp104(V74A) was associated with a1.8-fold increase in thermal aggregates and 
yeast containing Hsp104(P81L) had a 1.9-fold increase in thermal aggregate load 
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compared to wild-type Hsp104 (Figure 6). Therefore, the hsp104 mutations L54P, 
V74A, and P81L are associated with impaired reactivation of protein aggregates. 
 
Discussion 
The amino acid residues 1 – 163 in the N-domain of ClpB are thought to be 
important for early recognition of polypeptide substrates targeted for disaggregation 
(56 – 58). Research does not support that the entire N-domain is essential for 
thermotolerance or prion propagation (1). However, the inversion of Hsp104 residues 
110 – 121 (inversion of nucleotides 330 – 363) in the N-domain results in loss of both 
thermotolerance and prion propagation (59). Hsp104 overexpression has been shown 
to convert [PSI+] yeast to a [psi-] phenotype, thus “curing” yeast of the Sup35 amyloid 
(35, 54). By contrast, Hsp104 lacking the N-domain (Hsp104ΔNTD) does not cure 
[PSI+] yeast of Sup35 amyloid (1). It has been suggested that the N-domain of 
Hsp104 may fine-tune substrate recognition to prevent the nonspecific disaggregation 
of polypeptides and directly bind to amyloid substrates (60). Here, we provide 
evidence that specific residues in the N-domain of Hsp104 are necessary for 
substrate recognition of Sup35 amyloid. 
Hsp104 and its bacterial homolog ClpB are highly conserved and are found 
throughout bacteria, fungi, plants, and lower eukaryotes. Hsp104 disaggregates 
thermal aggregates and remodels stable, ordered aggregates, such as fibrillar Sup35 
and Ure2 (61 – 63). Previous studies have provided evidence that the N-domain of 
ClpB is important for recognition of substrate proteins and remodeling of aggregates; 
a hydrophobic substrate-binding site in the N-terminal domain of ClpB was identified 
by Rosenzweig and coworkers. Specifically, the residues W6A, L14A, L91A, L111A 
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were found to be important for ClpB binding to aggregates (64). A separate study 
found that the ClpB N-domain residues T7A, D103A, E109A are involved in substrate 
binding based on luciferase reactivation assays and the observation that the N-
domain supports the casein-induced activation of ClpB ATPase activity (58). Mapping 
these residues to the E. coli ClpB structure modeled on the crystal structure of T. 
thermophilus ClpB shows that the following residues are surface-exposed and are 
likely involved in direct substrate recognition of aggregated proteins:  T7, L91, L14, 
D103, and E109 (Figure 7A).  
Pairwise alignments of the Hsp104 N-domain and the ClpB N-domain were 
conducted using the EMBOSS Needle tool from EMBL-EBI (65, 66). The alignment of 
the Hsp104 N-domain (amino acid residues 1 – 165) to the ClpB N-domain (amino 
acid residues 1 – 149) using EMBOSS Needle results in a similarity score of 45.2%. 
The amino acid residue H34 is a highly conserved residue; the residue is conserved 
in the S. cerevisiae Hsp104 and E. coli ClpB N-domain sequences (Figure 7B). The 
mutation H34D identified during phenotypic screening is associated with an 
intermediate [PSI+] phenotype, which suggests that prion curing mediated by 
overexpression of Hsp104 is impaired. Notably, the biochemical change from 
histidine, a positively charged residue, to aspartic acid, a negatively charged residue 
may result in major functional changes of Hsp104. An additional mutation, A133D, 
occurs at a highly conserved site between the S. cerevisiae Hsp104 and E. coli ClpB 
sequences. The substitution of alanine, a nonpolar amino acid, with aspartic acid, a 
negatively charged amino acid, may change the binding properties and functional 
interactions of Hsp104. Notably, the mutations at H34D and A133D are associated 
with impaired thermotolerance and prion curing by Hsp104 overexpression. 
Furthermore, the hsp104 mutations L36V and V69F are conserved residues and are 
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associated with weakly [PSI+] and strongly [PSI+] phenotypes in S. cerevisiae, 
respectively. The hsp104 mutations L54P, V74A, P81L, A99T, and E138V are semi-
conserved residues. Therefore, it is possible that the sites H34 and A133 in ClpB and 
Hsp104 are evolutionary conserved and are important for direct binding to aggregated 
proteins.  
Thermotolerance assays conducted in this study suggest that hsp104 
mutations H34D, V69F, and A133D are associated with impaired cell viability after 
exposure to extreme thermal stress. Thus, these amino acid residues in Hsp104 may 
be important for thermotolerance. Based on our results, we propose a model of 
Hsp104-mediated disassembly of amyloid protein that involves initial substrate 
recognition by the Hsp70/40 co-chaperone system, binding of Hsp70 to the middle 
domain of Hsp104 to deliver substrate to Hsp104, and binding of amyloid substrate to 
the N-domain of Hsp104 before substrate translocation through the axial channel of 
Hsp104 into the central cavity for disaggregation (Figure 7C). Our results suggest that 
surface-exposed Hsp104 residues, including A133D, bind to Sup35 amyloid. The 
Hsp104 residues P81L, V74A, and L54P are associated with increased thermal 
aggregate load after extreme heat shock, suggesting a role for these residues in 
protein disaggregation. Thus, these residues may be involved in the recognition of 
amyloid fibrils. Our results suggest that conserved residues H34 and A133 in the N-
domain may engage amyloid substrate and enable Hsp104 to translocate Sup35, or 
other aggregated substrates through the axial channel for unfolding and reactivation 
in collaboration with Hsp70/40.  
The mutations in the Hsp104 N-domain identified by [PSI+] colorimetric 
screening in S.cerevisiae V69F and E138V are associated with complete loss of 
Hsp104-mediated curing of Sup35 prion as evidence by the reversion of colony color 
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from red, a [psi-] phenotype, to white, a strongly [PSI+] phenotype. Furthermore, the 
mutations Hsp104(H34D), Hsp104(L36V), Hsp104(L54P), Hsp104(V74A), 
Hsp104(P81L), and Hsp104(A133D) caused a conversion from the [psi-] phenotype to 
a weakly [PSI+] phenotype as evidenced by the colorimetric change in yeast colonies 
from red to pink or pale orange-pink. It is possible that these point mutations in 
hsp104 impair the oligomerization of Hsp104, thereby rendering wild-type Hsp104 
protein non-functional. Future research should address this hypothesis to determine if 
oligomerization of Hsp104 is affected by the point mutations H34D, L36V, L54P, 
V69F, V74A, P81L, and A133D described here. Moreover, in vitro disaggregation 
assays, ATP activity assays, and binding assays of Hsp104 containing the mutations 
H34D, L36V, L54P, V69F, V74A, P81L, A99T, and A133D would provide more 
mechanistic information about the point mutations in Hsp104 that are associated with 
complete or partial loss of Hsp104-mediated curing of Sup35 prion.  Here, we provide 
evidence that the N-domain of Hsp104 recognizes amyloid fibrils and is essential for 
substrate recognition of Sup35 prion. 
 
Materials and Methods 
The [PSI+] yeast strain used in this study is strain PSI+ [BSC783/4a], ATCC® MYA-
536™. The genotype of this strain is: MATa SUQ5 ade2-1 ura3-1 his3-11 his3-15 
leu2-3 leu2-112 [PSI+]. The [psi-] yeast strain used in this study is a prion-deficient 
mutant derived from the BSC783/4a strain and is designated 783/4a psi-, ATCC® 
MYA-537™. The [psi-] strain has the genotype MATa SUQ5 ade2-1 ura3-1 his3-11 
his3-15 leu2-3 leu2-112 [psi-]. Both yeast strains are haploid and have previously 
been used in prion studies (67). Yeast strains were grown at 30°C in synthetic 
dextrose media minus uracil solid media (SD-URA; 1.7 g yeast nitrogen base, 5 g 
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ammonium sulfate, 20 g dextrose per liter, and 17 g agar per liter) and yeast 
extract/peptone/dextrose media (YPD; containing 1% yeast extract, 2% 
bactopeptone, 2% glucose, and 40 mg of adenine sulfate per liter).  
 
Mutagenesis 
The Megawhop cloning method has been used to construct mutant libraries of 
specific protein domains (66). First, mutations in the N-domain of Hsp104 were 
introduced into the gene hsp104 using an error-prone DNA polymerase (Agilent 
Genemorph II Random Mutagenesis kit). The DNA fragment generated from the 
random mutagenesis polymerase chain reaction, or the “megaprimer”, was used to 
amplify the template pYS104 vector, resulting in nicked plasmid DNA (68). Parental 
plasmid DNA was removed by DpnI digestion and the digestion reaction products 
were transformed into Escherichia coli. Transformants were grown on LB Lennox 
media containing ampicillin. Plasmids recovered from E. coli were then purified and 
screened in Saccharomyces cerevisiae using a fluorescence-based [PSI+] assay. 
Site-directed mutagenesis of hsp104 on the vectorpYS104 (54) was carried out using 
the QuikChange Mutagenesis kit (Agilent Genomics). Primers were designed to 
introduce the following substitutions into hsp104: A99T, V74A, H34D, and E138V 
(Table 3). Yeast transformants were grown on synthetic dextrose plates lacking uracil 






Yeast Whole Cell Extraction and Western Blot 
 Yeast whole cell lysates were extracted under non-denaturing conditions as 
previously described. Yeast cells were grown on synthetic dextrose solid media 
lacking uracil and supplemented with 2 % galactose at 30°C. After five days of 
growth, yeast cells were scraped off the solid media and pelleted at 3,000 x g for 5 
minutes at 4°C. Cells were washed twice with ice-cold phosphate buffered saline and 
resuspended in yeast lysis buffer (50 mM Tris pH 8.0, 5 mM EDTA, 0.5 mM NaCl, 5% 
glycerol, 1% Triton X-100) containing protease inhibitors. Yeast cells were lysed by 
vortexing cells resuspended in lysis buffer with 0.5 mm glass beads (Scientific 
Industries, Inc.) eight times with two-minute cooling periods on ice between each 
vortex. The protein concentration of lysates was quantified using the bicinchoninic 
acid assay (Pierce BCA Protein Assay kit) and protein concentrations were 
subsequently normalized. Hsp104 antibody (Thermo Fisher Scientific) was diluted 
1:1,000 in Tris buffer containing 0.1% Tween-20 and 0.05% nonfat milk. All Western 
blot bands were normalized to beta-actin (Abcam) or GAPDH (Thermo Fisher 
Scientific). 
 
Fluorescence [PSI+] Assay 
Yeast whole cell lysates were normalized to a final protein concentration of 0.5 
mg/mL. Using a quartz cuvette, 80 μL of lysate was excited at 488 nm at PMT 750 V. 
Emission wavelengths were captured between 500 and 800 nm. The excitation slit 






Thermotolerance experiments were conducted with yeast strains as previously 
described (69, 70). Briefly, yeast cells were grown in SD-URA media to mid-
logarithmic phase (OD600 of 0.400 – 0.600) in SD-URA media. The synchronized 
liquid cultures of yeast were incubated for 30 minutes at 37°C with vigorous aeration 
to induce the expression of Hsp104. Subsequently, yeast cultures were moved to a 
52°C water bath and 1 mL aliquots of cultures were removed, transferred to ice 
briefly, and serial diluted five-fold in SD-URA media before spot plating onto SD-URA 
+ 2% galactose solid media 0 minutes and 5 minutes after heat shock at 52°C to 
determine cell viability. 
To measure thermal aggregate accumulation in [PSI+] yeast containing 
mutations in hsp104, yeast cultures were grown in 30°C to mid-logarithmic phase in 5 
mL of SD-URA media and pretreated at 37°C for 30 minutes with vigorous aeration. 
Cultures were then transferred to a 52°C water bath for 15 minutes. Subsequent to 
the extreme heat shock, yeast cultures were incubated at 30°C with vigorous aeration 
to allow cells to recover from the thermal stress. Yeast cells were harvested by 
centrifugation and protein was extracted by glass bead lysis in lysis buffer. Equal 
volumes (5 µL) of insoluble yeast protein were boiled in LDS sample buffer; the final 
sodium dodecyl sulfate (SDS) concentration of the protein samples was 2%. The 
insoluble protein samples were loaded in a 3 – 8% Tris-acetate gel and 
electrophoresed at 150V in Tris-acetate running buffer containing SDS. Gels were 
incubated in Coomassie stain to observe total protein levels across lanes. Intensity of 







Differences in mean fluorescence intensities were measured using an unpaired, one-
tailed t-test with alpha level equal to 0.05. Analysis of variance tests and post-hoc 
Tukey’s multiple comparison tests were conducted to determine differences in 
fluorescence intensities across more than two yeast strains. Statistical analyses were 
carried out using Graphpad Prism version 6.0, GraphPad Software, La Jolla, 
California, USA (www.graphpad.com).  
 
Pairwise protein alignment 
Protein sequences were globally aligned using the EMBOSS Needle tool (66) from 
the European Bioinformatics Institute (EMBL-EBI) (65). The default settings in 
EMBOSS Needle were used for protein alignment. 
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Table 1. Yeast strains used in the study. 





























Table 2. Mutations of interest in Hsp104 N-domain identified by [PSI+] assay. 





V69F White - Strongly [PSI+] 
L54P Orange-pink +/- Weakly [PSI+] 
A133D Dark orange-pink +/- Weakly [PSI+] 
H34D and E138V Light orange-pink +/- Weakly [PSI+] 
H34D Orange-pink +/- Weakly [PSI+] 
E138V Light pink +/- Weakly [PSI+] 
V74A and A99T Dark red + [psi-] 
V74A Light pink +/- Weakly [PSI+] 
A99T Dark red + [psi-] 
P81L Light pink - Strongly [PSI+] 
Q113A Light orange-pink +/- Weakly [PSI+] 





































































Figure 1. Red pigment in S. cerevisiae ade2-1 mutants is intrinsically 
fluorescent.  
A.) Red pigment accumulates in the [psi-] yeast strain that contains the ade2-1 
mutation. Yeast with soluble Sup35 accumulates red pigmentation.  
B.) The [psi-] and [PSI+] yeast strains have intrinsic fluorescence at 488 nm.  
C.) The fluorescence signal associated with red pigment accumulation is 
dependent on the protein concentration of [psi-] lysates; fluorescence signal 
increases with increasing protein concentration.  
D.) The fluorescence signal is time-dependent; the maximal colorimetric 
differences between [PSI+] and [psi-] strains occurs on day 5 of growth at 
30°C. The greatest difference between fluorescence signal of [PSI+] and [psi-] 
yeast occurs on day 5 (p-value = 0.0006) and day 7 (p-value = 0.006).  
E.) S. cerevisiae carrying the ade2-1 mutation and the [psi-] phenotype 
accumulate red pigment, which has intrinsic fluorescence. Yeast cells with the 
[PSI+] phenotype grow into white colonies on solid SD-URA plates + 2 % 
galactose and do not have endogenous fluorescence. Wavelength excitation 




























































Figure 2. Red pigment accumulation and endogenous fluorescence in yeast 
[PSI+] and [psi-] strains.  
A.) Streaks of [PSI+] yeast strains containing Hsp104, empty vector (pYES2), and 
Hsp104 E285Q. The Walker B mutation in the NBD1 domain of Hsp104 (E285Q) 
is weakly [PSI+], as evidenced by the pink colony phenotype on SD-URA solid 
media.  B.) Overexpression of Hsp104 in [PSI+] yeast results in red pigment 
accumulation, which has intrinsic fluorescence at 488 nm comparable to [psi-] 
yeast. Red pigmentation develops over time in yeast strains containing 
overexpressed Hsp104 in the vector pYS104. The maximal differences in 
fluorescence between [PSI+] yeast containing empty vector and [PSI+] yeast cured 
by Hsp104 occurs on day 5 of growth (p-value = 0.0008) and day 7 of growth (p-
value = 0.0035). Unpaired, one-tailed t-tests.   
C.) The differences in fluorescence signal between [PSI+] yeast containing empty 
vector pYES2 and pYS104 vector overexpressing Hsp104 is significant (p = 
0.0255) Fluorescence intensity at 565 nm is highly significantly different between 
[PSI+] yeast and [psi-] yeast containing empty vector (p-value = 0.0084). Yeast 
containing the Hsp104 Walker B mutant E285Q shows significantly less 
fluorescence than [PSI+] yeast overexpressing Hsp104 (p-value = 0.0359). 
Unpaired, one-tailed t-tests.  
D.) The intermediate [PSI+] phenotype has a similar emission profile as [PSI+]. 
Wavelength excitation 488 nm, wavelength emission 520 nm. Scale bar shown 
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Figure 3. Selection of mutations in the N-terminal domain of Hsp104.  
A.) Random mutagenesis of the N-terminal domain of Hsp104 was carried out using 
an error-prone DNA polymerase and primers that targeted the N-domain of Hsp104. 
The products of the random mutagenesis PCR were used as primers in a subsequent 
PCR to amplify the plasmid pYS104. The PCR products were transformed into 
chemically competent E. coli. Plasmids were isolated from E. coli and transformed into 
electrically competent S. cerevisiae for [PSI+] colorimetric screening.  
B.) The colorimetric [PSI+] assay screens for [psi
-
] and [PSI+] phenotypes. Yeast 
strains that carried mutations in Hsp104 associated with loss of prion curing appear 
white on SD-URA solid media and were sequenced and further analyzed. Here, a red 
box marks yeast strains that have loss-of-function Hsp104.  
C.) Protein expression levels of Hsp104 in yeast strains. Mutants of interest were 
further screened for analysis by determining protein expression levels of induced 
lysates. Western blot Hsp104 protein is made in all [PSI+] S. cerevisiae strains 
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Figure 4. Functional analyses of hsp104 mutations of interest.  
A.) Yeast strains carrying point mutations in hsp104 on day 3 of growth at 30 °C.  
B.) Model of Hsp104 N-terminal domain in S. cerevisiae (PDB 6AMN; Lee, J. et al., 
2017) containing mutations H34D (cyan), L36V (yellow), L54P (light blue), V69F 
(green), V74A (orange), P81L (violet), A99T (magenta), A133D (light pink), and 
E138V (wheat).  
C.) Yeast strains carrying mutations in hsp104 show maximal differences in 
fluorescence intensity at 565 nm when excited at 488 nm. One-way ANOVA of the 
fluorescence intensities was used to determine that the means of the fluorescence 
intensity of each strain at 565 nm is significantly different (p < 0.0001).  
D.) Confocal fluorescence microscopy of yeast cells grown on day 5 of growth. 
[PSI+] yeast carrying empty vector pYES2 (white colonies on SD-URA solid media) 
has decreased endogenous fluorescence compared to [PSI+] yeast overexpressing 
Hsp104 and [psi-] yeast containing pYES2. The loss-of-function V69F mutation in 
Hsp104 is associated with reduced endogenous fluorescence (pale pink colonies on 

































































Figure 5. Impaired thermotolerance of [PSI+] yeast containing mutations in 
the N-domain of Hsp104. Hsp104 NTD mutants were incubated at 37°C for 30 
minutes and subsequently transferred to 52°C for A.) 0 minutes of heat shock 
and B.) 5 minutes and yeast cultures were fivefold serially diluted onto SD-URA + 







































































Figure 6. Thermal aggregates accumulate in S. cerevisiae containing mutations 
in the Hsp104 N-domain. Yeast cells carrying mutations in hsp104 were grown in 
SD-URA + 2% galactose liquid media until early logarithmic growth. Cultures were 
incubated at 37°C for 30 minutes before heat shock at 52°C for 15 minutes. Cells 
recovered at 30°C for 20 minutes after heat shock. Insoluble protein fractions were 
electrophoresed on a 3-8% Tris-acetate gel and Coomassie stained. Cells with the 
mutation Hsp104(L54P) had a 1.8-fold increase in thermal aggregate accumulation 
compared to cells overexpressing wild-type Hsp104. Furthermore, mutations 
Hsp104(V74A) and Hsp104(P81L) were associated with a 1.8-fold and 1.9-fold 













































Figure 7. The role of the N-domain of Hsp104 in substrate binding of amyloid 
fibrils.  
A.) E. coli ClpB N-domain modeled on T. thermophilus ClpB crystal structure; PDB 
1QVR (Lee S, et al., 2003). The ClpB mutations T7 (yellow), L91 (orange), L14 
(pink), D103 (red), and E109 (green) are surface-exposed.  
B.) Protein alignment of S.cerevisiae Hsp104 N-domain (a.a. 1 – 165) and E.coli 
ClpB N-domain (a.a. 1 – 149). Residues highlighted in yellow are Hsp104 N-domain 
mutations. Residues highlighted in gray are identical. Red arrows denote highly 
conservative mutations. EMBOSS Needle (EMBL-EBI) pairwise protein alignment.  
C.) Model of Amyloid Binding to Hsp104. (I) Hsp70, bound to nucleotide exchange 
factor (NEF) and Hsp40, binds to amyloid protein substrate. Hsp104 is a hexameric 
protein with an axial channel and tyrosine pore loops. (II) Hsp70 binds to the middle 
domain of Hsp104 and a segment of the amyloid binds to the N-domain of Hsp104. 
Hsp104 pore loops translocate polypeptides through the axial channel. (III) Amyloid 
protein is threaded through the axial channel of Hsp104, driven by the movement of 
the pore loops coupled to rounds of ATP hydrolysis. (III) Amyloid protein is 










































































Figure S1. Thermal aggregates in S. cerevisiae strains containing 
mutations in the N-domain of Hsp104. Yeast lysates were loaded on a 
3 – 8% Tris-acetate gel and electrophoresed at 150V. The gel was 
subsequently Coomassie stained. Yeast containing L54P, V74A, and 
P81L mutations in Hsp104 show increased thermal aggregates in 
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ClpX is a member of the Clp/Hsp100 family of ATP-dependent chaperones 
and partners with ClpP, a compartmentalized protease, to degrade protein substrates 
bearing specific recognition signals. ClpX targets specific proteins for degradation 
directly or with substrate-specific adaptor proteins. Native substrates of ClpXP include 
proteins that form large oligomeric assemblies, such as MuA, FtsZ and Dps in 
Escherichia coli. To remodel large oligomeric substrates, ClpX utilizes multivalent 
targeting strategies and discriminates between assembled and unassembled 
substrate conformations. Although ClpX and ClpP are known to associate with protein 
aggregates in E. coli, a potential role for ClpXP in disaggregation remains poorly 
characterized. Here, we discuss strategies utilized by ClpX to recognize native and 
non-native protein aggregates and the mechanisms by which ClpX alone, and with 
ClpP, remodels the conformations of various aggregates. We show that ClpX 
promotes the disassembly and reactivation of aggregated Gfp-ssrA through specific 
substrate remodeling. In the presence of ClpP, ClpX promotes disassembly and 
degradation of aggregated substrates bearing specific ClpX recognition signals, 
including heat-aggregated Gfp-ssrA, as well as polymeric and heat-aggregated FtsZ, 
which is a native ClpXP substrate in E. coli. Finally, we show that ClpX is present in 
insoluble aggregates and prevents the accumulation of thermal FtsZ aggregates in 
vivo, suggesting that ClpXP participates in the management of aggregates bearing 







Maintaining cellular proteostasis relies on chaperone pathways that promote 
native protein folding. Typical strategies include targeting misfolded, unfolded, and 
aggregated polypeptides for reactivation or degradation (Bukau and Horwich, 
1998;Wickner et al., 1999;Stoecklin and Bukau, 2013). Misfolded proteins are 
generated during polypeptide elongation and as a complication of environmental 
stress (Powers and Balch, 2013). The challenges imposed on chaperone systems by 
proteotoxic stress are especially relevant in pathogenic organisms like E. coli, which 
experience extreme fluctuations in environmental conditions leading to accumulation 
of protein aggregates and subsequent proteotoxicity (Mogk et al., 2011). Protein 
quality control systems reactivate, degrade and remove damaged and aggregated 
proteins. Under thermal stress in E. coli, the heat shock response provides a cellular 
defense mechanism and upregulates heat shock protein and chaperone levels to 
restore proteostasis (Mogk et al., 2011). 
In addition to preventing protein aggregation, chaperone proteins mediate 
aggregate clearance through proteolysis of non-native proteins and aggregation 
reversal (Hartl et al., 2011;Mogk et al., 2011). Clearance of misfolded proteins in E. 
coli is carried out by AAA+ (ATPases Associated with diverse cellular Activities) 
proteins, which initiate substrate recognition, unfolding, and translocation into a 
proteolytic chamber (ClpP, HslV) (Snider and Houry, 2008;Sauer and Baker, 2011). 
Several AAA+ proteins, such as Lon and FtsH, contain both AAA+ chaperone and 
proteolytic domains within a single protomer (Sauer and Baker, 2011). The 
chaperone-protease Lon recognizes exposed aromatic and hydrophobic residues, 
which may contribute to less stringent substrate  selectivity and favor degradation of 
unfolded or misfolded proteins (Gur and Sauer, 2008).  
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The Clp ATPases of the AAA+ superfamily can be separated into two 
functional categories: degradation or disaggregation machines. Degradation 
machines, including ClpX, ClpA, and HslU form complexes with peptidases ClpP or 
HslV to remove misfolded proteins or specific substrates (Zolkiewski, 2006). 
Disaggregation machines, including Hsp104 and its bacterial homolog ClpB, 
disaggregate and reactivate aggregated proteins by an ATP-dependent mechanism 
and can function in cooperation with the Hsp70/DnaK system independent of protein 
degradation (Zolkiewski, 1999;Dougan et al., 2002;Doyle et al., 2007;Sweeny and 
Shorter, 2016). Through a collaborative mechanism, Hsp70, with Hsp40, binds first to 
a polypeptide segment of an aggregated protein and then the substrate is remodeled 
by Hsp104/ClpB (Zietkiewicz et al., 2004;Zietkiewicz et al., 2006;Acebron et al., 
2009).  
E. coli substrates that are degraded by ClpXP include a variety of cellular 
proteins, metabolic enzymes and several proteins capable of forming large 
conformational assemblies, including FtsZ, Dps and MinD (Flynn et al., 2003;Stephani 
et al., 2003;Neher et al., 2006;Camberg et al., 2009;Camberg et al., 2014;Conti et al., 
2015). ClpXP can associate with cellular aggregates in E. coli and can promote 
removal of cellular inclusions, but direct protein disaggregation in vitro is not well 
characterized for ClpX (Vera et al., 2005;Winkler et al., 2010). An early study 
suggested that ClpX, in the absence of ClpP, could protect the lambda O phage 
protein from aggregation and resolubilize lambda O aggregates (Wawrzynow et al., 
1995). In Bacillus subtilis, ClpX also localizes to protein aggregates, suggesting that it 
may be involved in protein disaggregation (Kruger et al., 2000;Kain et al., 
2008;Kirstein et al., 2008)Simmons et al., 2008). ClpX and ClpX substrates are 




ClpX associates with aggregated proteins and participates in their removal (Kain et 
al., 2008;Maisonneuve et al., 2008;Simmons et al., 2008).  
ClpXP comprises an asymmetric, hexameric ring of ClpX docked to two 
stacked heptameric rings of the ClpP serine protease (Wang et al., 1997;Glynn et al., 
2009). Although ClpX has been shown to independently remodel substrates, such as 
MuA, in the presence of ClpP, hydrophobic ‘IGF’ loops on the bottom surface of the 
ClpX hexamer contact hydrophobic pockets on the ClpP tetradecamer, allowing 
unfolded substrates to access the ClpP proteolytic chamber (Kim et al., 
2001;Abdelhakim et al., 2010;Baker and Sauer, 2012). Nucleotide binding by ClpX 
protomers, in the cleft between the large and small AAA+ subdomains, regulate the 
position of the subdomains relative to each other; these conformational changes 
enable ClpX to couple substrate translocation to ATP hydrolysis (Glynn et al., 
2009;Baker and Sauer, 2012). Substrates are then translocated into the ClpP 
chamber for degradation (Baker and Sauer, 2012).  
Substrates bind to the ClpX N-domain and to residues in the ClpX central 
channel (pore-loops) (Bolon et al., 2004;Park et al., 2007;Martin et al., 2008;Baker 
and Sauer, 2012). The N-domain of ClpX is separated from the AAA+ domain by a 
flexible linker and can dimerize independently. The N-domain is important for direct 
recognition of some substrates, including FtsZ and MuA, as well as adaptor proteins, 
but is not required for direct recognition of the ssrA-tag (Abdelhakim et al., 
2008;Martin et al., 2008;Camberg et al., 2009;Baker and Sauer, 2012). Adaptor 
proteins, such as RssB or SspB, promote the interaction and engagement of specific 
substrates, such as RpoS or ssrA-tagged substrates, respectively (Sauer and Baker, 
2011). The ssrA tag is an 11-residue degron appended to a nascent polypeptide 
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when the ribosome stalls during protein synthesis, targeting the misfolded protein for 
subsequent degradation (Gottesman et al., 1998;Levchenko et al., 2000).  
ClpXP is implicated in the degradation of diverse cellular substrates and more 
than 100 substrates have been reported (Flynn et al., 2003;Neher et al., 2006). Native 
substrates of ClpX contain recognition motifs at the N- or C-termini (Flynn et al., 
2003). Notably, the essential cell division protein FtsZ in E. coli has two distinct ClpX 
motifs: one in the flexible linker region and one near the C-terminus (Camberg et al., 
2014). FtsZ is a tubulin homolog that assembles into linear polymers in vitro and 
forms the septal ring critical for division in vivo, called the Z-ring (Erickson et al., 
2010). ClpXP degrades approximately 15% of FtsZ proteins during the cell cycle in E. 
coli and is capable of degrading both monomers and polymers in vitro (Camberg et 
al., 2009). ClpXP degrades polymers more efficiently, which is consistent with a 
common strategy of multivalent recognition of substrates by AAA+ ATPases (Davis et 
al., 2009;Camberg et al., 2014;Ling et al., 2015). In addition to FtsZ, several other 
ClpXP substrates form large oligomeric structures, including the tetrameric phage 
protein MuA, the dodecameric bacterial protein Dps, and the bacterial cell division 
ATPase MinD (Stephani et al., 2003;Neher et al., 2006;Abdelhakim et al., 2010;Conti 
et al., 2015). Like FtsZ, alternate monomeric and oligomeric conformations of MuA 
are also differentially recognized by ClpX (Abdelhakim et al., 2008;Abdelhakim et al., 
2010;Ling et al., 2015).  
In this study, we use engineered and native substrates to investigate the role 
of ClpX and ClpXP in the disassembly and degradation of protein aggregates that 
bear specific ClpX recognition signals. We observed that ClpX, with and without ClpP, 
destabilizes Gfp-ssrA aggregates in vitro. The native ClpXP substrate FtsZ forms 




induced aggregates. Our results show that ClpXP disassembles both heat-induced 
and linear polymers containing FtsZ. Finally, we also demonstrate that thermal stress 
promotes aggregation of FtsZ, which is exacerbated in cells deleted for clpX or clpP. 
Together, these results show bona fide chaperone activity for ClpX in vitro and 
suggest that ClpX, with or without ClpP, may play a broader role in rescue and 
disassembly of protein aggregates.  
 
Materials and Methods 
Bacterial strains and plasmids  
E. coli strains and plasmids used in this study are described in Table 1. An 
expression plasmid encoding FtsZ(ΔC67) was constructed by introducing a TAA stop 
codon (at residue 317 of FtsZ) into pET-FtsZ by site-directed mutagenesis (Camberg 
et al., 2009).  
 
Expression and purification of proteins 
Gfp-ssrA was purified as previously described (Yakhnin et al., 1998). ClpX, 
ClpP, FtsZ, and FtsZ(ΔC67) were each overexpressed in E. coli BL21 (λDE3) and 
purified as described (Maurizi et al., 1994;Grimaud et al., 1998;Camberg et al., 
2009;Camberg et al., 2014). ClpX(E185Q) was purified as described for wild type 
ClpX, except the expression strain, E. coli MG1655 ΔclpX carrying plasmid 
pClpX(E185Q), was induced with 1% arabinose (Table 1) (Camberg et al., 2011). 
Gfp(uv) containing an N-terminal histidine tag was overexpressed in E. coli BL21 
(λDE3) and grown to an OD600 of 1.0 and induced for 3 hours at 30 ºC. Cells were 
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lysed by French press in purification lysis buffer (20 mM HEPES, pH 7.5, 5 mM 
MgCl2, 50 mM KCl, and 10% glycerol). Soluble extracts were bound to TALON metal 
affinity resin (GE Healthcare), eluted with an imidazole gradient, and imidazole was 
removed by buffer exchange. Protein concentrations are reported as FtsZ monomers, 
ClpX hexamers, ClpP tetradecamers, and Gfp or Gfp-tagged monomers. For 
polymerization assays, FtsZ was labeled with Alexa Fluor 488 and active protein (FL-
FtsZ) was collected after cycles of polymerization and depolymerization as described 
(Gonzalez et al., 2003;Camberg et al., 2014). 
Dynamic light scattering 
Dynamic light scattering (DLS) measurements were made using a Zetasizer 
Nano ZS (Malvern Instruments). To determine size distribution, FtsZ (5 μM), aggFtsZ 
(5 μM), Gfp-ssrA (1.5 μM) and aggGfp-ssrA (1.5 μM) in reaction buffer (50 mM 
HEPES, pH 7.5, 100 mM KCl and 10 mM MgCl2) were added to polystyrene cuvettes 
and scanned at 23 °C with a detector angle of 173° and a 4 mW, 633 nm He–Ne 
laser. The reported intensity-weighted hydrodynamic diameters are based on 15 
scans. 
Heat denaturation, aggregation, disassembly and reactivation of aggregated 
substrates  
To heat-inactivate Gfp substrates, Gfp-ssrA (1.5 μM) or Gfp(uv) (1.5 μM) was 
added, where indicated, to buffer containing HEPES (50 mM, pH 7.5), KCl (100 mM), 
MgCl2 (10 mM), glycerol (10%) and dithiothreitol (DTT) (2 mM) in a volume of 800 μl 
and incubated at 85 °C for 15 minutes. Immediately following heat-treatment, the 
denatured substrate was placed on ice for 2 minutes and added to a reaction (50 μl) 
containing ClpX, (0.3 μM), ClpX (E185Q) (0.3 μM), ClpP (0.3 μM), ATP (4 mM), 
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ATPγS (1 mM), or ADP (2 mM), where indicated. Samples containing ATP were 
supplemented with an ATP-regenerating system containing phosphocreatine (5 mg 
ml-1) and creatine kinase (CK) (60 μg ml-1). Fluorescence recovery was monitored by 
measuring fluorescence in a Cary Eclipse fluorometer with excitation and emission 
wavelengths set at 395 nm and 510 nm, respectively. Readings were corrected for 
background signal by subtracting the fluorescence of buffer. Rates were calculated by 
fitting to a one-phase association model in GraphPad Prism (version 6.0b). 
Disaggregation was monitored by 90º-angle light scatter with excitation and emission 
wavelengths set to 550 nm. Readings were corrected for background signal by 
subtracting the scatter of the buffer and then plotted as percent of the initial turbidity. 
Heat-induced aggregation of Gfp-ssrA with time was monitored by 90º-angle light 
scatter with the temperature of the cuvette holder set to 80 ºC using a circulating 
water bath. 
To inactivate native FtsZ substrates, FtsZ and FtsZ(ΔC67) (5 µM) were heated 
for 15 minutes in reaction buffer (20 mM HEPES, pH 7.5, 100 mM KCl, 10 mM MgCl2) 
in a volume of 120 μl at 65 ºC, then cooled on ice for 40 seconds, and held at 23 °C 
until addition to reactions (60 μl volume) containing ClpX (0.5 µM or 1 µM), 
ClpX(E185Q) (0.5 µM), ClpP (1 µM), ATP (4 mM) and an ATP-regenerating system 
(phosphocreatine at 5 mg ml-1 and creatine kinase at 60 μg ml-1), where indicated. 
Disaggregation was monitored by 90º-angle light scatter with excitation and emission 
wavelengths set to 450 nm. Readings were corrected for background signal by 
subtracting the scatter of the buffer and then plotted as percent of the initial turbidity. 
Heat-induced aggregation of FtsZ with time was monitored by 90º-angle light scatter 




Polymerization and GTP hydrolysis assays 
FL-FtsZ was incubated with the GTP analog GMPCPP (0.5 mM) in the 
presence of increasing concentrations of ClpX and ClpP (0, 0.25, 0.5 or 1 µM) as 
indicated and in the presence of phosphocreatine at 5 mg ml-1 and creatine kinase at 
60 μg ml-1. Samples were incubated for 3 minutes in buffer containing MES (50 mM, 
pH 6.5), KCl (100 mM) and MgCl2 (10 mM) at 23 ºC, then centrifuged at 129,000 x g 
in a Beckman TLA 120.1 rotor for 30 minutes. Pellets were resuspended in 0.2 M 
NaCl with 0.01% Triton X-100 (100 μl) and the fluorescence associated with FL-FtsZ 
for supernatants and pellets was measured using a Cary Eclipse spectrophotometer. 
GTP hydrolysis rates for FtsZ and FtsZ(ΔC67) were measured before and after 
aggregation using the Biomol Green (Enzo Life Sciences) detection reagent as 
described (Camberg et al., 2014). 
 
Heat shock of wild type and deletion strains 
E. coli wild type and deletion strains were grown overnight, diluted 1:100 in 
fresh Lennox broth the next day and grown at 30 °C to an OD of 0.4. All strains were 
incubated in a water bath at 50 °C for 1 hour, followed by recovery at 30 °C for 35 
minutes. Cells were harvested by centrifugation and lysed with Bacterial Protein 
Extraction Reagent (B-PER) (ThermoFisher Scientific) (2 ml) and lysozyme (25 μg ml-
1). Insoluble fractions were collected by centrifugation at 15,000 x g for 5 minutes at 4 
°C, resuspended in lithium dodecyl sulfate sample buffer and analyzed by reducing 
SDS-PAGE. Total proteins were transferred to a nitrocellulose membrane and 
visualized by Ponceau (Fisher Scientific) staining and membranes were 
immunoblotted using antibodies to ClpX and FtsZ (Camberg et al., 2009;2011). Band 
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intensities were analyzed by densitometry (NIH ImageJ), normalized to the intensity of 
the average of the ‘no heat’ sample, and evaluated for significance by the Mann-
Whitney test. Where indicated, to test a mild heat shock condition, cells were 
incubated in a water bath at 42 °C for 30 minutes, followed by recovery at 30 °C for 
35 minutes, and analyzed as described. 
 
Results 
ClpXP degrades aggregates in vitro 
To determine if ClpX can remodel protein substrates from the aggregated 
state, we used the fusion protein, Gfp-ssrA, which forms aggregates upon heat 
treatment (Zietkiewicz et al., 2004;Zietkiewicz et al., 2006). Gfp-ssrA is rapidly 
degraded by ClpXP and has been extensively studied to understand substrate 
targeting by ClpXP. The Gfp moiety is widely used in protein disaggregation assays 
because it forms non-fluorescent aggregates when heated, but is disaggregated and 
reactivated by several chaperone systems (Zietkiewicz et al., 2004;Zietkiewicz et al., 
2006). Therefore, we heated Gfp-ssrA at 85 °C for 15 minutes to induce aggregation 
(aggGfp-ssrA), resulting in an 86% loss of fluorescence emitted (Figure 1A). Next, to 
measure the distribution of aggregates by size after heating, we performed dynamic 
light scattering (DLS) of untreated and heat-denatured Gfp-ssrA. We observed that 
without heating, the particle sizes are uniform with an average hydrodynamic 
diameter of 8-10 nm (Figure 1B). After heating, aggregates are approximately 500-
600 nm, and there is a narrow distribution of particle sizes and no small particles (i.e., 
less than 100 nm) (Figure 1C). Upon heat-treatment, aggregation of Gfp-ssrA (1.5 
μM) occurs rapidly and plateaus by 10 minutes by 90°-angle light scattering (Figure 
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1D). The heat inactivation is irreversible since incubation of aggregated Gfp-ssrA 
(aggGfp-ssrA) alone does not lead to appreciable fluorescence reactivation, which is 
consistent with previous reports using Gfp (Figure S1) (Zietkiewicz et al., 2004). To 
determine if ClpXP can bind to aggregates and degrade them, we incubated aggGfp-
ssrA with ClpXP and monitored turbidity by 90°-angle light scattering. Incubation of 
aggGfp-ssrA with ClpXP led to a 35% loss of turbidity in 2 hours (Figure 1E). 
However, when ClpXP was omitted from the reaction, there was very little change in 
turbidity over time (5% loss in 2 hours) (Figure 1E). This suggests that ClpXP targets 
aggregated substrates for degradation. To determine if degradation is required to 
reduce turbidity, we omitted ClpP and observed that ClpX is capable of reducing 
sample turbidity by 15% in 2 hours (Figure 1E). Finally, when ATP was omitted from 
the reaction containing ClpXP, we observed a less than 10% reduction in the turbidity 
of the reaction (Figure 1E). To confirm that ClpXP degrades aggGfp-ssrA, we 
incubated aggGfp-ssrA with combinations of ClpX, ClpP and ATP, and sampled 
degradation reactions after 2 hours. We observed that in the presence of ClpXP, 
aggGfp-ssrA is degraded, but not when ClpP or ATP was omitted (Figure 1F). 
Together, these results demonstrate that ClpXP targets aggregates for ATP-
dependent degradation and that ClpX is also capable of promoting disassembly in the 
absence of ClpP.  
FtsZ is a well-characterized ClpXP substrate that is essential for cell division 
and forms linear polymers in vitro in the presence of GTP (Erickson et al., 2010). We 
previously showed that ClpXP binds to GTP-stimulated FtsZ polymers and promotes 
FtsZ degradation (Camberg et al., 2009). ClpXP also recognizes and degrades non-
polymerized FtsZ, but less efficiently than polymerized FtsZ (Camberg et al., 2009). In 
vitro, FtsZ rapidly aggregates when heated at 65 °C and this aggregation is 
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associated with an increase in overall light scatter and a 97% loss of GTPase activity 
(Figure 2A and 2B). FtsZ, which purifies as a mixture of monomers (40.4 kDa) and 
dimers (80.8 kDa), has an average hydrodynamic diameter of 10-15 nm by DLS 
(Figure 2C). Heat treatment of FtsZ (5 μM) at 65 °C produces several particle sizes, 
including small (30-40 nm) and large aggregates (>300 nm) (Figure 2D). To 
determine if ClpXP reduces the turbidity associated with aggregated FtsZ (aggFtsZ), 
we incubated aggFtsZ with ClpXP and ATP and observed a 40% loss of turbidity after 
incubation with ClpXP for 2 hours (Figure 2E). However, in the absence of ClpXP, the 
light scatter signal remained stable for aggFtsZ (Figure 2E). Incubation of ClpX with 
aggFtsZ also resulted in a 25% loss in light scatter, suggesting that ClpX also 
promotes disassembly of aggregates similar to what we observed for aggGfp-ssrA 
(Figure 2E and 1E).  
Next, to confirm that aggFtsZ is degraded by ClpXP, we assembled reactions 
containing combinations of aggFtsZ, ClpX, ClpP and ATP and sampled these 
reactions at 0 and 120 minutes for analysis by SDS-PAGE. We observed that in the 
presence of ClpXP and ATP, 50% of the total aggFtsZ in the reaction is lost to 
degradation after 120 minutes (Figure 2F). Omission of either ClpP or ATP from the 
reaction prevents loss of aggFtsZ (Figure 2F). These results indicate that ClpXP 
degrades aggFtsZ. Furthermore, the amount of aggFtsZ after incubation with ClpX is 
unchanged despite the decrease in light scatter detected, suggesting that ClpX can 
disaggregate aggFtsZ (Figure 2E and 2F). 
In addition to forming aggregates upon heating, FtsZ also assembles into a 
linear head-to-tail polymer, which is a native, ordered aggregate, and distinct from the 
disordered aggregates which are induced by heating (aggFtsZ). We compared the 
loss of aggFtsZ by ClpXP to a similar reaction monitoring loss of native polymerized 
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FtsZ, which is a known substrate of ClpXP. Like aggFtsZ, we also observed a ~50% 
loss of polymeric FtsZ, stabilized by the GTP analog GMPCPP, after 120 minutes in 
reactions containing ClpXP and ATP (Figure 2F). GMPCPP promotes the assembly of 
stable polymers that are far less dynamic than polymers assembled with GTP (Lu et 
al., 2000). To test if ClpXP disassembles GMPCPP-stabilized FtsZ polymers, we 
incubated pre-assembled polymers with ClpXP and ATP. Then, we collected 
polymers by high-speed centrifugation. In these assays, we used active fluorescent 
FtsZ, labeled with Alexa fluor 488 (FL-FtsZ), to quantify the amount of polymerized 
FtsZ in the pellet fraction and soluble FtsZ in the supernatant. We observed that after 
incubation of GMPCPP-stabilized FtsZ polymers with increasing concentrations of 
ClpXP (0 μM to 1 μM), few FtsZ polymers were recovered in the pellet fractions 
containing ClpXP (26% of the total FtsZ was recovered in the reaction containing 1 
μM ClpXP), indicating that ClpXP is highly effective at promoting the disassembly of 
GMPCPP-stabilized FtsZ polymers (Figure 2G). 
 
ClpX reactivates heat-aggregated Gfp-ssrA 
Incubation of ClpX with aggGfp-ssrA resulted in loss of turbidity, suggesting 
that ClpX may function independently of ClpP to reactivate substrates (Figure 1E). 
Reactivation of misfolded proteins may occur through binding and stabilization of 
intermediates enabling proteins to adopt the native folded conformation, or through 
ATP-dependent chaperone-assisted unfolding. To determine if ClpX, which 
recognizes the ssrA amino acid sequence, is able to reactivate aggGfp-ssrA, we 
monitored fluorescence of aggGfp-ssrA in the presence and absence of ClpX and 
ATP. AggGfp-ssrA regains very little fluorescence alone, approximately 20 units, 
which is 8% of the initial fluorescence lost upon heating; however, in the presence of 
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ClpX, fluorescence recovers rapidly in the first 10 minutes of the reaction and then 
plateaus, regaining approximately 85 units, which is 27% of the initial fluorescence 
lost upon heating (Figure 3A).  
ClpX catalyzes ATP-dependent unfolding of substrates (Kim et al., 2000;Singh 
et al., 2000). To determine if ATP is essential for reactivation, we incubated aggGfp-
ssrA with ClpX under various nucleotide conditions including with ATP, the ATP 
analog ATPɣS, ADP and omission of nucleotide. We observed an 82% slower rate of 
fluorescence reactivation when ClpX and aggGfp-ssrA were incubated with ATPɣS 
than with ATP (0.02 AU min-1 and 0.11 AU min-1, respectively), and no recovery over 
background with ADP or without nucleotide (Figure 3B). Reactivation by ClpX and 
ATP is prevented in the presence of ClpP, and the residual fluorescence after heat 
treatment is lost upon degradation (Figure S2). Together, these results indicate that 
ClpX requires ATP to reactivate Gfp-ssrA and, surprisingly, that ATPɣS is also 
capable of promoting reactivation, although at a much slower rate than ATP (Figure 
3B).  
 
Reactivation and disaggregation by ClpX requires a specific recognition 
sequence  
Next, we determined if a ClpX recognition motif is important for efficient 
recognition of aggregated substrates by ClpX. We compared reactivation of aggGfp-
ssrA with heat-aggregated Gfp (aggGfp) without an ssrA tag. We observed that after 
incubation with ClpX and ATP for 60 minutes, approximately 30 units of fluorescence 
were recovered, which is 8% of the initial pre-heat fluorescence, indicating that 
aggGfp is a poor substrate for reactivation by ClpX  (Figure 4A). In contrast, aggGfp-
107 
 
ssrA recovered 33% (>100 units) of the initial pre-heat fluorescence after incubation 
with ClpX (Figure 4A). 
 Two regions of FtsZ are important for promoting degradation of E. coli FtsZ by 
ClpXP, one in the unstructured linker region (amino acids 352-358) and one near the 
C-terminus (residues 379 through 383) (Camberg et al., 2014). Using a truncated 
FtsZ mutant protein, FtsZ(ΔC67), which is deleted for 67 C-terminal amino acid 
residues, including both regions involved in ClpX recognition, we tested if ClpXP 
reduces the light scatter in reactions containing heat-aggregated FtsZ(ΔC67) 
[aggFtsZ(ΔC67)]. We heated FtsZ(ΔC67) at 65 °C for 15 minutes, the condition that 
promotes aggregation of full length FtsZ, and confirmed that heat treatment resulted 
in an 84% loss of GTP hydrolysis activity and an increase in light scatter, which is 
stable over time (Figure 4B and 4C). In the presence of ClpXP, we observed no 
decrease in light scatter for aggFtsZ(ΔC67) after incubation for 120 minutes (Figure 
4C), which is expected since FtsZ(ΔC67) is a poor substrate for ClpXP degradation 
(Figure S3). Together, these results demonstrate that for ClpX to recognize 
aggregates and promote disaggregation, disassembly and/or reactivation, a ClpX 
recognition motif is required. 
 
Impaired reactivation by ClpX(E185Q) 
ATP is required for reactivation of aggGfp-ssrA, however, it is unknown if this 
event requires ATP-hydrolysis and substrate unfolding. Therefore, we used the ClpX 
mutant protein ClpX(E185Q), which has a mutation in the Walker B motif and is 
defective for ATP-hydrolysis, but interacts with substrates (Hersch et al., 
2005;Camberg et al., 2014). We observed that ClpX(E185Q) is defective for 
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disaggregation of aggGfp-ssrA by monitoring turbidity by 90°-angle light scatter of 
reactions containing aggGfp-ssrA, ClpX(E185Q) and ATP (Figure 5A). We also tested 
if aggFtsZ is disassembled by ClpX(E185Q), and observed no reduction in light 
scatter in reactions containing aggFtsZ, ClpX(E185Q) and ATP after 120 minutes 
compared to ClpX (Figure 5B). Finally, we tested if reactivation of aggGfp-ssrA 
requires ATP hydrolysis using ClpX(E185Q) instead of ClpX. We observed that 
ClpX(E185Q) promotes a small amount of reactivation of aggGfp-ssrA and restores 
fluorescence, but to a much lesser extent than the level observed for wild type ClpX 
(Figure 5C). These results suggest that ATP hydrolysis by ClpX is required to 
promote efficient reactivation of aggGfp-ssrA and disassembly of large complexes 
containing aggFtsZ or aggGfp-ssrA (Figure 5A, 5B and 5C).  
 
ClpXP prevents accumulation of FtsZ aggregates in vivo under extreme thermal 
stress 
ClpX and ClpP were previously reported to localize to protein aggregates in E. 
coli, suggesting that ClpXP may target aggregates in vivo for direct degradation 
(Winkler et al., 2010). We used the native ClpXP substrate FtsZ, which aggregates 
upon heat treatment, to determine if ClpX and/or ClpXP modulates FtsZ aggregate 
accumulation after thermal stress by comparing the levels of FtsZ present in insoluble 
cell fractions (Figure 2A and 6A). Wild type cells and cells deleted for clpX, clpP, clpB, 
clpA, dnaK, lon, hslU and hslV were exposed to heat shock and insoluble protein 
fractions were collected and analyzed by immunoblot. We observed that FtsZ was 
present in the insoluble fraction of wild type cells (BW25113), and this amount was 
42% higher in cells exposed to heat shock at 50 °C (Figure 6A and S4A). However, 
FtsZ levels were even higher in the insoluble fractions of ΔclpX and ΔclpP strains 
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compared to the parental strain (2.4-fold and 2.3-fold, respectively), although the 
amount of total protein was similar to the wild type strain exposed to heat shock 
(Figure S4B). We detected less protein overall in the ΔdnaK strain after recovery, but 
this strain also had poor viability after heat shock and recovery (Figure S4C). In 
addition, we also detected ClpX in the insoluble fraction in all strains except the clpX 
deletion strain (Figure S4A). Next, we conducted a mild heat shock, 42 °C for 30 
minutes, followed by recovery, and observed that deletion of clpB had a larger effect 
on the accumulation of insoluble FtsZ than deletion of clpX (Figure S4D).  To 
determine the relative contributions of either clpB or clpX during a 40 minute recovery 
period after incubation at 50 °C, we analyzed insoluble FtsZ levels at 20 minute time 
intervals during recovery (Fig. 6B). Notably, we observed that in cells deleted for clpX, 
insoluble FtsZ was present immediately after heat treatment and continued to 
accumulate throughout the recovery period to a greater extent than in wild type or 
clpB deletion cells. These results suggest that ClpXP prevents accumulation of FtsZ 
aggregates in cells exposed to extreme thermal stress. Since we observed that 
insoluble FtsZ levels were elevated in ΔclpB strains exposed to mild heat shock 
(Figure S4D), we repeated the recovery time course in clpX and clpB deletion strains 
after mild heat shock, 42 °C for 30 minutes, to monitor insoluble FtsZ levels (Figure 
S4E). We observed that insoluble FtsZ accumulates during the recovery period in 
clpB deletion strains after mild heat shock (Figure S4E).  
Finally, if ClpXP is active in cells after severe heat shock, then it should not be 
a thermolabile protein. To determine if ClpXP remains active after exposure to 50 °C 
in vitro, we incubated ClpXP in buffer at 50 °C for one hour, and then measured 
activity after addition of Gfp-ssrA by monitoring the loss of Gfp-ssrA fluorescence. We 
observed that ClpXP remained active for unfolding and degradation of Gfp-ssrA after 
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incubation at 50 °C for one hour (Figure S4F). As a control, ClpXP was also incubated 
in buffer at 30 °C for one hour and then assayed for activity.  We observed that ClpXP 
incubated at 30 °C was more active than ClpXP incubated at 50 °C, suggesting that a 
partial loss of activity had occurred at high temperature (Figure S4F). However, this 
assay was performed in the complete absence of other cellular chaperones or 
substrates and suggests that some ClpXP likely continues to retain activity after 




Here, using both a native and an engineered aggregated substrate, we 
demonstrate that ClpXP has the operational capacity to disassemble and degrade 
large aggregates that have ClpX degrons. In this study, FtsZ, a native substrate of 
ClpXP in E. coli, was aggregated in vitro by thermal stress, and we further show that 
FtsZ also aggregates in vivo when cells are exposed to high temperature (Figure 2A 
and 6A). The observation that FtsZ is aggregation prone is in agreement with a prior 
study reporting the presence of FtsZ in intracellular aggregates of ΔrpoH cells 
incubated at 42 °C by mass spectrometry (Tomoyasu et al., 2001).  FtsZ aggregates 
are cleared in vitro and in vivo by ClpXP, and ClpXP does not require the assistance 
of additional chaperones (Figure 2E, 2F and 6A). Moreover, in the absence of ClpP, 
ClpX also promotes disassembly of FtsZ and Gfp-ssrA aggregates indicating that 
disassembly can also occur by a proteolysis-independent mechanism, although 
disaggregation is more efficient in the presence of ClpP. ClpXP-mediated 
disassembly of Gfp-ssrA aggregates requires ATP in experiments monitoring turbidity 
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(Figure 1E). In addition, the Walker B mutation in ClpX, E185Q, which impairs ATP 
hydrolysis, also impairs disaggregation of aggGfp-ssrA and, to a lesser extent, 
aggFtsZ. Aggregate disassembly and resolubilization by ClpX was previously 
described using the substrate lambda O protein, and here we show disassembly of 
aggregates and kinetic monitoring using two additional substrates, as well as 
reactivation of Gfp-ssrA fluorescence (Wawrzynow et al., 1995). Reactivation of Gfp-
ssrA is largely dependent on ATP hydrolysis (Figure 3B), since ClpX(E185Q) only 
weakly promotes reactivation of aggregated Gfp-ssrA (Figure 5C), yet ClpX(E185Q) is 
capable of stable interactions with substrates in the presence of ATP, although they 
are not unfolded (Hersch et al., 2005;Camberg et al., 2014). It is unlikely that there 
are soluble, unfolded Gfp-ssrA monomers in solution after heating, since we did not 
detect them by DLS and it has been demonstrated that soluble, unfolded Gfp rapidly 
refolds, in 20 to 30 seconds, by a spontaneous reaction that does not require 
chaperones (Figure 1C) (Makino et al., 1997;Tsien, 1998;Zietkiewicz et al., 2004). 
Therefore, it is likely that large aggregates contain loosely associated unfolded 
proteins, which can be removed and reactivated by ClpX and, in the case of Gfp-ssrA, 
allowed to spontaneously refold. As expected, recognition by ClpX is highly specific, 
as Gfp without an ssrA-tag is not reactivated (Figure 4A). 
We also detected partial disaggregation of aggFtsZ by ClpX, but not by 
ClpX(E185Q) (Figure 5B). Aggregation of FtsZ is induced at 65 °C, but the 
aggregates formed by FtsZ are smaller than those formed by Gfp-ssrA (30 nm and 
600 nm, respectively) (Figure 1C and 2D). FtsZ aggregates likely contain 8-10 
monomers, based on the average size of a folded FtsZ monomer, which is 
approximately 40 Å in diameter (Figure 2D) (Oliva et al., 2004). In contrast, Gfp 
aggregates in this study likely contain more than 120 subunits, based on an average 
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size of a folded Gfp monomer, which is approximately 50 Å across the long axis (van 
Thor et al., 2005). The small size of the FtsZ aggregate may allow it to be more 
susceptible to disassembly by ClpX than a larger aggregate.  
In the model for disassembly of aggregates by ClpXP, ClpX binds to exposed 
recognition tags on the surface of the aggregate and promotes removal, unfolding and 
degradation of protomers from within the aggregate (Figure 7A). Removal of 
protomers eventually leads to destabilization and fragmentation of the aggregate as 
well as degradation (Figure 1F and 2F). Although this process does not require ClpP, 
it occurs more robustly when ClpP is present than when ClpP is omitted (Figure 1E 
and 2E).   For aggregated substrate reactivation, ClpX likely engages unfolded 
protomers from the aggregate, which may be internal or loosely bound to the exterior 
of the aggregate, unfolds and release them. For small aggregates, this activity may be 
sufficient to lead to fragmentation and capable of promoting reactivation of substrates 
such as Gfp-ssrA (Figure 7B).  
Finally, we observed large increases in insoluble FtsZ when cells were 
exposed to two different temperatures, 50 °C, which represents extreme heat shock, 
and 42 °C, which represents a mild heat shock (Figure 6A, 6B and S4D). At 42 °C, 
deletion of clpB was associated with a large accumulation of insoluble FtsZ, 
suggesting that under mild heat stress, ClpB is the major factor that ensures FtsZ 
solubility (Figure S4D and S4E). However, we observed a remarkably different result 
after heat shock at 50 °C and throughout the recovery period. Specifically, in a clpX 
deletion strain, large amounts of insoluble FtsZ accumulate during the recovery period 
to a greater extent than in a clpB deletion strain (Figure 6A and 6B). It is unknown if 
ClpXP and ClpB are processing FtsZ aggregates directly in vivo, because we did not 




is typically present at very high levels (5,000 to 20,000 copies per cell) and is 
essential for cell division in E. coli (Bramhill, 1997). Interestingly, FtsZ also forms 
linear polymers as part of its normal biological function to promote cell division, and 
polymers are efficiently recognized, disassembled and degraded by ClpXP (Figure 2F 
and 2G) (Camberg et al., 2009;Camberg et al., 2014;Viola et al., 2017).  Given the 
diverse conformational plasticity of FtsZ, its use as a model disaggregation and 
remodeling substrate will be informative for studies of targeting and processing of 
multisubunit substrates by AAA+ proteins. As with FtsZ, many other ClpXP substrates 
are detectable in protein aggregates in cells (Flynn et al., 2003;Maisonneuve et al., 
2008). Moreover, a previous study showed that ClpXP is important for cell viability 
under thermal stress conditions in cells depleted of DnaK (Tomoyasu et al., 2001). 
Given that it is estimated that 2-3% of E. coli proteins are ClpXP substrates, ClpXP 
likely serves as an additional mechanism to manage accumulation of aggregation-
prone proteins in vivo, particularly under extreme stress conditions (Flynn et al., 
2003;Maisonneuve et al., 2008).  
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Genotype Source, reference, 
or construction 
Strains   
BW25113 F-, DE(araD-araB)567, lacZ4787(del)(::rrnB-3), LAM-, 
rph-1, DE(rhaD-rhaB)568, hsdR514 
Datsenko and 
Wanner, 2000 
JW0429 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), Δlon-
725::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW0428 F-, Δ(araD-araB)56, ΔlacZ4787(::rrnB-3), 
ΔclpX724::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW0427 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3),   
ΔclpP723::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW2573 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
ΔclpB757::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW0866 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
ΔclpA783::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW3902 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
ΔhslU790::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW3903 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
ΔhslV720::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW0013 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
ΔdnaK734::kan, λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
Baba et al., 2006 
JW0462 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-
3),ΔhtpG757::kan, λ-, rph-1, Δ(rhaD-rhaB)568, 
hsdR514 
Baba et al., 2006 




Plasmids   
pET-ClpX kan Camberg et al. 2009 
pET-ClpP kan Maurizi et al. 1994 
pET-FtsZ kan Camberg et al. 2009 
pET-
FtsZ(ΔC67) 
kan This study 
pET-H6-
Gfp(uv) 
kan This study 
pBad-Gfp-
ssrA 
amp Singh et al., 2000 
pClpX(E185Q) amp Camberg et al., 
2011 






                  
                    
                  Figure 1. Disaggregation and degradation of aggregated Gfp-ssrA by ClpXP.  
(A) The fluorescence emission spectra (450-600 nm) of Gfp-ssrA (1.0 μM) (green) 
and heat-treated Gfp-ssrA (1.0 μM) (black) (85 °C for 15 minutes) were measured 
using an excitation wavelength of 395 nm. Plotted curves are representative of three 
























































Figure 2. Aggregation and disaggregation of native ClpXP substrate FtsZ.  
(A) Aggregation by 90°–angle light scatter was measured for FtsZ (5 µM) (black circles) 
in a cuvette attached to a circulating water bath at 65 °C for 30 minutes as described in 
Materials and Methods. The curve shown is representative of at least three replicates.  
(B) Rates of GTP hydrolysis were measured for FtsZ (5 µM) (gray) and aggFtsZ (5 µM) 
(black) with GTP (1 mM) for 15 minutes at 30 °C, as described in Materials and Methods. 
The average rate was determined from at least four replicates. (C) DLS was performed 
for FtsZ (5 µM) (gray) as described to determine particle size (nm) distribution. (D) DLS 
was performed for aggFtsZ (5 µM) (black) as described to determine particle size (nm) 
distribution. (E) Disaggregation of aggFtsZ (5 µM) was monitored by 90°-angle light 
scatter as described in Materials and Methods. Disaggregation reactions contained 
aggFtsZ (5 µM) (black circles) or aggFtsZ (5 µM) and ClpX (1 µM) (blue circles), or 
aggFtsZ (5 µM), ClpX (1 µM), and ClpP (1 µM) (red circles), with ATP (4 mM) and a 
regenerating system. Light scattering was monitored for 120 minutes. The curves shown 
are representative of at least three replicates. (F) Degradation was monitored for FtsZ 
and aggFtsZ as described in Materials and Methods in reactions containing FtsZ (6 µM), 
aggFtsZ (6 µM), ClpX (0.5 µM), ClpP (0.5 µM), ATP (4 mM) and a regenerating system, 
where indicated. For degradation of FtsZ, GMPCPP (0.5 mM) was included to promote 
the assembly of stable polymers. Degradation reactions were incubated at 23 °C for 120 
minutes. To detect protein loss due to degradation, samples from 0 and 120 minutes 





































Figure 3. Reactivation of aggregated Gfp-ssrA in the presence of ClpX.  
(A) Reactivation of aggGfp-ssrA (1.0 μM) was monitored as described in 
Materials and Methods in the absence (black circles) and presence (blue circles) 
of ClpX (0.3 μM), ATP (4 mM), and a regenerating system. Fluorescence 
emission (AU) was monitored for 30 minutes. The curves shown are 
representative of at least three replicates.  
(B) Reactivation of aggGfp-ssrA (1.0 μM) was monitored in the absence (black 
circles) or presence of ClpX (0.3 μM), ATP (4 mM) and a regenerating system 
(blue circles), ATPγS (2 mM) (orange circles), ADP (2 mM) (green circles), or no 
nucleotide (gray circles), where indicated. Fluorescence emission (AU) was 























 Figure 4. Aggregation and disaggregation of ClpXP substrates with and 
without recognition motifs.  
(A) Reactivation of aggGfp-ssrA (1.0 μM) alone (dark gray circles) or in the 

























aggFtsZ(ΔC67) + ClpXP 










































Figure 5. Disaggregation and reactivation of ClpX substrates in the 
presence of ClpX(E185Q).  
(A) Disaggregation was monitored by 90°-angle light scatter, as described in 
Materials and Methods for aggGfp-ssrA (1.0 µM) alone (black circles) or in 
the presence of ClpX (0.5 μM) (blue circles) or ClpX (E185Q) (0.5 μM) (open 
circles), where indicated, with ATP (4 mM), and a regenerating system. Light 
scattering was monitored for 120 minutes. The curves shown are 
representative of at least three replicates.  
(B) Disaggregation was monitored by 90°-angle light scatter for aggFtsZ (5 
µM), ClpX (0.5 µM) or ClpX(E185Q) (0.5 µM) where indicated, ATP (4 mM), 
and a regenerating system for 120 minutes as described in Materials and 
Methods. The curves shown are representative of at least three replicates.  
(C) Reactivation was monitored as described in Materials and Methods for 
aggGfp-ssrA (1.0 μM) alone (black circles) or in the presence of ClpX (0.3 
μM) (blue circles) or ClpX (E185Q) (0.3 μM) (open circles), with ATP (4 mM) 
and a regenerating system, where indicated. Fluorescence emission (AU) 
was monitored for 90 minutes. The curves shown are representative of at 













































Figure 6. FtsZ aggregation in deletion strains after heat shock. 
 (A) FtsZ levels were compared in insoluble cell extracts prepared from single 
gene deletion strains (Table 1) after heat shock at 50°C for 1 hour and 
recovery (30°C) as described in Materials and Methods. Cells were collected 
and insoluble protein extracts were analyzed by immunoblotting using anti-
FtsZ antibodies. Relative FtsZ levels were quantified by densitometry from 
four independent experiments. Where indicated, ‘*’ represents a p-value of 
0.03.  
(B) Insoluble FtsZ levels were monitored during the 30°C recovery period (0, 
20 and 40 minutes) after heat shock at 50°C for 60 minutes in wild type, ΔclpB 













































Figure 7. Model of aggregate disassembly. 
 (A) ClpXP binds to aggregated substrates bearing a ClpX-recognition motif. 
ClpXP unfolds and degrades protomers from within the aggregate, leading 
to fragmentation and disassembly in an ATP-dependent manner.  
(B) ClpX binds to aggregates that contain unfolded proteins bearing a ClpX-
recognition motif. Unfolded proteins loosely associated with the aggregate 
surface are reactivated by ClpX through a direct protein interaction that 










































Supplemental Figure S1. Heat-aggregation of Gfp-ssrA. 
The fluorescence emission of aggGfp-ssrA (1.0 μM) (black 
circles) was monitored as described in Materials and Methods 












































Supplemental Figure S2. Unfolding and degradation of aggregated 
Gfp-ssrA by ClpXP. Unfolding and degradation were monitored for 
aggGfp-ssrA (1.0 μM) alone (black circles) or in the presence of ClpP (0.3 
μM) (gold circles), ClpX (0.3 μM) and ClpP (0. μM) (red circles) with ATP (4 
mM), where indicated. Fluorescence emission (AU) was monitored as 













































Supplemental Figure S3. Degradation of FtsZ and FtsZ(∆C67) 
by ClpXP. Degradation was monitored for FtsZ (6 µM) and 
FtsZ(∆C67), ClpXP (0.5 µM), ATP (4 mM), GMPCPP (0.5 mM), 
and a regenerating system where indicated at 23°C for 120 
minutes as described in Materials and Methods, and samples were 



































Supplemental Figure S4. Insoluble FtsZ in deletion strains after heat-
treatment.  
(A) Single gene deletion strains (Table 1) were incubated at 50 °C for 1 hour and 
recovered as described in Materials and Methods. Cells from deletion strains were 
collected and insoluble protein extracts were collected as described and analyzed by 
reducing SDS-PAGE. Immunoblots were performed with antibodies to FtsZ or ClpX as 
described.  
(B) Total protein present in insoluble cell extracts shown in (A) after heat shock at 50 °C 
and recovery was detected by transferring proteins to a nitrocellulose membrane and 
staining with Ponceau. 
 (C) Cell viability for all strains in (A) was determined by measuring colony forming units 
(CFU ml
-1
) of cultures before heating (‘pre-HS’), after heat treatment at 50 °C for 1 hour 
(‘post-HS’), and after 35 minutes of recovery at 30 °C (‘post-rec’). 
 (D) FtsZ levels were compared in single gene deletion strains after heat shock at 42 °C 
for 30 minutes and recovery (30 °C) as described in Materials and Methods. Cells were 
collected and insoluble protein extracts were analyzed by immunoblotting with 
antibodies to FtsZ as described.  
(E) Insoluble FtsZ levels were monitored in wild type, ΔclpX and ΔclpB deletion strains 
before heat shock (50 °C for one hour or 42 °C for 30 minutes, where indicated) and 
during the 30 °C recovery period (0, 20 and 40 minutes). At the indicated times, cells 
were collected from cultures and insoluble protein extracts were analyzed by 























Supplemental Figure S4. Insoluble FtsZ in deletion strains after heat-
treatment.  
(F) Thermal stability of ClpXP was assayed by incubation of ClpX (0.5 μM) and 
ClpP (0.7 μM) in phosphate buffered saline supplemented with ATP (4 mM) 
MgCl2 (10 mM), glycerol (15%), Triton X-100 (0.005%), and TCEP (1 mM). 
Reactions containing ClpXP were added to a preheated quartz cuvette attached to 
a circulating water bath set to 50 °C or 30 °C, where indicated, and incubated for 
one hour. The circulating water bath was rapidly cooled to 30 °C, the reactions 
were supplemented with ATP and regenerating system, Gfp-ssrA (0.2 μM) was 
added, and fluorescence was monitored with time in the absence (black) or 
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 Alzheimer’s disease is characterized by the hyperphosphorylation, 
mislocalization, and aggregation of tau into neurofibrillary tangles (Noble et al., 2013). 
Tau is an intrinsically disordered protein that lacks secondary structure, which 
provides the protein with flexibility (Mandelkow et al., 2012). In Alzheimer’s disease, 
tau changes conformation and becomes filamentous, forming ordered aggregates and 
is abnormally hyperphosphorylated. The extent of neurofibrillary tangle accumulation 
within the brain tissue of patients with Alzheimer’s disease highly correlates to 
disease severity and progression (Braak and Braak, 1991). It is thought that tau 
hyperphosphorylation causes deficits in neuronal functioning by whereby 
pathologically phosphorylated tau protein triggers the conformational change of tau 
into fibrils and highly ordered, fibrillar aggregates (Alonso et al., 2001). Here, we 
model tau hyperphosphorylation in vitro by treating human neuroblastoma SH-SY5Y 
cells with the protein phosphatase 2 (PP2A) inhibitor okadaic acid (Zhang and 
Simpkins, 2010). We find that chaperone protein levels change in response to 
different exposures of okadaic acid, indicating that chaperone proteins may be 





Alzheimer’s disease is characterized by the accumulation of filamentous 
amyloid-beta and tau protein into extracellular amyloid-beta plaques and intracellular 
neurofibrillary tangles (Crews and Masliah, 2010). The pathology of Alzheimer’s 
disease is thought to arise from alternative processing of the amyloid precursor 
protein by beta-secretase and gamma-secretase, which results in the formation and 
accumulation of amyloid-beta (Aβ) peptides that are 40 residues (Aβ40) and 42 
residues (Aβ42). The accumulation of Aβ42 peptide triggers amyloid fibril formation 
and deposition of amyloid plaques, which are thought to be cytotoxic and responsible 
for the neurodegeneration observed in Alzheimer’s disease (Kametani and 
Hasegawa, 2018). However, studies have reported that amyloid plaques in transgenic 
mouse brain tissue are not closely correlated with neurodegeneration or changes in 
cognitive functioning (Kim et al., 2007; Kim et al., 2013). Moreover, brain imaging 
studies have shown that amyloid plaques are distributed in brains of cognitively 
normal aged patients and are not specific to patients with Alzheimer’s disease 
(Edison et al., 2007; Li et al., 2008; Davis et al., 1999; Fagan et al., 2009; Price et al., 
2009; Chetelat et al., 2013). Thus, it is possible that amyloid plaques are not a 
defining pathological hallmark of Alzheimer’s disease, but instead accumulate as a 
result of aging. 
Deficits in amyloid precursor protein metabolic activity are thought to 
contribute to the formation of a pathological environment that triggers tau pathology 
(Tanzi and Bertram, 2005). Research from a double transgenic mouse model of 
Alzheimer’s disease that expressed both mutant amyloid precursors protein and wild-
type human tau showed that amyloid-beta oligomers accelerate the formation of 
neurofibrillary tangles and neurodegeneration (Hurtado et al., 2010). Neurofibrillary 
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tangles are intracellular deposits of paired helical filaments that accumulate in regions 
of the brain associated with cognitive functioning (Binder et al., 2005) and are 
associated with cognitive impairments (Santacruz et al., 2005; Di et al., 2016).  Both 
neurofibrillary tangles and amyloid-beta plaques are filamentous aggregates that have 
a cross-beta structure, similar to the human prion protein structure (Iqbal et al., 2005). 
The main constituent of the paired helical filaments is abnormally phosphorylated tau 
protein, referred to as hyperphosphorylated tau (Grundke-Iqbal et al., 1986; Kosik et 
al., 1986; Ihara et al., 1986).   
Microtubule-associated tau protein is transcribed from the MAPT gene on 
chromosome 17 and alternative splicing of exon2, exon3, and exon10 results in six 
different tau isoforms in the adult human brain (Goedert et al., 2010). The six isoforms 
of tau range from 37 to 46 kDa and differ based on the number of N-terminal inserts 
and C-terminal microtubule-binding regions (Guo et al., 2017). In the MAPT gene, 
exons 2 and 3 encode for 29 amino acid residue regions that are located in the N-
terminal domain of tau protein. Exons 9 – 12 encode for the microtubule-binding 
repeats in the C-terminal domain of tau (Guo et al., 2017). The longest tau isoform 
contains 2 N-terminal domain inserts and 4 microtubule-binding repeats (Mandelkow 
et al., 2012). The domain architecture of tau is divided into an acidic N-terminal 
projection domain (residues 1 – 150), a proline-rich domain (residues 151 – 243), a 
microtubule-binding domain, and the C-terminal domain (Mandelkow et al., 2012).  
Microtubule-associated tau protein functions to stabilize microtubules and 
support long-distance, microtubule-mediated axonal transport Drubin and Kirschner, 
1986; Johnson and Stoothoff, 2004). In a Drosophila melanogaster model of 
Alzheimer’s disease, overexpression of amyloid precursor protein caused axonal 
transport defects and deficits in short-term synaptic plasticity (Rusu et al., 2007). 
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Impaired axonal transport may therefore cause cognitive dysfunction in Alzheimer’s 
disease. Furthermore, the phosphorylated tau has greater binding affinity for the light 
chain of kinesin-1, a motor protein involved in axonal transport, whereas 
dephosphorylated tau shows decreased binding to kinesin-1 in rat cortical neurons 
(Cuchillo-Ibanez et al., 2008). Although soluble tau protein is primarily localized to the 
axons of healthy neurons, early in Alzheimer’s disease pathology 
hyperphosphorylated tau dissociates from microtubules and mislocalizes to the 
somatodendritic compartment (Morris et al., 2011; Braak et al., 2011). Without 
biologically functional, soluble tau protein, neuronal processes become disrupted. 
Microtubules become destabilized, axonal transport decreases, and synapses retract 
(Dubey et al., 2015). 
In Alzheimer’s disease, tau hyperphosphorylation is thought to result in a toxic 
gain of function and loss of normal tau function. Tau protein contains more than 45 
possible sites for phosphorylation (Hanger et al., 2007). Normally, tau contains 2 – 3 
mol phosphate/mol of protein; phosphorylation levels greater than this impair the 
ability of tau to bind microtubules and regulate microtubule assembly (Kӧpke et al., 
1993; Lindwall et al., 1984; Alonso et al., 1994). Furthermore, hyperphosphorylation 
of tau is thought to promote misfolding and aggregation of tau protein into paired 
helical filaments (Alonso et al., 1996). During Alzheimer’s disease pathogenesis, tau 
hyperphosphorylation at various sites occurs before the aggregation of tau fibrils into 
intracellular neurofibrillary tangles (Figure 1A). Thus, aberrant phosphorylation of tau 
may cause the aggregation (Kӧpke et al., 1993).  Previous research has shown that 
treating transgenic mice with kinase inhibitors changes the phosphorylation state of 
tau, decreases the number of tau-positive aggregates, reduces neurodegeneration, 
and improves motor function (Noble et al., 2005; LeCorre et al., 2006; Sundaram et 
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al., 2013). Evidence that hyperphosphorylation of tau at Thr212 induces the self-
assembly of tau into fibrils and aggregates in vitro further support the hypothesis that 
tau hyperphosphorylation induces self-assembly of tau (Alonso et al., 2010). 
Phosphorylation of the tau phosphorylation sites Thr212, Thr231, and Ser262 results 
in caspase-3 activation in 85% of transfected PC12 and CHO cells, suggesting that 
these residues may be important in Alzheimer’s disease neurodegeneration (Alonso 
et al., 2010). However, there is not a consensus in the field that tau 
hyperphosphorylation causes tau self-assembly into aggregates. Previous research 
showed that in vitro phosphorylation of tau at the KXGS motifs in the microtubule 
binding repeat domain does not facilitate tau aggregation into paired helical filaments 
(Schneider et al., 1999). Analysis of the expression of tau phospho-epitopes in post-
mortem brains of patients with different severities of Alzheimer’s disease pathology 
showed differential expression of specific phospho-tau epitopes during neurofibrillary 
tangle formation and deposition (Augustinack et al., 2002). Therefore, it is possible 
that specific sites of tau phosphorylation drive the aggregation of tau into paired 
helical filaments whereas other sites of tau phosphorylation, though important in 
dissociating tau from microtubules, do not contribute to tau assembly into aggregates. 
Protein quality control and Alzheimer’s Disease 
Neurofibrillary tangles sequester tau protein, preventing tau protein from 
associating with and stabilizing microtubules (Gendron and Pretrucelli, 2009). 
Furthermore, protein degradation pathways are dysfunctional in Alzheimer’s disease. 
Paired helical filaments from the brains of patients with Alzheimer’s disease and 
synthetic paired helical filaments both impair the proteasome, which prevents the 
clearance of pathological protein aggregates (Keck et al., 2003). Protein aggregates 
are a threat to cell viability because they disrupt membranes and promote misfolding 
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in the rest of the proteome (Taylor and Dillin, 2011; Gidalevitz et al., 2006). Within the 
cell, the protein quality control network safeguards against protein aggregation (Balch 
et al., 2008). When there is cellular stress, such as heat stress, proteins can become 
structurally damaged and misfold (Powers and Balch, 2013). Heat shock proteins, or 
molecular chaperone proteins, are upregulated in response to cell stress to manage 
protein misfolding (Morimoto, 2008). The transcription factor HSF-1 induces heat 
shock proteins in response to stress. Overexpression of HSF-1 prolongs lifespan in 
the model organisms D. melanogaster and C. elegans (Taylor and Dillin, 2011). 
During aging, the ability to mount a heat shock response to environmental stresses 
decreases (Ben-Zvi et al., 2009). Irreversibly misfolded proteins are normally removed 
from cell via two main degradation pathways: the ubiquitin-proteasome system and 
autophagy (Taylor and Dillin, 2011). With age, autophagy function decreases (Terman 
et al., 1995). Postmortem brains of patients with AD show extensive autophagosome 
accumulation within neurites, which may be due to impairment in the clearance of 
proteins by macroautophagy (Nixon et al., 2005). Thus, the cell’s ability to remove 
pathological protein aggregates declines with age, which makes aged neurons more 
susceptible to proteotoxic stressors. Additionally, the expression of ATP-dependent 
chaperone proteins, specifically Hsp90 and Hsp70, declines with age and even more 
so in Alzheimer’s disease (Brehme M et al., 2014).  
The role of ATP-dependent chaperones such as Hsp70 and Hsp90 in 
Alzheimer’s disease pathology is not well understood (Figure 1B). Inhibition of Hsp90 
decreases the aggregation of tau into neurofibrillary tangles (Salminen et al., 2011) 
and promotes the elimination of aggregated, hyperphosphorylated tau (Luo et al., 
2007). Thus, Hsp90 may be involved in a pathological pathway that promotes the 
aggregation of tau into paired helical filaments. By contrast, overexpression of Hsp70 
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increases the association of tau with microtubules, which is necessary for normal 
axonal transport and cytoskeletal integrity (Duo et al., 2003). Both Hsp70 and Hsp90 
bind to tau, suggesting a role for these chaperone proteins in modulating the folding 
of tau (Miyata et al., 2011; Thompson et al., 2012).  
In eukaryotes, Hsp90 is a critical regulator of protein folding, protein trafficking, 
and cell signaling; Hsp90 has 400 putative substrate proteins that it regulates (Pearl 
et al., 2006; Barrott and Haystead, 2013). Due to the diverse set of client proteins that 
Hsp90 interacts with, the conformation and nucleotide occupancy of Hsp90 is tightly 
regulated by a network of co-chaperone proteins and post-translational modifications, 
including phosphorylation, methylation, and acetylation (Pearl et al., 2006). It is known 
that Hsp90 binds more tightly, and thus has greater affinity for Tau P30L, a mutant of 
tau that is associated with tau aggregation, compared to wild-type tau protein (Luo et 
al., 2007). Furthermore, inhibiting Hsp90 in cell culture and in human tau transgenic 
mice mitigates tau aggregation and pathology (Luo et al., 2007). It is thought that 
Hsp90 stabilizes phosphorylated, pathological tau and prevents its degradation 
(Tortosa et al., 2009; Jinwal et al., 2010; Dickey et al., 2007). Moreover, the Hsp90 
co-chaperone protein ATPase homolog 1 (Aha1) has been shown to increase tau 
fibrillization into aggregates in vitro and in a mouse model (Shelton et al., 2017). The 
co-chaperone proteins FKBP51 and FKBP52 also form a complex with Hsp90 and 
have been shown to accelerate tau aggregation (Blair et al., 2013). In contrast, the 
co-chaperone protein carboxy terminus of Hsp70-interacting protein (CHIP), an E3 
ubiquitin ligase, forms a complex with Hsp90 and targets client proteins to the 
proteasome for clearance. Previous work has shown that CHIP in complex with 
Hsp90 targets hyperphosphorylated tau protein for proteasomal degradation (Dickey 
et al., 2007).  
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There is strong evidence in the literature for neuroprotective effects of Hsp70 
in Alzheimer’s disease pathology caused by tau and amyloid-beta aggregation. 
Research shows that Hsp70 promotes the degradation of hyperphosphorylated tau 
protein and has been shown to inhibit the aggregation of all six human tau isoforms 
with greater affinity for tau isoforms containing three microtubule-binding repeats 
(Voss et al., 2012). In vitro, the addition of Hsp70 to preformed aggregates of 
oligomeric and prefibrillar tau decreases tau aggregation and rescues fast axonal 
transport from tau-mediated pathology (Patterson et al., 2011). Furthermore, the 
overexpression of Hsp70 in transgenic mice resulted in decreased synaptic loss, 
amyloid-beta plaque load, and cognitive deficits (Hoshino et al., 2011). In vitro, the 
Overexpression of Hsp70 protected against toxicity associated with amyloid-beta 42 
(Magrané et al., 2004).  
The proline-directed kinases glycogen synthase kinase-3 and cyclin 
dependent kinases regulate tau phosphorylation at epitopes associated with 
Alzheimer’s disease pathology (Drewes et al., 1992; Ledesma et al., 1992; Hanger et 
al., 1992; Arioka et al., 1993). Dysregulation of phosphorylation is thought to be a 
contributing factor in Alzheimer’s disease pathology. Alzheimer’s disease is 
characterized by a decrease in the activity and expression of protein phosphatases 
(Braithwaite et al., 2012). Specifically, the downregulation of protein phosphatase 2A 
(PP2A) has been implicated in contributing to the hyperphosphorylation of tau in AD 
(Braithwaite et al., 2012; Gong et al., 2005). Furthermore, protein phosphatase 2A 
inhibitor 2 is mislocalized from the nucleus to the cytoplasm in the brains of patients 
with Alzheimer’s disease, which may trigger the hyperphosphorylation of tau (Arif et 




In vitro tau phosphorylation by okadaic acid 
Okadaic acid is a lipophilic polyether toxin produced by marine dinoflagellates 
of the Prorocentrum and Dinophysis genera that accumulates in filter-feeding 
shellfish; consumption of mollusks containing okadaic acid causes diarrheic shellfish 
poisoning in humans, which causes damage to the gastrointestinal tract and can be 
fatal (Dickey et al., 1990; Cembella et al., 1990; Ito et al., 1994; Edebo et al., 1988). 
Moreover, in vitro analysis of okadaic acid demonstrated that the toxin is absorbed by 
human digestive cells and can be readily transported into the bloodstream (Ehlers et 
al., 2011). In addition to enterotoxic effects, okadaic acid has carcinogenic properties. 
Research has shown that okadaic acid potently promote tumor formation, affecting 
the liver, skin, and stomach (Suganama et al., 1988; Sontag and Sontag, 2006; Fujiki 
and Suganama, 2009). Okadaic acid inhibits protein phosphatases, most notably 
protein phosphatase 2A (PP2A). The IC50 value of okadaic acid required to inhibit 
50% of PP2A activity is 0.1 – 0.3 nM and 15 – 50 nM of okadaic acid inhibits 50% of 
PP1 activity (Swingle et al., 2007). Additionally, okadaic acid inhibits protein 
phosphatase 4, protein phosphatase 5, and protein phosphatase 2B as well as PP2A 
under certain conditions (Louzauo et al., 2005). 
Pharmacologic inhibition of PP2A by okadaic acid has been shown to induce 
tau hyperphosphorylation and increase the accumulation of paired helical filaments in 
several models of Alzheimer’s disease. Increased tau phosphorylation was observed 
in human brain slices of the temporal lobe treated with okadaic acid (Harris et al., 
1993). In a cell culture model of Alzheimer’s disease, undifferentiated SH-SY5Y 
neuroblastoma cells treated with 0, 15, and 30 nM okadaic acid for 24 hours showed 
dose-dependent hyperphosphorylation and accumulation of neurofilament proteins 
localized to the cell body (Wang et al., 2001). Primary hippocampal cultures isolated 
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from rats at gestational day 18 develop strong SMI-3I immunoreactivity in the soma 
and dystrophic neurites, indicating neurofilament phosphorylation, when treated with 
10 nM okadaic acid for 36 hours (Kim et al., 1999). Treatment of human neuronal 
NT2N cells differentiated with retinoic acid and subsequently treated with PP2A 
inhibitors, including okadaic acid, showed increased tau phosphorylation, decreased 
binding of tau to microtubules, depolymerization of Glu-microtubules, and 
degeneration of axons (Merrick et al., 1997). Furthermore, cultured neurons showed 
an increase in paired helical filament 1 (PHF-1) expression in response to 10 nM 
okadaic acid for 6 hours, 12 hours, and 24 hours compared to cells not treated with 
okadaic acid, weakly induced expression of the AT8 epitope of tau, and cleaved tau 
protein into a 45 kDa fragment after 24 hours (Kim et al., 1999). Okadaic acid 
treatment has been reported to specifically enhance phosphorylation at the following 
tau phosphorylation epitopes: Ser396/404, Ser202/205, Ser262, and Thr205 (Ekinici 
and Shea, 1999; Alvarez-de-la-Rosa et al., 2005; Zhang and Simpkins, 2008). Thus, 
treatment of cells with okadaic acid is a useful in vitro model of tau 




Cell Culture Growth and Differentiation 
Human neuroblastoma SH-SY5Y cells were grown as monolayer cultures in 
T75 (Thermo Fisher Scientific) flasks in Dulbecco’s Modified Eagle Medium 
(DMEM)/F12 (Gibco) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 
100 µg/ml streptomycin, and 2 mM L-glutamine at 37°C incubator in a humid 
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environment (95% air, 5% CO2) as previously described (Bihaqi et al., 2017). Viable 
cells were stained with the exclusion dye Trypan blue solution, 0.4% (Thermo Fisher 
Scientific) and counted with a hemocytometer before seeding the cells into 6-well and 
96-well plates at cell densities of 1.0 x 105 cells/well and respectively. Twenty-four 
hours after subculturing the cells, the cells were differentiated with 10 µM all-trans-
retinoic acid (Sigma-Aldrich) for six days as previously described (Bihaqi et al., 2017). 
Briefly, lyophilized retinoic acid (50 mg) was dissolved in 1.67 ml of dimethyl sulfoxide 
(DMSO) and aliquoted. Retinoic acid stock solution was diluted in 100% ethanol and 
subsequently added to complete DMEM culture medium to a final concentration of 10 
µM. Retinoic acid causes morphological changes such as neurite outgrowth and 
activates expression of neuronal markers such as NeuN, NSE, and synaptophysin in 
SH-SY5Y cells (Cheung et al., 2009).  
 
Okadaic Acid Treatment 
Lyophilized okadaic acid sodium salt (Enzo Life Sciences) was reconstituted in 
100% ethanol to yield a stock solution of 1 mM okadaic acid, which was diluted in 
100% ethanol to a final working concentration of 0.1 mM okadaic acid. Okadaic acid 
solution was added to DMEM media to yield final concentrations of 10, 25, 50, and 
100 nM okadaic acid.  
 
Protein Extraction and Western Blotting 
Cells were collected by centrifugation at 1000 xg for 5 minutes at 4°C. Cell 
pellets were washed twice with ice-cold phosphate-buffered saline solution and 
subsequently resuspended in Radio-Immunoprecipitation Assay (RIPA) Buffer 
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containing phosphatase inhibitors and protease inhibitors. The composition of RIPA 
buffer was: 50 mM Tris-Cl, pH 7.4, 1% Nonidet-P40, 0.25% sodium deoxycholate, 
150 mM sodium chloride, 1 mM ethylene glycol tetraacetic acid, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM sodium orthovanate, 1mM sodium fluoride, and 1 
tablet of cOmplete™, mini protease inhibitor cocktail (Roche). For every 106 cells, 100 
µL of RIPA buffer was used to lyse cells. Lysates were vortexed for 5-minute intervals 
for a total of 30 minutes. Lysates were then centrifuged at 10,000 xg for 20 minutes at 
4°C. The BCA protein assay kit (Peirce) was used to determine total protein 
concentration in lysates. Samples were normalized and boiled in lithium dodecyl-
sulfate (LDS) sample buffer (Thermo Fisher Scientific) for 5 minutes at 95°C. Proteins 
were separated by SDS-PAGE and transferred to nitrocellulose membranes. 
Nonspecific protein binding was blocked by incubating the blots in 2% nonfat milk in 
TBS-T buffer (Tris-Cl buffer saline pH 7.6 containing 0.5% Tween-20) for 2 hours at 
room temperature. Membranes were incubated in primary antibody solutions 
overnight at 4°C. Chaperone protein expression levels were determined using 
antibodies against Hsp90 (Thermo Fisher Scientific), Hsp110 (Enzo Life Sciences), 
Hsp90 (Thermo Fisher Scientific), and Hsp70 (Rockland Inc.). Total tau protein levels 
were found with anti-tau antibody against the human 46 kDa tau isoform (Sigma-
Aldrich). Phosphorylated tau epitopes were detected using antibodies against Thr212 
(Sigma-Aldrich), AT8 (Thermo Fisher Scientific), and Ser396 (Cell Signaling 
Technology). Blots were stripped with mild stripping buffer (15 g glycine, 1 g SDS, 
0.1% SDS, 10 ml Tween-20; pH 2.2) for 10 minutes at room temperature and probed 
for housekeeping protein beta-actin (Abcam) or GAPDH (Thermo Fisher Scientific). 
Membranes were incubated in HRP-conjugated secondary antibody dilutions for 1 
hour at room temperature before developing the blots with chemiluminescent West 
Pico Plus reagent (Thermo Fisher Scientific).  
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Cell Death and Cell Viability Assay 
To determine the effects of okadaic acid on differentiated cell morphology, 
cells in 6-well plates were visualized with phase-contrast microscopy using EVOS FL 
Auto Cell Imaging System.  Cell viability was determined using the CellTiter 96® 
Aqueous One Solution Cell Proliferation Assay (Promega). Briefly, CellTiter 96® Aqueous 
One Solution Cell Proliferation Reagent was thawed in a 37°C water bath and 20 μl of 
MTS reagent was added to each well of the 96-well containing 100 μl DMEM culture 
medium not containing serum. After incubation of the 96-well plates at 37°C for 3 
hours, plates were gently shaken and the absorbance was read at 490 nm in a 
microplate reader. Absorbance values were background-corrected for DMEM culture 
medium containing MTS reagent alone in wells that did not contain cells. Cell viability 




Statistical analyses were conducted with Graphpad Prism version 6.0, GraphPad 
Software, La Jolla, California, USA (www.graphpad.com).  Error bars represent mean 
+/- standard error mean (SEM). One-way analysis of variance (ANOVA) followed by 
Tukey’s post hoc multiple comparisons test was used to analyze data sets containing 
more than two groups. P-values less than 0.05 were considered significant. 
 
Results 
Phosphatase inhibition by okadaic acid in undifferentiated neuronal cells 
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 To monitor the effects of increased phosphorylation of tau on the physiology 
and chaperone protein expression of neuroblastoma cells, we first treated 
undifferentiated SH-SY5Y cells with okadaic acid, which inhibits PP2A phosphatase 
leading to tau hyperphosphorylation (schematic in Figure 1C) (Bialojan and Takai, 
1988). As shown in Figure 2A, undifferentiated cells do not develop neurite 
extensions and are not post-mitotic, in contrast to differentiated neuroblastoma cells 
(Figure 2B). Undifferentiated SH-SY5Y cells were cultured at a density of 1.6 x 106 
cells/ml and treated with 0 nM, 50 nM, and 100 nM of okadaic acid for 24 hours, 
doses of okadaic acid that have previously been used to study tau 
hyperphosphorylation in a cell culture model of Alzheimer’s disease (Zhang and 
Simpkins, 2010; Choi et al., 2015). We probed cell lysates of undifferentiated cells 
treated with okadaic acid for Hsp70, Hsp90 and Hsp110 and observed that while 
levels of Hsp90 and Hsp110 do not change, Hsp70 appeared to be induced upon 
okadaic acid treatment. Previous reports of protein phosphatase 2A inhibition by 
okadaic acid treatment showed that in vitro levels of the tau phosphorylation epitope 
Thr212 increased in response to okadaic acid (Wu et al., 2017). Thus, we probed for 
phosphorylated tau using the phosphorylated Thr212 epitope to determine if 
undifferentiated SH-SY5Y treated with 50 nM and 100 nM okadaic acid have 
increased phosphorylated Tau levels compared to control cells that were not treated 
with okadaic acid. We observed a modest migration shift in phosphorylated tau (pTau) 
at Thr212 suggesting that in response to okadaic acid treatment, tau may accumulate 
additional modifications. However, phosphorylation intensity at Thr212 appears to be 
similar (Figure 2C). Together, undifferentiated SH-SY5Y cells appear to have only 
modest changes resulting from incubation with okadaic acid, although the increase in 




Phosphatase PP2A inhibition by okadaic acid leads to reduced chaperone 
function and tau phosphorylation in differentiated neuronal cells 
Next, we differentiated SH-SY5Y cells with retinoic acid to generate cells with 
neurite extensions and produce physiology that is more relevant to neurons (Figure 
2B). Then we treated differentiated cells with okadaic acid to investigate cell viability, 
tau hyperphosphorylation and levels of chaperone proteins in response to treatment. 
After differentiation with retinoic acid, cells were treated with 0 nM, 25 nM, 50 nM, and 
100 nM of okadaic acid (n = 4 per treatment group) for 3 hours (Figure 3A) and 8 
hours (Figure 3B) and overall cell morphology was monitored by phase-contrast 
microscopy. After 3 hours of okadaic acid exposure, SH-SY5Y cells in the 0 nM and 
25 nM okadaic acid treatment groups had apparent normal morphology defined as 
cells that had phase-bright soma and neuritic processes, as established by previous 
reports of SH-SY5Y healthy phenotype (Kim et al., 1999) (Figure 3A). However, 
treatment of cells with either 50 nM or 100 nM okadaic acid for 3 hours caused 
widespread cell death as evidenced by loss of neurite extensions, cell rounding, and 
cell detachment from the plate (Figure 3A). We observed similar results when cells 
were incubated with okadaic acid for 8 hours with high doses associated with cell 
detachment and death but normal physiology observed at the lower dose (Figure 3B). 
These results suggest that cytoxicity associated with okadaic acid is enhanced in 
differentiated cells compared to undifferentiated cells. 
Next, we measured cell viability of differentiated SH-SY5Y cells after exposure 
to okadaic acid using the MTT colorimetric assay to detect metabolic activity. SH-
SY5Y cells were seeded at a cell density of 5.0 x 104 cells/ml in a 96-well plate. 
Twenty-four hours post-seeding, cells were differentiated with retinoic acid and then 
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treated with 0 nM, 10 nM, and 25 nM for 3 hours, 6 hours, and 24 hours. The MTT 
assay conducted at the 3-hour and 6-hour exposures to 0 nM, 10 nM, and 25 nM 
okadaic acid did not show any significant differences in cell viability compared to cells 
treated with only vehicle (0.1% ethanol) (Figure 3C and 3D). However, the 10 nM and 
25 nM doses of okadaic acid were associated with reduced metabolic function in the 
cells at the 24-hour time point suggesting reduced cell viability (Figure 3E and 3F). 
Consistent with this, we also observed that after 24 h exposure to low doses of 
okadaic acid cells, cells became rounded and detached (Supplemental Figure S1A). 
Viability continued to decrease across a range of okadaic acid concentrations during 
prolonged incubations (42 h) (Supplemental Figure S1B and S1C). 
 Since differentiated SH-SY5Y cells displayed phenotypically normal 
morphologies and no significant loss of viability after low-dose (10 nM and 25 nM) 
short-term (3 hr) treatment with okadaic acid (Figure 3A, 3C, 3G and S1A), we 
harvested cell lysates under these conditions to probe for changes in expression 
levels of Hsp70 and Hsp90 and to detect increased levels of phosphorylated tau using 
phospho-specific antibodies for the Ser396, Thr212, and Thr181 epitopes. Del Barrio 
and colleagues have shown that undifferentiated SH-SY5Y cells treated with 30 nM of 
okadaic acid for 16 hours show significant changes in tau phosphorylation at the 
Ser396/404 epitope (Del Barrio et al., 2011). After 3 hours of treatment with okadaic 
acid, we detected increased levels of Tau phosphorylated at Thr212 and, to a lesser 
extent, Ser396, most notably at the 25 nM dose (Figure 4A). However, we observed 
no increase in Tau phosphorylated at Thr181, indicating that not all sites are uniformly 
affected by okadaic acid. Interestingly, Hsp70 protein levels decrease dramatically 
after exposure to 25 nM okadaic acid for 3 h, and we also observed slightly less 
Hsp90 after treatment (Figure 4A).  
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 Next, to determine if changes in protein levels that we detected get more 
pronounced with extended incubation with okadaic acid, we harvested cells at 6 h and 
probed lysates for Hsp70, Hsp90 and phosphorylated-tau (Thr212) (Figure 4B). We 
observed that levels of Hsp70 and Hsp90 continued to decrease over time, indicating 
that the reductions in levels were both dose-dependent and time-dependent. 
Moreover, we continued to observe elevated levels of tau phosphorylated at Thr212. 
Finally, long-term exposure to okadaic acid does not impact overall tau levels as 
detected by total tau antibody, which reacts with multiple tau isoforms (Supplemental 
Figure S2A and S2B). Together, these results demonstrate that inhibition of protein 
phosphatases leads to enhanced phosphorylation of tau and correlates with reduced 
function of ATP-dependent chaperones in differentiated SH-SY5Y cells. 
 
Discussion 
Protein aggregation is observed throughout several neurodegenerative 
diseases, such as Alzheimer’s disease (AD), Parkinson’s disease, and Huntington’s 
disease (Pruisner, 2013). Proteins misfold into a biologically nonfunctional, insoluble 
state and proceed to form detergent-resistant aggregates that cannot be degraded by 
cellular degradation mechanisms, such as the ubiquitin proteasome pathway in 
humans (Jucker and Walker, 2013; Vashist et al., 2011). It is hypothesized that 
protein aggregates form in diseases as a result of inefficient protein quality control, 
possibly due to aging (Saez and Vilchez, 2014). Research provides evidence that 
amyloids and amyloid-like fibers interfere with neuronal functions, including cell 
communication, which may contribute to neuronal cell death in neurodegenerative 
diseases (Kakkar et al., 2014). In Alzheimer’s disease, tau becomes 
hyperphosphorylated and both mouse and human hyperphosphorylated tau have 
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been shown to aggregate in vitro (Alonso et al., 2001; Chohan et al., 2005). Tau 
hyperphosphorylation is not exclusive to Alzheimer’s disease; aberrant 
phosphorylation of tau and formation of tau-positive inclusions occurs in several 
human neurodegenerative diseases, including Pick’s disease, progressive 
supranuclear palsy, corticobasal degeneration, and frontotemporal dementia and 
Parkinsonism linked to chromosome-17 (Goedert et al., 2010).  
Cells have robust protein quality control networks that resolubilize misfolded 
proteins and degrade aggregated proteins. Within this network, molecular chaperones 
function to stabilize properly folded proteins, refold misfolded or partially unfolded 
proteins, and degrade misfolded proteins that are unamenable to refolding 
mechanisms (Bukau and Horwich, 1998). There is evidence that molecular 
chaperones may be involved in the progression of Alzheimer’s disease pathology. 
Research shows that expression levels of ATP-dependent molecular chaperones, 
Hsp90 and Hsp70, decrease during the course of aging and neurodegenerative 
diseases (Salminen et al., 2011; Brehme et al., 2014). Normally, cellular stress 
triggers the upregulation of heat shock proteins, which regulate the folding of unfolded 
or misfolded proteins and degrade irreversibly misfolded proteins (Morimoto and 
Santoro, 1998). Studies have shown that increasing the expression of heat shock 
proteins in animal models of neurodegenerative diseases can be neuroprotective. The 
overexpression of Hsp70 mitigates pathological phenotypes in transgenic mouse 
models of spinal and bulbar muscular atrophy (Adachi et al., 2003; Katsuno et al., 
2005).  
In this study we sought to determine if okadaic acid, a known inhibitor of 
PP2A, alters chaperone protein levels in differentiated human neuroblastoma SH-
SY5Y cells. It is thought that inhibition of PP2A may have a role in Alzheimer’s 
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disease pathogenesis. In the brains of patients with Alzheimer’s disease there is an 
increase in both the levels of mRNA and expression of inhibitor 1 of PP2A (I1PP2A) and 
in vitro expression of I1PP2A hyperphosphorylates tau in NIH3T3 cells (Wang et al., 
2015). Here, we found that long-term exposure to okadaic acid significantly impairs 
the viability of differentiated SH-SY5Y cells treated with 10 nM, 30 nM, and 50 nM 
okadaic acid for 24 and 42 hours. However, cells tolerated short-term exposure to 10 
nM and 25 nM okadaic acid (3 h) without significant loss of viability. These 
observations suggest that 24-hour exposure of okadaic acid to differentiated SH-
SY5Y cells is toxic. Future experiments that measure caspase-3 activation in 
response to 24-hour exposure of 10 nM and 25 nM okadaic acid to differentiated SH-
SY5Y cells could investigate this further. 
Reduced chaperone function could exacerbate defects in overall cell viability 
and neurodegeneration. Notably, both Hsp70 and Hsp90 chaperone protein levels 
decreased in response to increasing doses of okadaic acid at the 3-hour and 6-hour 
exposures of okadaic acid to SH-SY5Y cells. Although after 24 hours, we did observe 
a surprising increase in Hsp70 levels (data not shown), but the cells had become 
rounded and detached with widespread cell death. Together, increasing doses of 
okadaic acid seemed to correlate with decreased levels of Hsp70 and Hsp90 in 
differentiated cells. It is possible that Hsp70 is downregulated or degraded in 
response to phosphatase inhibition. Further research that investigates the mRNA 
levels, localization and protein turnover of of Hsp70 and Hsp90 are warranted. Hsp70 
and Hsp90 are both also known to be phosphorylated, and phosphorylation states 




Okadaic acid has been widely used to inhibit protein phosphatases and model 
tau hyperphosphorylation and dissociation of tau from microtubules in cultured human 
neuroblastoma cells (Caillet-Boudin et al., 1996; Shea et al., 1996). Furthermore, 
okadaic acid has been shown to inhibit PP2A and PP1 in vivo. Rat brains injected 
with okadaic acid have shown decreased expression of PP2A and PP1 (Arendt et al., 
1998). However, the use of okadaic acid and other small molecule inhibitors 
commonly used to inhibit protein phosphatases, such as calyculin A, tautomycin, 
nodularin, microcystin-LR, and fostriecin, have several limitations (Swingle et al., 
2007). Calyculin A, nodularin, and microcystin-LR are the most potent phosphatase 
inhibitors; nanomolar concentrations of these compounds inhibit PP2A, PP1, PP4, 
and PP5 (Swingle et al., 2007). A drawback to using small molecule inhibitors to 
inhibit phosphatases is their ability to effectively enter the cell and selectively inhibit a 
given phosphatase. For example, cell membranes are permeable to calyculin A and 
okadaic acid, but the hydrophobicity of calyculin A and, to a lesser extent, okadaic 
acid limit their solubility in cell culture media (Swingle et al., 2007). This study 
assumed that okadaic acid effectively entered cells and sought to determine which 
doses of okadaic acid could alter tau phosphorylation in vitro. However, it is possible 
that okadaic acid did not efficiently inhibit PP2A using the doses 10 nM and 25 nM 
and exposure times of 6 and 24 hours. Living cells contain concentrations of PP2A 
and PP1 between 0.1 – 1.0 μM depending on the cell line (Cohen et al., 1990). For 
future experiments, it is possible to inhibit phosphatases more efficiently by adding a 
protein phosphatase inhibitor, such as microcystin or nodularin, directly to cell 
extracts and immunoblotting lysates to determine possible alterations in the 




Phase-contrast microscopy clearly showed neuronal degeneration in response 
to short exposures (3 hours, 8 hours) of 50 nM and 100 nM okadaic acid but it is 
difficult to determine the extent of phosphorylation inhibition due to widespread cell 
death and low protein yield in cell extracts. Okadaic acid toxicity could be due in part 
to impaired cytoskeletal architecture and loss of cell-cell contact (Opsahl et al., 2013). 
The toxin has previously been shown to impair cell adhesion and reorganize 
filamentous actin, resulting in morphological rearrangement (Vale and Botana, 2008; 
Franchini et al., 2010). Previous reports demonstrated that okadaic acid within the 
range of 100 – 500 nM alters cytoskeletal structure and induces apoptotic cell death 
in human neuroblastoma cells (Kahn et al., 2012, Valdiglesias et al., 2011). Stable 
isotope labeling of amino acids in undifferentiated SH-SY5Y cells treated with 400 nM 
okadaic acid followed by isolation of lipid rafts and mass spectroscopy analysis 
identified 167 phosphoepitopes of 67 proteins associated with the actin cytoskeleton, 
mictrotubules, and cell adhesion structures that are affected by okadaic acid (Opsahl 
et al., 2013). Thus, okadaic acid may exert cytotoxicity by promoting the breakdown of 
the cytoskeleton and inducing cell detachment.  
Furthermore, okadaic acid causes oxidative damage, genotoxicity, and 
activation of apoptosis in various cell lines.  Treatment of leukocytes, HepG-2 cells, 
and SH-SY5Y cells with okadaic acid resulted in altered cell morphology in all cell 
lines tested and changes in the cell cycle of leukocytes and SH-SY5Y cells with the 
greatest impairment observed in SH-SY5Y cells (Valdiglesias et al., 2011). Moreover, 
treatment of the cell lines with okadaic acid both increased the rate of apoptosis and 
caspase-3 activation in leukocytes, HepG-2 cells, and SH-SY5Y cells (Valdiglesias et 
al., 2011). Okadaic acid treatment has also been shown to induce both direct and 
indirect oxidative damage to SH-SY5Y cells in culture (Valdiglesias et al., 2011). 
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Additionally, DOK cells treated with 10 nM okadaic acid showed evidence of 
cytotoxicity based on LDH release and the same dose of okadaic acid induced 
caspase-3-dependent apoptosis and DNA damage in HepG-2 hepatic cells (Souid-
Mensi et al., 2008). 
The most selective phosphatase inhibitors are tautomycin/tautomycetin, 
okadaic acid, and fostriecin (Swingle et al., 2007). Of these, fostriecin, a phosphate 
ester, has the most selectivity, inhibiting PP2A/PP4 compared to PP1/PP5 with 
selectivity > 104, whereas the selectivity of okadaic acid to inhibit PP2A/PP4 
compared to PP1/PP5 is <102 (Swingle et al., 2007). Furthermore, fostricein is water 
soluble and readily enters living cells via the reduced folate transporter (Fry et al., 
1984). Therefore, fostriecin has advantages over okadaic acid in models of in vitro 
and in vivo phosphorylation. A drawback of using fostriecin is the instability of the 
compound due to its lactone ring compared to okadaic acid, which is stable in organic 
solvents (Swingle et al., 2007). However, fostriecin can be stored in buffered solution 
containing ascorbate with a pH range of 5.5 – 7.5 to prevent oxidation and exposure 
to light (Swingle et al., 2007). The use of fostriecin to inhibit PP2A in human 
neuroblastoma SH-SY5Y cells is a more selective, and possibly less toxic, 
experimental approach compared to okadaic acid. Moreover, it is possible to model 
the phosphorylation of tau by mutating Ser/Thr residues to Glu, or 
pseudophosphorylate tau to determine which phosphoepitopes of tau are directly 
involved in Alzheimer’s disease pathogenesis (Alonso et al., 2010).  
Here, we used okadaic acid as it has previously been reported to alter tau 
phosphorylation (Harris et al., 1993). Phase-contrast microscopy clearly showed 
neuronal degeneration in response to short exposures (3 hours, 8 hours) of 50 nM 
and 100 nM okadaic acid (Figure 3), but it is difficult to determine the extent of 
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phosphorylation inhibition due to widespread cell death and low protein yield in cell 
extracts. Okadaic acid toxicity could be due in part to impaired cytoskeletal 
architecture and loss of cell-cell contact (Opsahl et al., 2013). The toxin has 
previously been shown to impair cell adhesion and reorganize filamentous actin, 
resulting in morphological rearrangement (Vale and Botana, 2008; Franchini et al., 
2010). Previous reports demonstrated that okadaic acid within the range of 100 – 500 
nM alters cytoskeletal structure and induces apoptotic cell death in human 
neuroblastoma cells (Kahn et al., 2012, Valdiglesias et al., 2011). Stable isotope 
labeling of amino acids in undifferentiated SH-SY5Y cells treated with 400 nM okadaic 
acid followed by isolation of lipid rafts and mass spectroscopy analysis identified 167 
phosphoepitopes of 67 proteins associated with the actin cytoskeleton, mictrotubules, 
and cell adhesion structures that are affected by okadaic acid (Opsahl et al., 2013). 
Thus, okadaic acid may exert cytotoxicity by promoting the breakdown of the 
cytoskeleton and inducing cell detachment under high exposure conditions. 
Furthermore, okadaic acid causes oxidative damage, genotoxicity, and activation of 
apoptosis in various cell lines.  Treatment of leukocytes, HepG-2 cells, and SH-SY5Y 
cells with okadaic acid resulted in altered cell morphology in all cell lines tested and 
changes in the cell cycle of leukocytes and SH-SY5Y cells with the greatest 
impairment observed in SH-SY5Y cells (Valdiglesias et al., 2011b). Moreover, 
treatment of the cell lines with okadaic acid both increased the rate of apoptosis and 
caspase-3 activation in leukocytes, HepG-2 cells, and SH-SY5Y cells (Valdiglesias et 
al., 2011b). Okadaic acid treatment has also been shown to induce both direct and 
indirect oxidative damage to SH-SY5Y cells in culture (Valdiglesias et al., 2011c).  
Based on our results, chaperone protein expression of Hsp70 decrease in 
response to increasing exposure and dosage of okadaic acid. However, Hsp90 
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expression increases in response to increasing exposure and concentration of 
okadaic acid. It is possible that Hsp70 destabilize fibrils and aggregates of 
hyperphosphorylated tau and the levels of these chaperones may decrease in 
correlation to increasing aggregate load (Figure 5). By contrast, Hsp90 may stabilize 
aberrantly phosphorylated tau protein and could be involved in the assembly of tau 
fibrils into neurofibrillary tangles. Our results show that Hsp70 levels consistently 
decrease in response to increasing concentration of okadaic acid over 3 hours and 6 
hours of exposure. However, differentiated SH-SY5Y cells treated with okadaic acid 
for 24 hours show a two-fold increase in Hsp70 levels compared to vehicle-treated 
cells (Supplemental Figure S3). We could not probe for changes in Hsp70 expression 
in cells treated with 25 nM okadaic acid for 24 hours due to widespread cell death and 
low protein concentration. Thus, further research should be done to investigate long-
term effects of okadaic acid on cultured human neuroblastoma cells differentiated with 
retinoic acid to investigate changes in chaperone levels over chronic exposure. 
Treating differentiated neuroblastoma cells with low doses of okadaic acid, such as 5 
nM and 10 nM okadaic acid for 24 hours and 48 hours would provide more 
information to compare to the findings discussed here. Moreover, future experiments 
should be carried out that expose differentiated SH-SY5Y cells to okadaic acid for 24 
hours, remove the cell culture medium containing okadaic acid, replace with growth 
medium containing fetal bovine serum, and monitor cells over time for changes in 
Hsp90, Hsp70, and Hsp110 chaperone protein levels.  
A caveat of the okadaic acid model of hyperphosphorylated tau is that 
inhibition of PP2A and to a lesser extent, PP1, could phosphorylate the chaperone 
proteins Hsp70 and Hsp90. Phosphorylation of Hsp90 and Hsp70 in eukaryotes may 
change the functional activities and interactions of these chaperone proteins with co-
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chaperone proteins. Post-translational modifications that regulate Hsp90 conformation 
and binding to co-chaperone proteins include phosphorylation, methylation, 
acetylation, ubiquitylation, nitrosylation, and sumoylation (Kargӧz and Rüdiger, 2015; 
Wandinger et al., 2008). Therefore, excessive phosphorylation of chaperone proteins 
could alter their accessibility for nucleotides and substrate proteins. It is interesting to 
note that the proline-directed kinase Gsk3β, which regulates tau phosphorylation, is a 
client of Hsp90 (Lochhead et al., 2006; Tortosa et al., 2009; Banz et al., 2009). It is 
possible that Hsp90 may contribute to Alzheimer’s disease by facilitating the 
phosphorylation activity of the tau kinase Gsk3β. Overall, it is clear that ATP-
dependent chaperone proteins are involved in Alzheimer’s disease tau pathology and 
it remains to be understood how molecular chaperone proteins are affected by the 
aggregation and accumulation of hyperphosphorylated tau protein. 
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Figure 1. Tau protein hyperphosphorylation and chaperone proteins.  
A.) Human tau phosphorylation in Alzheimer’s disease. Exon 2 and 3 are 
located near the N-terminus of tau protein.  
B.) Chaperone protein structures. Hsp110: crystal structure of Sse1, yeast 
Hsp110 as a complex with ATP, PDB 2QXL (Liu Q and Henderson WA, 2007). 
Full-length Hsp90 crystal structure of HtpG from E. coli is shown bound to ADP 
(PDB 2IOP; Shiau AK, et al., 2006). The crystal structure of human Hsp70 
nucleotide binding domain with the mutation R272K is shown bound to ADP 
(PDB 5BN9; Narayanan D, et al., to be published). 
 C.) Experimental setup for okadaic acid treatment of undifferentiated (1) and 
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Figure 2. Undifferentiated SH-SY5Y cell response to okadaic acid 
treatment.  
A.) Undifferentiated SH-SY5Y morphology. Scale bar indicates 100 μm.  
B.) Morphology of SH-SY5Y cells after retinoic acid-induced 
differentiation. SH-SY5Y cells were treated with retinoic acid (10μM) for 
six days to induce morphological changes such as neurite extension. 
Scale bar indicates 100 μm.  
C.) Western blots of undifferentiated SH-SY5Y cells. Cells were treated 
with 0 nM, 50 nM, and 100 nM okadaic acid for 24 hours in culture media. 
Antibodies were used to determine protein levels of Hsp90, Hsp70, 
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Figure 3. Differentiated cell response to okadaic acid. A.) Cells treated with 
0 nM, 25 nM, 50 nM, and 100 nM okadaic acid for 3 hours. Microscopy of the 
cells shows that the 50 nM dose of okadaic acid at 3 hours is lethal to cells 
(40x objective). Cells are rounded and floating when treated with 100 nM 
okadaic acid for 3 hours (20x objective). The 50 nM dose of okadaic acid at 8 
hours causes cells to lose morphology (40x objective). The 100 nM dose of 
okadaic acid at 8 hours causes widespread cell death (20x objective). After 3 
hours of okadaic acid exposure, cells treated with 10 and 25 nM okadaic acid 
do not show changes in morphology or viability compared to vehicle-treated 
cells. B.) Cells do not show changes in cell viability after 8 hours of exposure 
to 10 nM and 25 nM okadaic acid. C.) Cells treated with 10 nM and 25 nM 
okadaic acid for 3 hours do not have significantly different percent cell viability 
compared to vehicle-treated cells. D.) Cells exposed to 10 nM and 25 nM 
okadaic acid for 6 hours show reduced cell viability compared to vehicle-
treated cells. E.) Cells treated with 10 nM and 25 nM okadaic acid show a 
significant decrease in viability after 24 hours of treatment. F.) Absorbance 
values at 490 nm over 3, 6, and 24 hours of okadaic acid treatment of 
differentiated SH-SY5Y cells. Cell viability decreases over time and levels off 
at 24 hours of okadaic acid treatment. G.) Morphology of differentiated SH-
SY5Y cells treated with 10 nM okadaic acid for 3 hours. For all microscopy 
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Figure 4. Chaperone protein expression levels in okadaic 
acid-treated differentiated SH-SY5Y cells over time.  
A.) SH-SY5Y cells were exposed to okadaic acid for 3 hours and 
25 µg of cell lysate was run on SDS-PAGE and immunoblotted.   
B.) SH-SY5Y cells were exposed to okadaic acid for 6 hours and 
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Figure 5. Model of chaperone-mediated tau assembly into 
neurofibrillary tangles. Hsp70 and Hsp110 destabilize fibrils and 
aggregates of tau. By contrast, Hsp90 stabilizes misfolded tau and 






























































Figure S1. Time-course viability of differentiated SH-SY5Y cells in 
response to okadaic acid treatment.  
A.) SH-SY5Y cells were treated with retinoic acid (10 μM) for 6 days and 
subsequently treated with 0, 10, and 25 nM okadaic acid for 3, 6, and 24 hours. 
Phase-contrast microscopy. Scale bar indicated 100 µm.  
B.) Percentage of viable cells decreases in response to increasing doses of 
okadaic acid after 24 hours of exposure. Cells treated with vehicle only, 0.1% 
ethanol, had 100% viability.  
C.) Cell viability in response to treatment with 0, 10, and SH-SY5Y cells treated 




























































Figure S2. Differentiated SH-SY5Y morphology and chaperone protein 
expression in response to okadaic acid.  
A.) Microscopy of differentiated SH-SY5Y were treated with 0 nM okadaic 
acid and 25 nM of okadaic acid for 24 hours and with 50 nM okadaic acid for 
3 hours.  
B.) Cells were treated with 50 nM okadaic acid for 3 hours and 25 nM 
okadaic acid for 24 hours. Tau protein levels after okadaic acid treatment. 
Total tau levels do not change, but the phospho-Tau epitope Thr212 is 
reactive to okadaic acid-induced tau hyperphosphorylation.  
C.) ATP-dependent chaperone protein levels after okadaic acid treatment. 
Cells were treated with 50 nM okadaic acid for 3 hours and 25 nM okadaic 
acid for 24 hours. Hsp70 levels decrease in response to prolonged OA 
exposure. Hsp90 shifted in migration in response okadaic acid induced 
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Figure S3. Expression of Hsp70 in SH-SY5Y cells treated with 
okadaic acid for 24 hours. Cells treated with 10 nM okadaic acid 




















Okadaic acid (nM)          0      10 
70 kDa Hsp70 



















40 nM 8 hours  Ser404 
 
Ma XH, et al. Brain Res. 2018; 
1690: 
1 – 11. 






Wu X, et al. European Journal 
of Pharmaceutical Sciences. 
2017; 110: 101 – 108. 
100 nM 3 hours  Thr205 
 
Zhang Z and Simpkins JW. 
Brain Res. 2010; 1345: 176 – 
181. 
50 nM and 
100 nM 
2 hours  Ser202/Thr205 
 
Choi S, et al. Cell Mol 
Neurobiol. 2015; 35: 1049 – 
1059. 





Publication status: formatted for submission as a short communication to Journal of 
Molecular Biology  
Title: Engineering AAA+ Chaperone Proteases with Enhanced Substrate Specificity 
for Amyloid Protein Aggregates 
 
Authors: Shannon E. May1,2 and Jodi L. Camberg1,2,3 
Author Affiliations: 
1 Interdisciplinary Neurosciences Program, University of Rhode Island, Kingston, RI 
02881 
2 George and Anne Ryan Institute for Neuroscience, University of Rhode Island, 
Kingston, RI 02881 
3 Department of Cell and Molecular Biology, College of the Environment and Life 
Sciences, University of Rhode Island, Kingston, RI 02881 
  
Author Contributions: S.E.M. designed experiments, performed experiments, 
interpreted data and wrote paper; J.L.C. designed experiments, interpreted data, and 
wrote paper. 
Address correspondence to: Jodi L. Camberg, 120 Flagg Road, CBLS, Room 470, 
University of Rhode Island, Kingston, RI 02881 





Protein aggregates are thought to be the end result of derailed protein quality 
control pathways, which are impaired during aging (1). The protein quality control 
system involves different pathways that manage and regulate protein folding and 
aggregation. Misfolded proteins such as Aβ peptide, tau, alpha-synuclein, and yeast 
prion proteins (insoluble Sup35 protein) share the motif of stacked, in-register beta 
sheets; thus, these misfolded proteins represent different types of amyloid protein (2). 
Amyloid proteins have stable, low-energy conformations that are resistant to protein 
degradation (3). Important components of the protein quality control network are 
molecular chaperones. Restoring protein homeostasis by modulating chaperone 
proteins may provide disease-modifying therapeutic strategies for managing 
neurodegenerative diseases (4). We hypothesize that E. coli ClpX and ClpXP 
expressed in S.cerevisiae will not recognize Sup35 amyloid fibers. Decreasing the 
substrate specificity of the chaperone protein complex ClpXP may result in a novel 
chaperone tool with enhanced specificity for amyloid aggregates that can both bind 
and degrade amyloids. Thus, we constructed and expressed a novel chimeric protein 
in the [PSI+] yeast prion system, an extensively utilized model of amyloid assembly, to 






In the cell, protein homeostasis is regulated by chaperone proteins that can 
remodel and degrade misfolded, unfolded, and aggregate proteins. ClpXP and 
Hsp104 are chaperone proteins that belong to the AAA+ superfamily of ATPases (5). 
The AAA+ (ATPases associated with diverse cellular activities) superfamily of ATP-
dependent enzymes have highly conserved domains and function as chaperones 
and/or proteases to manage protein folding and multiprotein complexes (5). The 
Clp/Hsp100 family of ATP-dependent enzymes within the AAA+ protein superfamily 
includes the cytosolic proteins ClpX, ClpA, and Hsp104. Members of the Clp/Hsp100 
family refold or degrade protein assemblies, misfolded proteins, and aggregated 
proteins (6). Within the Clp/Hsp100 family, ATPases (ClpX) partner with a peptidase 
(ClpP) to form stacked, barrel-like structures that functions as chaperone proteases 
(6). The chaperone ATPase component of this complex threads polypeptides through 
the central axial channel of the chaperone protease complex into the peptidase 
chamber for degradation (7).  
ClpXP is an ATP-dependent chaperone protease that binds to and degrades 
an estimated 50 substrate proteins based on proteomic analysis (8). ClpX forms a 
hexameric ring that binds to ClpP, which forms stacked heptameric rings; thus, there 
is asymmetrical binding between ClpX and ClpP (9, 10). ClpX contains an N-domain, 
a large nucleotide-binding domain (AAA+ domain), and a small AAA+ domain (11).  
The N-domain of ClpX forms dimers that are connected to the large AAA+ domain by 
a flexible linker region and functions to bind adaptors, client proteins, and stabilize the 
hexameric structure of ClpX (12). Substrate recognition by ClpX requires the 
presence of short peptide sequences, or degradation tags, on client proteins, on the 
C-terminus or N-terminus of client proteins (5, 83). An example of a C-terminal 
degradation tag recognized by ClpX is the ssrA tag, an 11-amino acid peptide 
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signaling sequence on substrate proteins (8, 13, 14, 15). The ClpX N-domain is 
required for recognition of several client proteins, such as the λO protein and the 
UmuD subunit of UmuD.D’ DNA polymerase (11). 
The chaperone ATPase ClpXP couples ATP binding and hydrolysis to 
mechanical force, which is required for translocation of polypeptides through the axial 
channel of ClpX into the cavity of ClpP, a serine protease (16). The pore loops 
(GYVG) in the axial channel of ClpX grip and processively thread unfolded 
polypeptides through the narrow central channel of ClpX into the ClpP barrel (11, 13, 
17). ClpX also functions independently of ClpP as a chaperone protein to remodel 
misfolded proteins in vitro and in vivo and disassemble protein complexes, notably the 
MuA transposase tetramer (19 – 21). Biochemical studies have shown that ClpX 
functions at small step sizes to perform mechanical work, which allows the enzyme to 
generate substantial force to remodel diverse sets of substrate proteins (21). 
Lon is a chaperone protease that belongs to the AAA+ superfamily of 
ATPases. Unlike ClpX, Lon can bind to a wider range of substrates and recognizes 
surface-exposed hydrophobic residues on misfolded or unfolded proteins (22). Both 
ClpXP and Lon bind to proteins via the recognition of degradation signals on the C-
terminus or N-terminus of substrate proteins (5, 8). The N-domain of Lon contains 
three amino acid residues that bind to the degradation signal of the substrate SulA 
(23). ClpX and Lon associate with aggregates in bacteria, but it is currently unknown if 
Lon can disassemble aggregates in vivo (24, 25). 
The only member of the Clp/Hsp100 proteins within the AAA+ protein 
superfamily that can disaggregate proteins is the chaperone protein Hsp104 (26). In 
Saccharomyces cerevisiae, deletion and overexpression of Hsp104 modulate prion 
propagation and thus alter the [PSI+] prion phenotype in yeast; thus, changes in the 
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basal levels of Hsp104 “cures” yeast of the [PSI+] prion phenotype (27, 28). The N-
domain of Hsp104 (amino acid residues 1 – 147) is required for [PSI+] prion curing in 
S. cerevisiae, but is not required for thermotolerance or [PSI+] prion propagation 
(Hung and Masison, 2006). Overexpression of Hsp104 is neuroprotective in models of 
Parkinson’s disease, suggesting that Hsp104 can also bind to human prion proteins, 
such as alpha-synuclein (30). 
Engineered chimeric AAA+ chaperone proteases can refold aggregates and 
degrade misfolded proteins. The ClpB variant referred to as BAP associates with the 
ClpP peptidase and functions to both disaggregate and degrade aggregates in 
cooperation with the co-chaperone bacterial protein DnaK (31). Moreover, an Hsp104 
variant called HAP was engineered to display both disaggregation and proteolytic 
activity; HAP consists of Hsp104 in association with ClpP (32). Replacing the helix-
loop-helix region of Hsp104 and ClpB with the helix-loop-helix from ClpA containing 
the IGL/F motif required for ClpP association allows both ClpB and Hsp104 to 
translocate segments of polypeptides extracted from misfolded proteins into the ClpP 
protease barrel (31, 32). Therefore, we hypothesized that engineering a novel 
chaperone protease containing the N-domain of Hsp104 and the ClpXΔNTD 
sequence in association with ClpP could bind to and proteolytically degrade amyloid 
proteins.  
Before testing this hypothesis, we first tested if AAA+ chaperone proteins 
could affect prion propagation in the [PSI+] yeast prion model of amyloid assembly. 
We utilized two approaches to answering this research question. First, we screened 
domain-specific mutations Lon in the S. cerevisiae [PSI+] model of amyloid assembly 
to identify variants with enhanced amyloid substrate recognition. Next, we engineered 
a novel chaperone protease and expressed the construct in the [PSI+] yeast amyloid 
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model to determine if the chimeric protein had enhanced recognition of amyloid. We 
hypothesized that the chimeric protein would resolubilize amyloid protein, thereby 
abrogating prion propagation.  
 
Results 
Random mutations in the N-domain of Lon (amino acid residues 1 – 307) were 
generated with an error-prone DNA polymerase with the goal of decreasing substrate 
specificity of Lon. Decreasing the substrate specificity of Lon could result in substrate 
recognition of fibrillar amyloid proteins. We hypothesized that wild-type Lon would not 
recognize Sup35 amyloid fibers in yeast. After cloning wild-type lon into the double 
expression vector pYES2 and transforming this construct in [PSI+] yeast, we observed 
that the phenotype of the colonies was the same as [PSI+] yeast cells containing the 
empty vector pYES2 (Figure S1). This suggests that prion propagation was not 
altered by the expression of the E. coli chaperone protease Lon in S. cerevisiae. Next, 
we investigated if the expression of E. coli ClpXP affects prion propagation and 
amyloid assembly in [PSI+] yeast by transforming the construct pESC-URA + ClpXP 
(Marissa Viola) into yeast. We observed expression of ClpXP in [PSI+] yeast did not 
change the prion phenotype; yeast colonies were white, which is associated with a 
[PSI+] prion phenotype (Figure S2A). We analyzed the phenotype of yeast lysates 
containing ClpXP using a novel spectrophotometric liquid assay to detect the red 
pigment from ade2-1 yeast mutants that accumulates in [psi-] yeast cells. Extraction of 
protein from yeast cells using Y-PER (Thermo Fisher Scientific), normalization of 
yeast lysates, and excitation of lysates at 488 nm showed that yeast expressing 
ClpXP has a similar emission profile as [PSI+] yeast containing empty pYES2 vector 
(Figure SB). Thus, wild-type Lon and ClpXP do not recognize Sup35 prion in the 
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[PSI+] amyloid model system in vivo and do not modulate prion propagation or curing 
of [PSI+] prion in yeast. 
 Mutations were randomly generated at a low frequency in the Lon N-domain 
and transformed into XL Gold E. coli cells. Clonal isolate plasmid DNA was recovered 
and transformed into [PSI+] S. cerevisiae. In total, 116 clonal isolates derived from the 
random mutagenesis of the N-domain of Lon were screened in [PSI+] yeast. Of these 
mutations, no hits in the [PSI+] colorimetric screen were found. A hit in the screen was 
defined as a mutation in lon that was associated with a uniform pink or red phenotype 
in [PSI+] S. cerevisiae. Hits in the screen were sequenced to classify the mutation(s) 
in lon. Sequencing results showed that a hit in the screen had multiple mutations (> 5 
mutations) and a frameshift mutation at nucleotide base pair 157. Therefore, we did 
not identify any residues in Lon associated with altered substrate recognition by 
domain-specific point mutations. Thus, we did not discover mutant gene copies of lon 
that modified the interaction between Lon and Sup35 amyloid to improve amyloid 
recognition. 
 Next, we investigated if engineered chaperone proteases could recognize and 
disassemble Sup35 prion fibrils in vivo. The AAA+ protein superfamily consists of a 
diverse set of ATP-dependent chaperone proteins that have highly conserved 
domains (Figure 1A). Within the AAA+ superfamily, distinct families of chaperone 
proteins are grouped together based on their domain architecture (67). We cloned the 
N-domain of Hsp104 and the ClpXΔNTD sequence into pESC-URA+ClpXP. First, 
clpX was constructed and expressed in the double expression vector pYES2 
(Invitrogen). Primers were designed to insert a HindII restriction enzyme site 
upstream of the clpX sequence and insert an XhoI restriction enzyme site 
downstream of the clpX sequence (Table 1). Site-directed mutagenesis was carried 
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out using the QuikChange II XL Site-directed Mutagenesis kit. To express the ClpX 
sequence without the N-terminal domain (ClpXΔNTD), both pYES2 and pYES2+ClpX 
were double digested using the restriction enzymes SacI and NotI (New England 
Biolabs), resulting in linearized DNA that was subsequently ligated overnight at 16°C. 
The ligation products were heat inactivated at 65°C and ligation products were 
transformed into XL Blue chemically competent Escherichia coli cells (Agilent). 
Sanger sequencing of the construct confirmed that the ClpXΔNTD sequence (1092 
base pairs) was successfully cloned into the pYES2 vector.   
In order to express the Hsp104 N-terminal domain (amino acid residues 1 – 
161) in the pYES2+ClpXΔNTD construct, restriction enzyme sites flanking the 
Hsp104 N-domain sequence were cloned into the pYS104 vector using the 
polymerase chain reaction (PCR). Upstream of the Hsp104 N-domain, a KpnI site, 5’ 
GGTACC 3’, was inserted and downstream of the Hsp104 N-domain a SacI site was 
inserted. The pYS104 construct containing SacI and KpnI sites and the vector pYES2 
were double digested with KpnI and SacI. Ligation was carried out with 80 ng of 
pYES2 vector. Subsequently, a NotI restriction enzyme site, 5’ GCGGCCGC 3’, was 
inserted at the beginning of the N-domain of ClpX and a SacI site was inserted at the 
end of the ClpX sequence in the vector pYES2. 
Sanger sequencing of the vector pYES2 + Hsp104 N-domain + ClpXΔNTD 
showed that a spontaneous mutation arose; a transition substitution occurred at 
nucleotide base pair 928 of the ClpXΔNTD sequence. To correct this, primers were 
designed to mutate thymine to cytosine at base pair 928 of ClpXΔNTD. In order to 
express the Hsp104 N-domain + ClpXΔNTD construct in the vector pESC-ura+ClpP 
(constructed by Marissa Viola), the pYES2 + Hsp104 N-domain + ClpXΔNTD 
construct and the pESC-URA + ClpP construct were double digested using the 
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restriction enzymes NotI and SacI (New England Biolabs).  Subsequently, ligation 
reactions were carried out with 100 ng of pESC-URA + ClpP vector (9000 base pairs) 
per reaction. Ligation products were heat inactivated and transformed into XL Blue 
chemically competent E. coli cells.  
The chimeric protein Hsp104 + ClpXΔNTD + ClpP has an N-terminal domain 
from Hsp104, and ATPase domain from ClpX, and the ClpP full-length sequence 
(Figure 1B). The chimeric protein Hsp104 + ClpXΔNTD + ClpP was transformed into 
[PSI+] yeast and grown on SD-URA plates for five days at 30°C. The chimeric protein 
did not alter [PSI+] phenotype in yeast (Figure 1C). To determine if ClpX and ClpP 
protein were expressed in yeast, lysates were extracted, normalized, and 
immunoblotted. We found that yeast containing the chimeric protein did express ClpX 
and ClpP (Figure 2A). Moreover, spectrophotometric analysis of yeast lysates using a 
novel [PSI+] assay that we developed showed that level of red pigmentation, which 
accumulates in [psi-] yeast, is reduced in yeast expressing the chimeric proteins 
Hsp104 NTD + ClpXΔN and Hsp104   NTD + ClpXΔN + ClpP compared to yeast 
overexpressing Hsp104 from the plasmid PYS104 and yeast expressing the Walker B 
NBD1 mutation Hsp104(E285Q) (Figure 2B).  
 Based on our findings, the chimeric protein Hsp104   NTD + ClpXΔN + ClpP 
does not cure [PSI+] yeast of Sup35 prion. However, it is possible that the novel 
chaperone protease could enhance prion propagation by severing amyloid fibrils and 
generating amyloid seeds for nucleated polymerization of Sup35 protein, thereby 
facilitating the amyloid assembly of Sup35 (Figure 3). The chimeric protein Hsp104   
NTD + ClpXΔN + ClpP hypothetically could recognize all targets of Hsp104. Future 
biochemical assays with this protein should be done to determine if the protein has 
enhanced binding of amyloid compared to Hsp104 wild-type protein. Degradation 
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assays would determine whether the chimeric protein is degrading amyloid fibrils into 
small peptides and thereby functioning as a chaperone protease. 
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Figure 1. Domain organization and phenotype of chimeric protein.  
A.) Domain architecture of ClpX and Hsp104. ClpX contains an N-domain that 
dimerizes, a large nucleotide-binding domain, and a small nucleotide-binding 
domain. Hsp104 contains an N-domain, two nucleotide-binding domains, and a 
unique coiled-coil middle domain.  
B.) Proposed surface structure of chimeric chaperone protease Hsp104 NTD + 
ClpXΔNTD + ClpP. Hsp104 N-domain structure (PDB 6AMN; Lee et al., 2017). 
ClpXΔNTD structure (PDB 3HWS; Glynn et al., 2009). ClpP structure (PDB 
1TYF; Wang et al., 1997).  
C.) [PSI+] yeast containing the chimeric protein Hsp104 NTD + ClpXΔN + ClpP 
has white colony color and thus carry a [PSI+] phenotype. [PSI+] yeast 
containing the plasmid pYS104 overexpress Hsp104, which resolubilizes 
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Figure 2. Expression of chimeric protein in S. cerevisiae and 
functional analysis.  
A.) Western blots shows bands reactive to ClpX and ClpP for lysate 
extracted from yeast cells transformed with Hsp104 NTD + ClpXΔN + 
ClpP. 
B.) Functional analysis of Hsp104 NTD + ClpXΔN + ClpP shows that 
the level of red pigmentation, which correlates to soluble Sup35 levels, 
is decreased in yeast expressing the chimeric proteins Hsp104 NTD + 
ClpXΔN and Hsp104   NTD + ClpXΔN + ClpP compared to yeast 
overexpressing Hsp104 and the Hsp104 Walker B mutation E285Q. 































Figure 3. Model of Sup35 amyloid fibril severing by Hsp104 NTD + 
ClpXΔNTD + ClpP. Polypeptide segments of amyloid aggregate is 
threaded through the central channel of Hsp104 and substrate is 
translocated into the ClpX central channel where it is threaded into the 
ClpP proteolytic barrel. The degradation products, short polypeptide 
segments, may serve as amyloid seeds to propagate Sup35 prion in 
yeast. Both substrate translocation and degradation of polypeptide 








































































Supplemental Figure S1. Phenotype of [PSI+] yeast carrying pyes2 + 
Lon wild-type construct. Yeast expressing the full-length lon sequence 
in the vector pYES2 have [PSI+] phenotype, which is associated with the 
presence of insoluble Sup35 fibrils.    
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